var title_f25_25_26000="Transducer version";
var content_f25_25_26000=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F69164&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F69164&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 509px\">",
"   <div class=\"ttl\">",
"    Method of using an ultrasound transducer to guide the vertex into the pelvis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 489px; height: 304px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_25_26000=[""].join("\n");
var outline_f25_25_26000=null;
var title_f25_25_26001="Femoral vein cannulation";
var content_f25_25_26001=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F71713&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F71713&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Femoral vein cannulation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 393px; height: 414px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The landmarks for the cannulation of the femoral vein are identified. The patient is placed in a frog-leg position with the hip externally rotated and abducted. The femoral vein is located by feeling for the femoral pulse. The vein is found medial to the pulse. In the patient without a pulse, the vein can be approximately located midway between the pubic symphysis and the anterior superior iliac spine, distal to the inguinal ligament.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_25_26001=[""].join("\n");
var outline_f25_25_26001=null;
var title_f25_25_26002="Glove technique";
var content_f25_25_26002=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F62819&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F62819&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Glove method of ring removal",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 306px; height: 465px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This technique has the advantage of causing minimal additional pain, and can be used with finger fractures or soft tissue injuries and lacerations. Cut one finger from a surgical glove to form a cylindrical sleeve. A) Place this sleeve on the involved digit and slip the proximal end circumferentially under the ring using a hemostat. B) Once in place, pull the proximal end back over the ring and toward the tip of the digit in a twisting motion, advancing the ring distally. Avoid pulling so hard that the glove rips or pulls out from under the ring.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Fuchs SM. Ring removal. In: Textbook of Pediatric Emergency Procedures, 2nd ed, King C, Henretig FM (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2008. Copyright &copy; 2008 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_25_26002=[""].join("\n");
var outline_f25_25_26002=null;
var title_f25_25_26003="Sleep apnea in adults";
var content_f25_25_26003=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Sleep apnea in adults (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?25/25/26003/contributors\">",
"       Author",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/25/26003/contributors\" id=\"au2593\">",
"       Wolfgang Schmidt-Nowara, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?25/25/26003/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/25/26003/contributors\" id=\"se4878\">",
"       Robert C Basner, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?25/25/26003/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/25/26003/contributors\" id=\"de8764\">",
"       April F Eichler, MD, MPH",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"UTD.htm?25/25/26003?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      INTRODUCTION",
"     </span>",
"    </p>",
"    <p>",
"     Normally during sleep, air moves through the throat and in and out of the lungs at a regular rhythm. In a person with sleep apnea, air movement is periodically diminished or stopped. There are two types of sleep apnea: obstructive sleep apnea and central sleep apnea. In obstructive sleep apnea, breathing is abnormal because of narrowing or closure of the throat. In central sleep apnea, breathing is abnormal because of a change in the breathing control and rhythm.",
"    </p>",
"    <p>",
"     Sleep apnea is a serious condition that can affect a person's ability to safely perform normal daily activities and can affect long term health. Approximately 25 percent of adults are at risk for sleep apnea of some degree [",
"     <a class=\"abstract\" href=\"UTD.htm?25/25/26003/abstract/1\">",
"      1",
"     </a>",
"     ]. Men are more commonly affected than women. Other risk factors include middle and older age, being overweight or obese, and having a small mouth and throat.",
"    </p>",
"    <p>",
"     This topic review focuses on the most common type of sleep apnea in adults, obstructive sleep apnea (OSA).",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      HOW SLEEP APNEA OCCURS",
"     </span>",
"    </p>",
"    <p>",
"     The throat is surrounded by muscles that control the airway for speaking, swallowing, and breathing. During sleep, these muscles are less active, and this causes the throat to narrow (",
"     <a class=\"graphic graphic_figure graphicRef51217 \" href=\"UTD.htm?31/37/32336\">",
"      figure 1",
"     </a>",
"     ). In most people, this narrowing does not affect breathing. In others, it can cause snoring, sometimes with reduced or completely blocked airflow (",
"     <a class=\"graphic graphic_figure graphicRef75747 \" href=\"UTD.htm?14/56/15237\">",
"      figure 2",
"     </a>",
"     ). A completely blocked airway without airflow is called an obstructive apnea. Partial obstruction with diminished airflow is called a hypopnea. A person may have apnea and hypopnea during sleep.",
"    </p>",
"    <p>",
"     Insufficient breathing due to apnea or hypopnea causes oxygen levels to fall and carbon dioxide to rise. Because the airway is blocked, breathing faster or harder does not help to improve oxygen levels until the airway is reopened. Typically, this requires the person to awaken to activate the upper airway muscles. Once the airway is opened, the person then takes several deep breaths to catch up on breathing. As the person awakens, he or she may move briefly, snort or snore, and take a deep breath. Less frequently, a person may awaken completely with a sensation of gasping, smothering, or choking.",
"    </p>",
"    <p>",
"     If the person falls back to sleep quickly, he or she will not remember the event. Many people with sleep apnea are unaware of their abnormal breathing in sleep, and all patients underestimate how often their sleep is interrupted. Awakening from sleep causes sleep to be unrefreshing and causes fatigue and daytime sleepiness.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H3\">",
"     <span class=\"h2\">",
"      Causes of obstructive sleep apnea",
"     </span>",
"     &nbsp;&mdash;&nbsp;Most patients have OSA because of a small upper airway. As the bones of the face and skull develop, some people develop a small lower face, a small mouth, and a tongue that seems too large for the mouth. These features are genetically determined, which explains why OSA tends to cluster in families. Obesity is another major factor. Tonsil enlargement can be an important cause, especially in children.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H4\">",
"     <span class=\"h1\">",
"      SLEEP APNEA SYMPTOMS",
"     </span>",
"    </p>",
"    <p>",
"     The main symptoms of OSA are loud snoring, fatigue, and daytime sleepiness. However, some people have no symptoms. For example, if the person does not have a bed partner, he or she may not be aware of the snoring. Fatigue and sleepiness have many causes and are often attributed to overwork and increasing age. As a result, a person may be slow to recognize that they have a problem. A bed partner or spouse often prompts the patient to seek medical care.",
"    </p>",
"    <p>",
"     Other symptoms may include one or more of the following:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Restless sleep",
"      </li>",
"      <li>",
"       Awakening with choking, gasping, or smothering",
"      </li>",
"      <li>",
"       Morning headaches, dry mouth, or sore throat",
"      </li>",
"      <li>",
"       Waking frequently to urinate",
"      </li>",
"      <li>",
"       Awakening unrested, groggy",
"      </li>",
"      <li>",
"       Memory impairment, difficulty concentrating, low energy",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5\">",
"     <span class=\"h2\">",
"      Risk factors",
"     </span>",
"     &nbsp;&mdash;&nbsp;Certain factors increase the risk of sleep apnea.",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Increasing age. OSA occurs at all ages, but it is more common in middle and older age adults.",
"      </li>",
"      <li>",
"       Male sex. OSA is two times more common in men, especially in middle age.",
"      </li>",
"      <li>",
"       Obesity. The more obese a person is, the more likely they are to have OSA",
"      </li>",
"      <li>",
"       Sedation from medication or alcohol interferes with the ability to awaken from sleep and can lengthen periods of apnea (no breathing), with potentially dangerous consequences.",
"      </li>",
"      <li>",
"       Abnormality of the airway.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H6\">",
"     <span class=\"h1\">",
"      SLEEP APNEA COMPLICATIONS",
"     </span>",
"    </p>",
"    <p>",
"     Complications of sleep apnea can include daytime sleepiness and difficulty concentrating. The consequence of this is an increased risk of accidents and errors in daily activities. Studies have shown that people with severe OSA are more than twice as likely to be involved in a motor vehicle accident as people without these conditions. People with OSA are encouraged to discuss options for driving, working, and performing other high-risk tasks with a healthcare provider.",
"    </p>",
"    <p>",
"     In addition, people with untreated OSA may have an increased risk of cardiovascular problems such as high blood pressure, heart attack, abnormal heart rhythms, or stroke [",
"     <a class=\"abstract\" href=\"UTD.htm?25/25/26003/abstract/2\">",
"      2",
"     </a>",
"     ]. This risk may be due to changes in the heart rate and blood pressure that occur during sleep.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H7\">",
"     <span class=\"h1\">",
"      SLEEP APNEA DIAGNOSIS",
"     </span>",
"    </p>",
"    <p>",
"     The diagnosis of OSA is best made by a knowledgeable sleep medicine specialist who has an understanding of the individual's health issues. The diagnosis is usually based upon the person's medical history, physical examination, and testing, including:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       A complaint of snoring and ineffective sleep",
"      </li>",
"      <li>",
"       Neck size (greater than 17 inches in men or 16 inches in women) is associated with an increased risk of sleep apnea.",
"      </li>",
"      <li>",
"       A small upper airway: difficulty seeing the throat because of a tongue that is large for the mouth",
"      </li>",
"      <li>",
"       High blood pressure, especially if it is resistant to treatment",
"      </li>",
"      <li>",
"       If a bed partner has observed the patient during episodes of stopped breathing (apnea), choking, or gasping during sleep, there is a good possibility of sleep apnea.",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     Testing is usually performed in a sleep laboratory. A full sleep study is called a polysomnogram. The polysomnogram measures the breathing effort and airflow, blood oxygen level, heart rate and rhythm, duration of the various stages of sleep, body position, and movement of the",
"     <span class=\"nowrap\">",
"      arms/legs.",
"     </span>",
"    </p>",
"    <p>",
"     Home monitoring devices are available that can perform a sleep study. This is a reasonable alternative to conventional testing in a sleep laboratory if the clinician strongly suspects moderate or severe sleep apnea and the patient does not have other illnesses or sleep disorders that may interfere with the results.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H8\">",
"     <span class=\"h1\">",
"      SLEEP APNEA TREATMENT",
"     </span>",
"    </p>",
"    <p>",
"     Sleep apnea is best treated by a knowledgeable sleep medicine specialist. The goal of treatment is to maintain an open airway during sleep. Effective treatment will eliminate the symptoms of sleep disturbance; long-term health consequences are also reduced. Most treatments require nightly use. The challenge for the clinician and the patient is to select an effective therapy that is appropriate for the patient's problem and that is acceptable for long term use.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H9\">",
"     <span class=\"h2\">",
"      Continuous positive airway pressure (CPAP)",
"     </span>",
"     &nbsp;&mdash;&nbsp;The most effective treatment for sleep apnea uses a mechanical device to keep the upper airway open during sleep. A CPAP (continuous positive airway pressure) (",
"     <a class=\"graphic graphic_figure graphicRef65324 \" href=\"UTD.htm?39/30/40419\">",
"      figure 3",
"     </a>",
"     ) device uses an air-tight attachment to the nose, typically a mask, connected to a tube and a blower which generates the pressure [",
"     <a class=\"abstract\" href=\"UTD.htm?25/25/26003/abstract/3\">",
"      3",
"     </a>",
"     ]. Devices that fit comfortably into the nasal opening, rather than over the nose, are also available. CPAP should be used any time the person sleeps (day or night).",
"    </p>",
"    <p>",
"     The CPAP device is usually used for the first time in the sleep lab, where a technician can adjust the pressure and select the best equipment to keep the airway open. While the treatment may seem uncomfortable, noisy, or bulky at first, most people accept the treatment after experiencing better sleep. However, difficulty with mask comfort and nasal congestion prevent up to 50 percent of people from using the treatment on a regular basis.",
"    </p>",
"    <p>",
"     Continued follow up with a healthcare provider helps to ensure that the treatment is effective and comfortable. Changes in treatment may be needed if the person gains or loses weight, or if symptoms do not improve.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H10\">",
"     <span class=\"h2\">",
"      Adjust sleep position",
"     </span>",
"     &nbsp;&mdash;&nbsp;Adjusting sleep position (to stay off the back) may help improve sleep quality in people who have OSA when sleeping on the back. However, this is difficult to maintain throughout the night and is rarely an adequate solution.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11\">",
"     <span class=\"h2\">",
"      Weight loss",
"     </span>",
"     &nbsp;&mdash;&nbsp;Weight loss may be helpful for obese or overweight patients. Weight loss may be accomplished with dietary changes, exercise,",
"     <span class=\"nowrap\">",
"      and/or",
"     </span>",
"     surgical treatment. However, it can be difficult to maintain weight loss; the five-year success of non-surgical weight loss is only 5 percent, meaning that 95 percent of people regain lost weight. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?33/5/33876?source=see_link\">",
"      \"Patient information: Weight loss treatments (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H12\">",
"     <span class=\"h2\">",
"      Avoid alcohol and other sedatives",
"     </span>",
"     &nbsp;&mdash;&nbsp;Alcohol can worsen sleepiness, potentially increasing the risk of accidents or injury. People with OSA are often counseled to drink little to no alcohol, even during the daytime. Similarly, people who take anti-anxiety medications or sedatives to sleep should speak with their healthcare provider about the safety of these medications.",
"    </p>",
"    <p>",
"     People with OSA must notify all healthcare providers, including surgeons, about their condition and the potential risks of being sedated. People with OSA who are given anesthesia",
"     <span class=\"nowrap\">",
"      and/or",
"     </span>",
"     pain medications require special management and close monitoring to reduce the risk of a blocked airway.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H13\">",
"     <span class=\"h2\">",
"      Dental devices",
"     </span>",
"     &nbsp;&mdash;&nbsp;A dental device, called an oral appliance or mandibular advancement device, can reposition the jaw (mandible), bringing the tongue and soft palate forward as well. This may relieve obstruction in some people [",
"     <a class=\"abstract\" href=\"UTD.htm?25/25/26003/abstract/4\">",
"      4",
"     </a>",
"     ].",
"    </p>",
"    <p>",
"     This treatment is excellent for reducing snoring, although the effect on OSA is often limited [",
"     <a class=\"abstract\" href=\"UTD.htm?25/25/26003/abstract/4\">",
"      4",
"     </a>",
"     ]. As a result, dental devices are best used for mild cases of OSA when relief of snoring is the main goal. While dental devices are not as effective as CPAP for OSA, some patients prefer a dental device to CPAP. Side effects of dental devices are generally minor but may include changes to the bite with prolonged use.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H13825791\">",
"     <span class=\"h2\">",
"      Nasal valves",
"     </span>",
"     &nbsp;&mdash;&nbsp;Valves that retard expiratory flow can be inserted into each nostril during sleep. This raises the air pressure in the throat and may decrease airway narrowing. The treatment is attractive for travel and camping, and for patients who are unable to tolerate CPAP. However, some patients find the treatment uncomfortable and success is limited in others [",
"     <a class=\"abstract\" href=\"UTD.htm?25/25/26003/abstract/5\">",
"      5",
"     </a>",
"     ]. Nasal valves are best used for mild cases of OSA when relief of snoring is the main goal.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H14\">",
"     <span class=\"h2\">",
"      Surgical treatment",
"     </span>",
"     &nbsp;&mdash;&nbsp;Surgery is generally reserved for patients who cannot tolerate or do not improve with non-surgical treatments such as CPAP or oral devices. Surgical procedures can reshape structures in the upper airways or surgically reposition the facial bones. Uvulopalatopharyngoplasty (UPPP) is one of the most commonly performed surgical procedures; it removes the uvula and excessive tissue in the throat, including the tonsils, if present.",
"    </p>",
"    <p>",
"     However, this surgery and other surgeries of the soft palate have a poor rate of success (less than 50 percent) and have a high rate of relapse (when OSA symptoms return after surgery) [",
"     <a class=\"abstract\" href=\"UTD.htm?25/25/26003/abstract/6\">",
"      6",
"     </a>",
"     ]. As a result, throat surgery is only recommended in a minority of patients and should be considered with caution.",
"    </p>",
"    <p>",
"     Tracheostomy is a surgical procedure that creates a permanent opening in the neck. It is reserved for people with severe disease in whom less drastic measures have failed or are inappropriate. Although it is always successful in eliminating obstructive sleep apnea, tracheostomy requires significant lifestyle changes and carries some serious risks (eg, infection, bleeding, blockage).",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H15\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11284408\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11284416\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?16/25/16786?source=see_link\">",
"      Patient information: Sleep apnea (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?38/4/38978?source=see_link\">",
"      Patient information: Daytime sleepiness (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?35/5/35921?source=see_link\">",
"      Patient information: What is a sleep study? (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11284441\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?33/5/33876?source=see_link\">",
"      Patient information: Weight loss treatments (Beyond the Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11284458\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/62/44006?source=see_link\">",
"      Adherence with continuous positive airway pressure (CPAP)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/47/18169?source=see_link\">",
"      Cardiovascular effects of obstructive sleep apnea",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/29/44502?source=see_link\">",
"      Central sleep apnea: Risk factors, clinical presentation, and diagnosis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/20/39239?source=see_link\">",
"      Central sleep apnea: Treatment",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/40/41607?source=see_link\">",
"      Clinical presentation and diagnosis of obstructive sleep apnea in adults",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/38/44649?source=see_link\">",
"      Evaluation of suspected obstructive sleep apnea in children",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/3/10296?source=see_link\">",
"      Initiation of positive airway pressure therapy for obstructive sleep apnea in adults",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/6/8294?source=see_link\">",
"      Liabilities of sleep deprivation and sleep disorders",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/48/2826?source=see_link\">",
"      Management of obstructive sleep apnea in adults",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/17/40217?source=see_link\">",
"      Management of obstructive sleep apnea in children",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/56/24454?source=see_link\">",
"      Mechanisms and anatomic sites of upper airway obstruction in obstructive sleep apnea in adults",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/36/9801?source=see_link\">",
"      Mechanisms and predisposing factors for sleep related breathing disorders in children",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/42/1704?source=see_link\">",
"      Oral appliances in the treatment of obstructive sleep apnea in adults",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/13/6359?source=see_link\">",
"      Overview of obstructive sleep apnea in adults",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/45/3801?source=see_link\">",
"      Pharmacologic treatment of obstructive sleep apnea in adults",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/30/38374?source=see_link\">",
"      Polysomnography in obstructive sleep apnea in adults",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/20/17734?source=see_link\">",
"      Portable monitoring in obstructive sleep apnea in adults",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/59/15286?source=see_link\">",
"      Sleep related breathing disorders in adults: Definitions",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/18/16677?source=see_link\">",
"      Upper airway imaging in obstructive sleep apnea in adults",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/healthtopics.html\">",
"      www.nlm.nih.gov/medlineplus/healthtopics.html",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Heart, Lung, and Blood Institute",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nhlbi.nih.gov/\">",
"      www.nhlbi.nih.gov",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       American Academy of Sleep Medicine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.aasmnet.org/\">",
"      www.aasmnet.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Sleep Foundation",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.sleepfoundation.org/\">",
"      www.sleepfoundation.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       American Sleep Apnea Association",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.sleepapnea.org/\">",
"      www.sleepapnea.org",
"     </a>",
"     )",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 24, 2012.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"UTD.htm?25/25/26003?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/25/26003/abstract/1\">",
"      Young T, Palta M, Dempsey J, et al. The occurrence of sleep-disordered breathing among middle-aged adults. N Engl J Med 1993; 328:1230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/25/26003/abstract/2\">",
"      Marin JM, Carrizo SJ, Vicente E, Agusti AG. Long-term cardiovascular outcomes in men with obstructive sleep apnoea-hypopnoea with or without treatment with continuous positive airway pressure: an observational study. Lancet 2005; 365:1046.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/25/26003/abstract/3\">",
"      Gay P, Weaver T, Loube D, et al. Evaluation of positive airway pressure treatment for sleep related breathing disorders in adults. Sleep 2006; 29:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/25/26003/abstract/4\">",
"      Ferguson KA, Cartwright R, Rogers R, Schmidt-Nowara W. Oral appliances for snoring and obstructive sleep apnea: a review. Sleep 2006; 29:244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/25/26003/abstract/5\">",
"      Rosenthal L, Massie CA, Dolan DC, et al. A multicenter, prospective study of a novel nasal EPAP device in the treatment of obstructive sleep apnea: efficacy and 30-day adherence. J Clin Sleep Med 2009; 5:532.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/25/26003/abstract/6\">",
"      Sundaram S, Bridgman SA, Lim J, Lasserson TJ. Surgery for obstructive sleep apnoea. Cochrane Database Syst Rev 2005; :CD001004.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f25_25_26003=[""].join("\n");
var outline_f25_25_26003=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           INTRODUCTION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           HOW SLEEP APNEA OCCURS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H4\">",
"           SLEEP APNEA SYMPTOMS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H6\">",
"           SLEEP APNEA COMPLICATIONS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H7\">",
"           SLEEP APNEA DIAGNOSIS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H8\">",
"           SLEEP APNEA TREATMENT",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H15\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        GRAPHICS",
"       </h1>",
"       <div id=\"relatedGraphics\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          FIGURES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"UTD.htm?31/37/32336\" title=\"figure 1\">",
"           Normal airway sleeping PI",
"          </a>",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"UTD.htm?14/56/15237\" title=\"figure 2\">",
"           Airway in a person with sleep apnea PI",
"          </a>",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"UTD.htm?39/30/40419\" title=\"figure 3\">",
"           CPAP PI",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f25_25_26004="Dorzolamide: Patient drug information";
var content_f25_25_26004=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Dorzolamide: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/30/23012?source=see_link\">",
"     see \"Dorzolamide: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?18/63/19443?source=see_link\">",
"     see \"Dorzolamide: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F162751\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Trusopt&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F162752\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Sandoz-Dorzolamide;",
"     </li>",
"     <li>",
"      Trusopt&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10023787\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10023789\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691860",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat glaucoma.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10023788\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701601",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to benzalkonium chloride, dorzolamide, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701385",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a sulfa (sulfonamide) allergy, talk with your doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10023793\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698504",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your eye pressure checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697788",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may get sunburned more easily. Avoid sun, sunlamps, and tanning beds. Use sunscreen and wear clothing and eyewear that protects you from the sun.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10023794\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698045",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Eye irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697912",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Blurred eyesight. Use care when driving or doing other tasks that call for clear eyesight.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696432",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Bad taste in your mouth. This most often goes back to normal.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10023796\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699086",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sudden change in eyesight, eye pain, or irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699049",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10023791\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694913",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For the eye only.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696257",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wash your hands before and after use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695783",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take out contact lenses before using this drug. Lenses may be put back in 15 minutes after this drug is given. Do not put contacts back in if your eyes are irritated or infected.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694779",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not touch the container tip to the eye, lid, or other skin.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696124",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tilt your head back and drop drug into the eye.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694401",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       After use, keep your eyes closed. Put pressure on the inside corner of the eye. Do this for 1 to 2 minutes. This keeps the drug in your eye.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695617",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Space each eye drug by 10 minutes.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10023792\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696583",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696485",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use 2 doses or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10023797\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10023798\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12396 Version 36.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-122.72.76.133-7ADB670DEC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_25_26004=[""].join("\n");
var outline_f25_25_26004=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F162751\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F162752\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023787\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023789\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023788\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023793\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023794\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023796\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023791\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023792\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023797\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023798\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?22/30/23012?source=related_link\">",
"      Dorzolamide: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?18/63/19443?source=related_link\">",
"      Dorzolamide: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f25_25_26005="Sarcoidosis alopecia";
var content_f25_25_26005=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F57221&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F57221&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Alopecia secondary to sarcoidosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Sarcoidal alopecia. Erythematous plaques with areas of follicular loss and scarring are present on the frontal scalp.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_25_26005=[""].join("\n");
var outline_f25_25_26005=null;
var title_f25_25_26006="Diagnostic challenge and desensitization protocols for NSAID reactions";
var content_f25_25_26006=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Diagnostic challenge and desensitization protocols for NSAID reactions",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/25/26006/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/25/26006/contributors\">",
"     Ronald A Simon, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/25/26006/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/25/26006/contributors\">",
"     N Franklin Adkinson, Jr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/25/26006/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/25/26006/contributors\">",
"     Anna M Feldweg, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?25/25/26006/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 31, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nonsteroidal antiinflammatory drugs (NSAIDs) (including",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    ) can cause several distinct types of allergic and pseudoallergic reactions. These reactions are categorized by the presumed underlying mechanism and whether the reaction is elicited by multiple NSAIDs or by a single agent.",
"   </p>",
"   <p>",
"    There are no in vitro or skin testing methods available to diagnose these reactions, and a provocative challenge procedure is the only means of obtaining a definitive diagnosis if there is a legitimate medical need for future NSAID therapy. These procedures are also used to desensitize patients to NSAIDs in some situations. Challenge protocols involve cautiously administering gradually increasing doses of an NSAID, usually",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    , in an appropriately monitored medical setting.",
"   </p>",
"   <p>",
"    The various challenge and desensitization protocols that are used by allergy specialists to evaluate patients with reactions to NSAIDs will be reviewed here. The clinical features of NSAID reactions and the use of alternative medications, either highly selective COX-2 inhibitors or NSAIDs that weakly inhibit COX-1, are presented elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/59/31672?source=see_link\">",
"     \"NSAIDs (including aspirin): Allergic and pseudoallergic reactions\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     REACTION TYPES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The different types of pseudoallergic and allergic reactions to NSAIDS are summarized briefly here and reviewed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/59/31672?source=see_link\">",
"     \"NSAIDs (including aspirin): Allergic and pseudoallergic reactions\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Pseudoallergic",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pseudoallergic reactions are related to COX-1 inhibition and are elicited by multiple NSAIDs. These typically occur in patients with underlying asthma, chronic rhinosinusitis and nasal polyposis, or in those with chronic urticaria.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Type 1",
"      </strong>",
"      :",
"      <span class=\"nowrap\">",
"       ASA/NSAID",
"      </span>",
"      exacerbated respiratory disease (also called",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      exacerbated respiratory disease or AERD)",
"     </li>",
"     <li>",
"      <strong>",
"       Type 2",
"      </strong>",
"      :",
"      <span class=\"nowrap\">",
"       ASA/NSAID-induced",
"      </span>",
"      <span class=\"nowrap\">",
"       urticaria/angioedema",
"      </span>",
"      in patients with underlying chronic urticaria",
"     </li>",
"     <li>",
"      <strong>",
"       Type 3",
"      </strong>",
"      :",
"      <span class=\"nowrap\">",
"       ASA/NSAID-induced",
"      </span>",
"      <span class=\"nowrap\">",
"       urticaria/angioedema",
"      </span>",
"      in otherwise asymptomatic individuals",
"     </li>",
"     <li>",
"      <strong>",
"       Type 4",
"      </strong>",
"      : Blended (involving both the respiratory tract and skin) reactions in otherwise asymptomatic individuals",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Allergic",
"    </span>",
"    &nbsp;&mdash;&nbsp;Allergic reactions are presumed to be IgE-mediated and are elicited by a single NSAID (not reported to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    itself; rarely by more than one agent with similar chemical structures).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Type 5",
"      </strong>",
"      : NSAID-induced allergic reactions",
"     </li>",
"     <li>",
"      <strong>",
"       Type 6",
"      </strong>",
"      : NSAID-induced anaphylaxis (ie, a more severe reaction than Type 5 to the same, single NSAID)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     GENERAL ISSUES IN NSAID CHALLENGES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Indications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Drug challenges are not without risk. The benefits of the information gathered from the challenge must be weighed against the risks for each patient individually. The following are general guidelines:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The use of these procedures simply to determine if a person with a suggestive history is allergic to an NSAID is NOT recommended.",
"     </li>",
"     <li>",
"      In contrast, if a patient has a medical indication for NSAID therapy (eg, cardiovascular risk factors, confirmed cardiac disease, or a chronic inflammatory condition such as arthritis) it is usually appropriate to proceed and determine the specific type of reaction present. The information can then be used to determine what other NSAIDs the patient may safely take. Alternatively, patients can sometimes be desensitized to an NSAID that is then taken on a daily basis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Contraindications to challenge",
"    </span>",
"    &nbsp;&mdash;&nbsp;Any concurrent cardiopulmonary conditions should be under optimal control before a patient is challenged. In patients with asthma, it is our practice to perform oral challenge only if the pre-bronchodilator FEV1 is &ge;70 percent of the patient's best and &ge;1.5 liters.",
"   </p>",
"   <p>",
"    Patients with past NSAID reactions that involved possible anaphylaxis should not be on any medications that may increase the likelihood of anaphylaxis or interfere with treatment of anaphylaxis, such as ACE-inhibitors or beta-blockers, although there may be individual exceptions to this.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1361264\">",
"    <span class=\"h2\">",
"     Safety issues",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      NSAID challenges should only be performed by clinicians with the expertise to manage any resultant symptoms, and in settings equipped with the necessary medications, equipment, and support staff. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/29/35290?source=see_link\">",
"       \"Anaphylaxis: Rapid recognition and treatment\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The appropriate setting is determined by the historical features of past reactions and the clinician's knowledge about what types of reactions are in the differential diagnosis. In most cases, these protocols may be safely performed in specially-equipped outpatient allergy clinics, while in other cases, admission to the hospital or intensive care unit is indicated. Oral challenges in patients with previous anaphylaxis should be performed in an ICU or in an area where ICU transfer is readily available, although severe reactions are generally avoidable. The decision about where to perform challenges requires clinical judgment and each case must be considered individually.",
"     </li>",
"     <li>",
"      In some patients, intravenous access should be obtained prior to challenge in case emergency medications or fluids are required. This is indicated in patients believed to be at risk for moderate to severe symptoms during the challenge procedure, and in those with significant underlying cardiopulmonary disease.",
"     </li>",
"     <li>",
"      Lastly, informed consent should be obtained from all adult patients or from the guardians of children under 18 years of age.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1361168\">",
"    <span class=\"h1\">",
"     REFERRAL",
"    </span>",
"    &nbsp;&mdash;&nbsp;NSAIDs cause an array of different reactions, some of which can be severe or life threatening. In addition, the signs and symptoms of the various types of reactions may be overlapping, and distinguishing among them can require some expertise. For these reasons, referral to an allergy specialist should be considered whenever possible.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1362865\">",
"    <span class=\"h1\">",
"     PROTOCOLS FOR ORAL CHALLENGES",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are several basic oral challenge procedures (",
"    <a class=\"graphic graphic_table graphicRef58610 \" href=\"UTD.htm?42/18/43308\">",
"     table 1",
"    </a>",
"    ). These protocols differ in the starting dose and the time interval between doses. The recommended doses and intervals are based upon extensive analysis of different types of NSAID reactions [",
"    <a class=\"abstract\" href=\"UTD.htm?25/25/26006/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1362897\">",
"    <span class=\"h2\">",
"     Choice of NSAID",
"    </span>",
"    &nbsp;&mdash;&nbsp;At the author&rsquo;s institution and many others,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    is the drug most often utilized in oral challenges. There is more experience with aspirin than any other NSAID and aspirin has the additional advantage of not having been implicated in any confirmed cases of anaphylaxis. The few instances in which we perform challenges with NSAIDs other than aspirin are pointed out in the discussions below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1362904\">",
"    <span class=\"h2\">",
"     Use of placebo doses",
"    </span>",
"    &nbsp;&mdash;&nbsp;We do not usually include placebos when a challenge is performed solely for the purposes of patient management. However, there are some situations in which the use of placebo doses is clinically useful. As an example, placebo doses are helpful in the evaluation of the patient who is suspected of not having sensitivity to NSAIDs at all, in whom challenge is indicated to prove that the patient tolerates NSAIDs. We sometimes give such patients an initial dose of placebo, and also end the challenge with one or more placebo doses (so that the patient receives placebo when expecting the largest dose of the day) with one or more placebo doses in between. Informed consent should be obtained for inclusion of placebos.",
"   </p>",
"   <p>",
"    In contrast, placebo doses are essential in research studies in which challenge is performed for the purposes of confirming the diagnosis. Many protocols include an initial day in which only placebos are administered, to control for nonspecific changes in pulmonary function that some patients demonstrate in a challenge environment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1362992\">",
"    <span class=\"h2\">",
"     Premedication",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antihistamines are normally withheld prior to NSAID challenges, as these agents could obscure detection of early or mild allergic symptoms. Both H1 and H2 antihistamines should be discontinued at least 48 hours before the challenge unless otherwise noted in the discussion below.",
"   </p>",
"   <p>",
"    Patients with AERD who experienced moderate to severe bronchospastic reactions to NSAIDs in the past should be premedicated with antileukotriene agents prior to undergoing oral or bronchial challenges. Challenge and desensitization in patients with AERD are discussed in more detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/54/18281?source=see_link\">",
"     \"Aspirin exacerbated respiratory disease: NSAID challenge and desensitization\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1361315\">",
"    <span class=\"h1\">",
"     CHOICE OF PROTOCOL",
"    </span>",
"    &nbsp;&mdash;&nbsp;The patient&rsquo;s clinical history is used to determine the most likely type of reaction. The signs and symptoms of the reaction, and whether the reaction was elicited by one or multiple NSAIDs are the most important elements of the history. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/59/31672?source=see_link&amp;anchor=H13#H13\">",
"     \"NSAIDs (including aspirin): Allergic and pseudoallergic reactions\", section on 'History'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1363033\">",
"    <span class=\"h2\">",
"     Patients with respiratory reactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who experienced rhinorrhea or bronchospasm following exposure to an NSAID may have either type 1 or type 4 pseudoallergy. They may also have anaphylaxis to that NSAID (type 6, allergic reaction). Other symptoms that can accompany respiratory reactions, particularly in patients with AERD, are flushing, conjunctival injection, and laryngospasm. Thus, type 1 pseudoallergy and anaphylaxis can be difficult to differentiate clinically. However, patients with type 1 pseudoallergy usually have underlying AERD (ie, asthma, chronic rhinosinusitis, and nasal polyposis).",
"   </p>",
"   <p>",
"    Patients with past respiratory reactions can undergo the oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    challenge described in row 1 (",
"    <a class=\"graphic graphic_table graphicRef58610 \" href=\"UTD.htm?42/18/43308\">",
"     table 1",
"    </a>",
"    ), following premedication with a leukotriene modifying drug. The starting dose is either 40.5 mg and this is doubled at intervals of three hours, until the patient reacts or the desired therapeutic dose is reached. This approach would also be safe if the patient had anaphylaxis to an NSAID because anaphylaxis to aspirin has not been described.",
"   </p>",
"   <p>",
"    Issues that are specific to NSAID challenges in patients with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    exacerbated respiratory disease (AERD) are discussed in greater detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/54/18281?source=see_link\">",
"     \"Aspirin exacerbated respiratory disease: NSAID challenge and desensitization\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Patients with urticaria/angioedema reactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who react to multiple NSAIDs with symptoms of",
"    <span class=\"nowrap\">",
"     urticaria/angioedema",
"    </span>",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    have a history consistent with chronic urticaria may undergo the oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    challenge described in row 2 (",
"    <a class=\"graphic graphic_table graphicRef58610 \" href=\"UTD.htm?42/18/43308\">",
"     table 1",
"    </a>",
"    ). The starting dose is either 81 or 162 mg and this is doubled at intervals of three hours, until the patient reacts or the desired therapeutic dose is reached. The diagnosis of a type 2 or type 3 reaction is confirmed in patients who develop urticaria",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    angioedema, depending on the presence of an underlying chronic urticaria.",
"   </p>",
"   <p>",
"    For patients who reacted to a single NSAID with urticaria",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    angioedema and do NOT have a history of underlying chronic urticaria, performing an oral challenge to ASA is the most prudent course (row 3) (",
"    <a class=\"graphic graphic_table graphicRef58610 \" href=\"UTD.htm?42/18/43308\">",
"     table 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If a patient does",
"      <strong>",
"       not",
"      </strong>",
"      develop symptoms, then pseudoallergy is excluded and the patient is only sensitive to the drug that caused the initial reaction and has a type 5 or 6 reaction. The patient can safely receive an NSAID that is structurally different from the one that caused the initial reaction.",
"     </li>",
"     <li>",
"      If a patient with a history of chronic urticaria develops urticaria or angioedema in response to challenge, then the diagnosis is type 2 pseudoallergy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Patients with anaphylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients who have a history suggestive of single NSAID reactivity with anaphylaxis (type 6), performing an oral challenge to ASA is a safe first step in the evaluation (row 4) (",
"    <a class=\"graphic graphic_table graphicRef58610 \" href=\"UTD.htm?42/18/43308\">",
"     table 1",
"    </a>",
"    ). As mentioned previously, anaphylaxis to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    itself has not been convincingly demonstrated. Thus, pseudoallergy can be excluded with certainty if the patient does not react to aspirin.",
"   </p>",
"   <p>",
"    A typical starting dose in these patients is 162 mg of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    , which is then doubled every three hours [",
"    <a class=\"abstract\" href=\"UTD.htm?25/25/26006/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An uneventful oral challenge rules out sensitivity to multiple NSAIDs and confirms the diagnosis of a type 6 reaction to the NSAID that caused the initial reaction.",
"   </p>",
"   <p>",
"    There may be uncommon clinical situations in which a challenge is performed to a NSAID other than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    . In this situation, the starting dose should be much lower, ie,",
"    <span class=\"nowrap\">",
"     1/1000",
"    </span>",
"    or",
"    <span class=\"nowrap\">",
"     1/100",
"    </span>",
"    of a dose, which is then increased 10-fold every three hours, since anaphylaxis to other NSAIDs is possible. This scenario may arise if a patient has experienced possible anaphylaxis to a specific NSAID, needs NSAIDs for occasional use, but cannot tolerate other chemically different groups of NSAIDs for various reasons. In this situation, an aspirin challenge would be performed first to exclude the possibility of pseudoallergy. If the patient does not react to aspirin, then their initial reaction was likely anaphylaxis to the specific NSAID in question. In order to determine if a similar but not identical NSAID could be safely taken, a challenge with the desired alternative agent would be required.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     DESENSITIZATION FOR PSEUDOALLERGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;NSAID desensitization is a process of inducing tolerance to NSAIDs in a patient with pseudoallergic reactions. Desensitization is essentially a continuation of the challenge process until the patient reaches the desired dose without reacting. The drug must be taken regularly following desensitization, since tolerance is lost if exposure is interrupted.",
"   </p>",
"   <p>",
"    Desensitization is",
"    <strong>",
"     rarely attempted",
"    </strong>",
"    for patients with allergic reactions (types 5 and 6 - presumed IgE-mediated reactions to single NSAIDs) because an array of different NSAIDs are available that can be used instead of the culprit drug. Patients with these types of reactions should avoid the causative agent and other NSAIDs in the same chemical group (",
"    <a class=\"graphic graphic_table graphicRef70067 \" href=\"UTD.htm?23/54/24431\">",
"     table 2",
"    </a>",
"    ). NSAIDS that are structurally dissimilar to the drug that caused the initial reaction may be safely taken. Other options for management are discussed separately. (See",
"    <span class=\"nowrap\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/59/31672?source=see_link&amp;anchor=H15#H15\">",
"      \"NSAIDs (including aspirin): Allergic and pseudoallergic reactions\", section on 'Management'",
"     </a>",
"     .)",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Indications",
"    </span>",
"    &nbsp;&mdash;&nbsp;NSAID/",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    desensitization is appropriate for patients who have a medical need for daily",
"    <span class=\"nowrap\">",
"     NSAID/aspirin",
"    </span>",
"    therapy, such as an inflammatory disorder or atherosclerotic cardiovascular disease. Daily aspirin therapy is also a treatment for the airway inflammation of AERD.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6476487\">",
"    <span class=\"h2\">",
"     Desensitization protocol for pseudoallergic reactions (Types 1 - 4)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Desensitization of patients with pseudoallergic NSAID reactions involves extending the challenge procedure used for diagnosis (",
"    <a class=\"graphic graphic_table graphicRef58610 \" href=\"UTD.htm?42/18/43308\">",
"     table 1",
"    </a>",
"    ). Once the patient has developed symptoms and these have been treated, the challenge is resumed by repeating the same dose that elicited the reaction. If there is another reaction, the symptoms are",
"    <strong>",
"    </strong>",
"    again treated and the same dose is given again until there is no further reaction.",
"   </p>",
"   <p>",
"    This process of inducing symptoms, treating, and repeating the culprit dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    is continued until the patient tolerates the target dose without further symptoms. At that point, the patient is desensitized. Once desensitized, the patient must ingest aspirin or an equivalent COX-1 inhibiting NSAID daily in order to maintain tolerance.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6476269\">",
"    <span class=\"h2\">",
"     Success of desensitization for different types of pseudoallergy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Desensitization can be safely attempted in all types of pseudoallergy, although the anticipated success varies depending upon the type of reaction present.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Type 1",
"      </strong>",
"      &mdash; Desensitization is most often performed in patients with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      exacerbated respiratory disease (AERD) and type 1 pseudoallergy and it is nearly always successful when performed properly. Desensitization in this patient group is discussed in more detail elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/54/18281?source=see_link\">",
"       \"Aspirin exacerbated respiratory disease: NSAID challenge and desensitization\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Type 2",
"      </strong>",
"      &mdash; Patients with type 2 pseudoallergic reactions (ie,",
"      <span class=\"nowrap\">",
"       ASA/NSAID-induced",
"      </span>",
"      <span class=\"nowrap\">",
"       urticaria/angioedema",
"      </span>",
"      with underlying chronic urticaria) are the most difficult to desensitize. Even when desensitization is initially successful, tolerance is often lost over time.",
"      <br/>",
"      <br/>",
"      Despite this, patients with type 2 reactions who need",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      for cardioprotection can sometimes tolerate 81 mg dose of aspirin daily without significant worsening of their symptoms. To determine this, we usually give one-half of a tablet (40.5 mg) initially, wait approximately three hours, and then give 81 mg. If the patient reacts to either step, we repeat that step until it is tolerated. Other management options (such as use of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"       acetaminophen",
"      </a>",
"      , selective COX-2 inhibitors, or weak COX-1 inhibitors) are reviewed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/59/31672?source=see_link&amp;anchor=H18#H18\">",
"       \"NSAIDs (including aspirin): Allergic and pseudoallergic reactions\", section on 'Types 1 to 4 - treatment options'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Types 3 and 4",
"      </strong>",
"      &mdash; Many patients with types 3 and 4 pseudoallergic reactions",
"      <span class=\"nowrap\">",
"       (urticaria/angioedema",
"      </span>",
"      or blended reactions in otherwise asymptomatic individuals) may tolerate 81 mg or even 325 mg without developing",
"      <span class=\"nowrap\">",
"       urticaria/angioedema",
"      </span>",
"      or other symptoms, and may be able to continue on these doses long-term.",
"      <br/>",
"      <br/>",
"      Types 3 and 4 patients can also be desensitized, although this can be challenging because the urticaria",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      angioedema that develop during the procedure may be difficult to control. It is our approach to initiate therapy with both non-sedating oral antihistamines and leukotriene modifying agents (LTMDs) and when the reaction subsides, repeat the provoking dose and continue the desensitization process. Systemic glucocorticoids may be necessary for resistant cases. When the desired dose is reached without symptoms, the patient is desensitized. Once desensitized, the antihistamine and LTMD can be discontinued. This approach has been successful in the author&rsquo;s experience [",
"      <a class=\"abstract\" href=\"UTD.htm?25/25/26006/abstract/3\">",
"       3",
"      </a>",
"      ], although it has not been formally studied.",
"      <br/>",
"      <br/>",
"      Other treatment options are reviewed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/59/31672?source=see_link&amp;anchor=H18#H18\">",
"       \"NSAIDs (including aspirin): Allergic and pseudoallergic reactions\", section on 'Types 1 to 4 - treatment options'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Provocative NSAID challenges are required to make a definitive diagnosis of a pseudoallergic or allergic NSAID reaction. Challenge is usually indicated only in patients who have a legitimate medical need for future NSAID therapy. Simple avoidance of NSAIDs is a more practical option for patients who have no specific need for these mediations. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'General issues in NSAID challenges'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Challenges should be performed by allergy specialists in specially equipped clinics or in an intensive care unit, depending on the severity of the patient's past reaction(s). (See",
"      <a class=\"local\" href=\"#H1361168\">",
"       'Referral'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most challenge protocols use oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      . The characteristics of the past NSAID reaction determine the protocol that should be used for challenge (",
"      <a class=\"graphic graphic_table graphicRef58610 \" href=\"UTD.htm?42/18/43308\">",
"       table 1",
"      </a>",
"      ) (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Reaction types'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Patients with underlying",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      exacerbated respiratory disease (AERD) who develop",
"      <span class=\"nowrap\">",
"       nasal/ocular/respiratory",
"      </span>",
"      reactions to multiple NSAIDs should be challenged with the protocol shown in row 1 (",
"      <a class=\"graphic graphic_table graphicRef58610 \" href=\"UTD.htm?42/18/43308\">",
"       table 1",
"      </a>",
"      ). Challenge is expected to induce symptoms and premedication with leukotriene modifying agents before oral challenge is recommended, as reviewed in detail separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/54/18281?source=see_link\">",
"       \"Aspirin exacerbated respiratory disease: NSAID challenge and desensitization\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients with urticaria",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      angioedema in response to NSAIDs should be challenged with the protocol in row 2 if there is a history of underlying chronic urticaria, or with the protocol in row 3 if there is no such history (",
"      <a class=\"graphic graphic_table graphicRef58610 \" href=\"UTD.htm?42/18/43308\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Patients with urticaria/angioedema reactions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with anaphylaxis in response to an NSAID in the past should be challenged with the protocol in row 4 (",
"      <a class=\"graphic graphic_table graphicRef58610 \" href=\"UTD.htm?42/18/43308\">",
"       table 1",
"      </a>",
"      ). This is sometimes performed in the intensive care unit. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Patients with anaphylaxis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <span class=\"nowrap\">",
"       NSAID/",
"       <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"        aspirin",
"       </a>",
"      </span>",
"      desensitization is a process of inducing tolerance to NSAIDs in a patient with",
"      <strong>",
"       pseudoallergic",
"      </strong>",
"      reactions. Desensitization involves extending the diagnostic challenge procedure. Once desensitized, the patient must ingest aspirin or an equivalent COX-1 inhibiting NSAID daily in order to maintain this state of acquired tolerance. (See",
"      <a class=\"local\" href=\"#H25\">",
"       'Desensitization for pseudoallergy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      NSAID desensitization is appropriate for patients who have a medical need for daily NSAID therapy, such as an inflammatory disorder or atherosclerotic cardiovascular disease. Daily",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      therapy is also a treatment for the airway inflammation of AERD. (See",
"      <a class=\"local\" href=\"#H26\">",
"       'Indications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The success of desensitization varies depending upon the type of pseudoallergy present: (See",
"      <a class=\"local\" href=\"#H6476269\">",
"       'Success of desensitization for different types of pseudoallergy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Desensitization is successful in nearly all patients with type 1 reactions and AERD.",
"     </li>",
"     <li>",
"      Desensitization in patients with type 2 reactions (NSAID-induced",
"      <span class=\"nowrap\">",
"       urticaria/angioedema",
"      </span>",
"      in patients with underlying chronic urticaria) is usually not successful long-term, although some of these individuals will tolerate low-dose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      Desensitization is variably successful in patients with type 3 and 4 reactions, although a suggested approach is provided.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/25/26006/abstract/1\">",
"      Gollapudi RR, Teirstein PS, Stevenson DD, Simon RA. Aspirin sensitivity: implications for patients with coronary artery disease. JAMA 2004; 292:3017.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/25/26006/abstract/2\">",
"      Hope AP, Woessner KA, Simon RA, Stevenson DD. Rational approach to aspirin dosing during oral challenges and desensitization of patients with aspirin-exacerbated respiratory disease. J Allergy Clin Immunol 2009; 123:406.",
"     </a>",
"    </li>",
"    <li>",
"     The Scripps Clinic, San Diego, California. Dr. Simon may be reached at simon.ronald@scrippshealth.org.",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2085 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-203.80.222.8-89ED0DCEDC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_25_26006=[""].join("\n");
var outline_f25_25_26006=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H33\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      REACTION TYPES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Pseudoallergic",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Allergic",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      GENERAL ISSUES IN NSAID CHALLENGES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Indications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Contraindications to challenge",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1361264\">",
"      Safety issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1361168\">",
"      REFERRAL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1362865\">",
"      PROTOCOLS FOR ORAL CHALLENGES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1362897\">",
"      Choice of NSAID",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1362904\">",
"      Use of placebo doses",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1362992\">",
"      Premedication",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1361315\">",
"      CHOICE OF PROTOCOL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1363033\">",
"      Patients with respiratory reactions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Patients with urticaria/angioedema reactions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Patients with anaphylaxis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      DESENSITIZATION FOR PSEUDOALLERGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Indications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6476487\">",
"      Desensitization protocol for pseudoallergic reactions (Types 1 - 4)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6476269\">",
"      Success of desensitization for different types of pseudoallergy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ALLRG/2085\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/2085|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?42/18/43308\" title=\"table 1\">",
"      NSAID oral chal protocols",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/54/24431\" title=\"table 2\">",
"      Nonopioid analgesic and NSAID table",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/29/35290?source=related_link\">",
"      Anaphylaxis: Rapid recognition and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/54/18281?source=related_link\">",
"      Aspirin exacerbated respiratory disease: NSAID challenge and desensitization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/59/31672?source=related_link\">",
"      NSAIDs (including aspirin): Allergic and pseudoallergic reactions",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f25_25_26007="Clinical manifestations, pathologic features, and diagnosis of precursor B cell acute lymphoblastic leukemia/lymphoma";
var content_f25_25_26007=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical manifestations, pathologic features, and diagnosis of precursor B cell acute lymphoblastic leukemia/lymphoma",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/25/26007/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/25/26007/contributors\">",
"     Arnold S Freedman, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/25/26007/contributors\">",
"     Jon C Aster, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/25/26007/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/25/26007/contributors\">",
"     Andrew Lister, MD, FRCP, FRCPath, FRCR",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/25/26007/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/25/26007/contributors\">",
"     Rebecca F Connor, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?25/25/26007/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 10, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the REAL and WHO classification systems for hematologic malignancies, the lymphoblastic neoplasms, which may present as leukemia",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    lymphoma, are divided into two general categories based upon lineage (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/53/21337?source=see_link\">",
"     \"Classification of the hematopoietic neoplasms\"",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?25/25/26007/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Precursor B cell lymphoblastic",
"      <span class=\"nowrap\">",
"       leukemia/lymphoma,",
"      </span>",
"      also called precursor B cell acute lymphoblastic leukemia (precursor B cell ALL)",
"     </li>",
"     <li>",
"      Precursor T cell lymphoblastic",
"      <span class=\"nowrap\">",
"       leukemia/lymphoma",
"      </span>",
"      (precursor T-LBL), also called precursor T cell acute lymphoblastic leukemia (precursor T cell ALL)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This is largely done because the prognosis and treatment differ between neoplasms of B and T cell lineage. These can be further divided into either lymphoblastic lymphoma or lymphoblastic leukemia:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Clinically, a case is defined as lymphoma (LBL) if there is a mass lesion in the mediastinum or elsewhere and &lt;25 percent blasts in the bone marrow.",
"     </li>",
"     <li>",
"      It is classified as leukemia (ALL) if there are &gt;25 percent bone marrow blasts, with or without a mass lesion.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Within each lineage group, there is significant biological and clinical overlap between neoplasms diagnosed as LBL and ALL. Although some patients present with predominantly lymphomatous involvement (eg, a mediastinal mass or another defined lesion), most have or later develop marrow involvement. Similarly, patients who present with leukemia may have or develop extramedullary tumors. Accordingly, lymphoblastic lymphoma and acute lymphoblastic leukemia should be considered the same disease with different clinical presentations [",
"    <a class=\"abstract\" href=\"UTD.htm?25/25/26007/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The pathobiology, diagnosis, and clinical presentation of precursor B lymphoblastic",
"    <span class=\"nowrap\">",
"     leukemia/lymphoma",
"    </span>",
"    will be discussed here. The diagnosis of precursor T lymphoblastic",
"    <span class=\"nowrap\">",
"     leukemia/lymphoma",
"    </span>",
"    and the treatment of these disorders are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/5/23642?source=see_link\">",
"     \"Induction therapy for Philadelphia chromosome negative acute lymphoblastic leukemia in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/11/9400?source=see_link\">",
"     \"General principles of hematopoietic cell transplantation for acute lymphoblastic leukemia in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CELL OF ORIGIN",
"    </span>",
"    &nbsp;&mdash;&nbsp;Precursor B-lymphoblastic",
"    <span class=\"nowrap\">",
"     leukemia/lymphoma,",
"    </span>",
"    also called precursor B cell acute lymphoblastic leukemia (precursor B cell ALL), is postulated to arise from precursor B cells at varying stages of differentiation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Precursor",
"    <span class=\"nowrap\">",
"     B-ALL/LBL",
"    </span>",
"    accounts for approximately 2 percent of the lymphoid neoplasms diagnosed in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?25/25/26007/abstract/5\">",
"     5",
"    </a>",
"    ]. It occurs most frequently in childhood, but can also be seen in adults, with an overall median age in adults of 39 [",
"    <a class=\"abstract\" href=\"UTD.htm?25/25/26007/abstract/6\">",
"     6",
"    </a>",
"    ]. In the United States, the incidence is approximately 11 cases per million persons per year [",
"    <a class=\"abstract\" href=\"UTD.htm?25/25/26007/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Precursor B-ALL occurs slightly more frequently in males than females, and three times as frequently in whites as in blacks [",
"    <a class=\"abstract\" href=\"UTD.htm?25/25/26007/abstract/7\">",
"     7",
"    </a>",
"    ]. Hispanics have the highest incidence of any ethnic group. Incidence appears to be increased in certain areas of Central and South America (eg, Guatemala, Peru) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/25/26007/abstract/8\">",
"     8",
"    </a>",
"    ]. The bases for these variations in incidence are unknown.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Precursor",
"    <span class=\"nowrap\">",
"     B-ALL/LBL",
"    </span>",
"    more frequently presents in its leukemic form (precursor B cell ALL) than its lymphomatous form (precursor B cell LBL). The disease tempo is variable with some patients presenting with symptoms progressing slowly over weeks to months and with others presenting more acutely.",
"   </p>",
"   <p>",
"    Patients with precursor B cell ALL typically present with symptoms related to anemia, thrombocytopenia, and neutropenia due to replacement of the bone marrow with tumor. Symptoms can include fatigue, easy or spontaneous",
"    <span class=\"nowrap\">",
"     bruising/bleeding,",
"    </span>",
"    and infections. B-symptoms, such as fever, night sweats, and unintentional weight loss are often present, but may be mild. Hepatomegaly, splenomegaly, and lymphadenopathy can be seen in up to half of adults on presentation. Central nervous system (CNS) involvement is common and can be accompanied by cranial neuropathies or symptoms, predominantly meningeal, related to increased intracranial pressure.",
"   </p>",
"   <p>",
"    By definition, patients with precursor B cell LBL present with a mass lesion and have &lt;25 percent blasts in the bone marrow. Unlike precursor T cell LBL, mediastinal masses are rare but lymph nodes and extranodal sites, such as the skin, are more frequently involved [",
"    <a class=\"abstract\" href=\"UTD.htm?25/25/26007/abstract/9\">",
"     9",
"    </a>",
"    ]. A study of 53 children with B cell LBL enrolled on three prospective trials reported the following areas as the main location of disease at the time of diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?25/25/26007/abstract/10\">",
"     10",
"    </a>",
"    ]: osteolytic bone lesions (26 percent), skin or subcutaneous lesions (23 percent), mediastinal or pleural disease (11 percent), bone marrow (13 percent), lymph nodes alone (13 percent), gonads (6 percent), head and neck (4 percent), or kidney and digestive system (2 percent each). Upon further evaluation, 43 percent had bone marrow involvement and 6 percent had CNS involvement at diagnosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H498317\">",
"    <span class=\"h1\">",
"     PATHOLOGIC FEATURES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Morphology",
"    </span>",
"    &nbsp;&mdash;&nbsp;On peripheral blood smears, lymphoblasts vary from small cells with scant cytoplasm, condensed nuclear chromatin, and indistinct nucleoli to larger cells with moderate amounts of cytoplasm, dispersed chromatin, and multiple nucleoli (",
"    <a class=\"graphic graphic_picture graphicRef83240 \" href=\"UTD.htm?11/16/11526\">",
"     picture 1",
"    </a>",
"    ). A few azurophilic cytoplasmic granules may be present. Auer rods are never present.",
"   </p>",
"   <p>",
"    In tissue sections, the tumor cells are small to medium-sized, with scant cytoplasm, round, oval, or convoluted nuclei, fine chromatin and indistinct or small nucleoli (",
"    <a class=\"graphic graphic_picture graphicRef83239 \" href=\"UTD.htm?30/13/30936\">",
"     picture 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef83241 \" href=\"UTD.htm?4/18/4390\">",
"     picture 3",
"    </a>",
"    ). Occasional cases have larger cells. Precursor B",
"    <span class=\"nowrap\">",
"     LBL/ALL",
"    </span>",
"    is morphologically indistinguishable from precursor T",
"    <span class=\"nowrap\">",
"     ALL/LBL.",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Histochemistry and immunophenotype",
"    </span>",
"    &nbsp;&mdash;&nbsp;Evaluation often includes both histochemistry and flow cytometry, the latter being more informative. On histochemistry, the blasts often show \"chunky\" positivity on periodic acid Schiff (PAS) staining, variable positivity for nonspecific esterase and sudan black B, and universal negativity for myeloperoxidase.",
"   </p>",
"   <p>",
"    Of greater importance is characterization with antibody stains, which are usually carried out by flow cytometry (",
"    <a class=\"graphic graphic_figure graphicRef83238 \" href=\"UTD.htm?43/6/44131\">",
"     figure 1",
"    </a>",
"    ). The blasts are virtually always positive for terminal deoxytransferase (TdT) (",
"    <a class=\"graphic graphic_picture graphicRef83237 \" href=\"UTD.htm?29/25/30103\">",
"     picture 4",
"    </a>",
"    ) and variably express the B cell markers CD19, CD22, CD20 and CD79a, leukocyte common antigen CD45 and common acute lymphoblastic leukemia antigen CD10 (CALLA). T cell markers such as CD3 are negative.",
"   </p>",
"   <p>",
"    The constellation of antigens identified defines the stage of differentiation, ranging from (earliest to latest):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Early precursor B (pro-B-ALL) &mdash; membrane CD19+, CD79a+, and cytoplasmic CD22+",
"     </li>",
"     <li>",
"      Common ALL &mdash; CD10+",
"     </li>",
"     <li>",
"      Late pre-B ALL &mdash; CD20+, cytoplasmic mu heavy chain",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Approximately 40 percent of cases will express the lineage-independent stem cell antigen CD34.",
"   </p>",
"   <p>",
"    Co-expression of myeloid antigens is seen in up to 30 percent of cases, most commonly CD13 (14 percent)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    CD33 (16 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/25/26007/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. Expression of CD13 and CD33 is associated with the presence of rearrangements involving the ETV6 gene (previously called TEL), usually as part of a t(12;21)(p12;q22) that creates an ETV6-CBFA2 (or TEL-AML1) fusion gene. Co-expression of CD68, CD15, and CD33 is seen in cases with rearrangements involving the MLL gene, such as t(4;11) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/25/26007/abstract/12\">",
"     12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/25/22938?source=see_link\">",
"     \"Cytogenetics in acute lymphoblastic leukemia\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H7\">",
"     'Genetic features'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Genetic features",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rearrangement of antigen receptor genes is variable in lymphoblastic neoplasms, and may not be lineage-specific; thus, precursor B cell neoplasms may have either or both immunoglobulin heavy chain and T cell receptor gamma or beta chain gene rearrangements, or may lack rearrangements [",
"    <a class=\"abstract\" href=\"UTD.htm?25/25/26007/abstract/13-15\">",
"     13-15",
"    </a>",
"    ]. As such, we rely upon an analysis of immunophenotype to designate T cell or B cell lineage.",
"   </p>",
"   <p>",
"    Chromosomal abnormalities are common in precursor-B lymphoblastic neoplasms. Although not specifically used in the diagnosis of precursor B cell",
"    <span class=\"nowrap\">",
"     LBL/ALL,",
"    </span>",
"    they are important for prognosis. They are typically divided into:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Numerical changes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Numerical changes in chromosomes include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Hyperdiploidy &gt;50 chromosomes",
"     </li>",
"     <li>",
"      Hypodiploidy &lt;45 chromosomes",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       Pseudodiploidy/translocations",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The frequency of these abnormalities varies between children and adults, and some are associated with characteristic immunophenotypes",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    clinical behavior.",
"   </p>",
"   <p>",
"    Hyperdiploidy (51 to 65 chromosomes; DNA index 1.16-1.6) is seen in up to 50 percent of cases of childhood precursor B-ALL and is associated with a good prognosis, particularly those with trisomies of chromosomes 4, 10, 17 and 18. This is due in part because of its association with the t(12;21), which is the most common translocation in childhood B-ALL. Both abnormalities are much less common in adult ALL.",
"   </p>",
"   <p>",
"    Hypodiploidy (less than 45 chromosomes) is uncommon, occurring in around 1 percent of B-ALL in children and adolescents, and is associated with poor event-free survival and overall outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?25/25/26007/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Translocations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many different translocations have been reported in B-ALL, three of which are clearly associated with treatment failure or success when using intensive chemotherapy. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The Philadelphia chromosome: t(9;22)(a34;q11);",
"      <span class=\"nowrap\">",
"       BCR/ABL:",
"      </span>",
"      associated with a poor prognosis, this is the most frequent rearrangement in adult ALL. It is present in 25 percent of adult and 3 percent of childhood cases. The incidence of t(9;22) increases with age and is present in 40 to 50 percent of patients older than 60 years. A high fraction of Philadelphia chromosome positive B-ALLs are associated with loss of function mutations in Ikaros (encoded by the IKZF1) [",
"      <a class=\"abstract\" href=\"UTD.htm?25/25/26007/abstract/17\">",
"       17",
"      </a>",
"      ], a transcriptional repressor that regulates lymphoid development. Of interest, a subset of B-ALL with Ikaros mutations that lacks the Philadelphia chromosome has also been described recently; these, too, are associated with a very poor prognosis [",
"      <a class=\"abstract\" href=\"UTD.htm?25/25/26007/abstract/18\">",
"       18",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/25/22938?source=see_link&amp;anchor=H5#H5\">",
"       \"Cytogenetics in acute lymphoblastic leukemia\", section on '4;11 translocation'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      t(v;11q23); MLL rearranged: associated with a poor prognosis, seen in infants &lt;1 year and adults [",
"      <a class=\"abstract\" href=\"UTD.htm?25/25/26007/abstract/19\">",
"       19",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      t(12;21)(p12;q22)",
"      <span class=\"nowrap\">",
"       TEL/AML1:",
"      </span>",
"      associated with a good prognosis and hyperdiploidy, this is the most common rearrangement seen in children [",
"      <a class=\"abstract\" href=\"UTD.htm?25/25/26007/abstract/20\">",
"       20",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The t(9;22) and t(v;11q23) are often associated with a pro-B immunophenotype and a poor prognosis [",
"    <a class=\"abstract\" href=\"UTD.htm?25/25/26007/abstract/11,19\">",
"     11,19",
"    </a>",
"    ], while the t(12;21) is associated with common pre-B ALL. Reports have also described a cryptic t(X;14) involving the IgH locus and the cytokine receptor gene CRLF2 that is also associated with Ikaros mutations and a poor outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?25/25/26007/abstract/21\">",
"     21",
"    </a>",
"    ]. A more detailed discussion of chromosomal abnormalities in ALL is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/25/22938?source=see_link\">",
"     \"Cytogenetics in acute lymphoblastic leukemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of precursor B-lymphoblastic",
"    <span class=\"nowrap\">",
"     leukemia/lymphoma",
"    </span>",
"    is made based upon the results of a bone marrow aspirate with or without biopsy, and aspirate with or without biopsy of other involved tissues, such as lymph nodes or skin. In addition to histological analysis, portions of the aspirated material should be sent for flow cytometry and cytogenetic evaluation.",
"   </p>",
"   <p>",
"    It is essential to find blasts in the peripheral blood, bone marrow, or tissue biopsy. Their morphology varies, but is identical in precursor B",
"    <span class=\"nowrap\">",
"     LBL/ALL",
"    </span>",
"    and precursor T",
"    <span class=\"nowrap\">",
"     ALL/LBL.",
"    </span>",
"    In some instances, the blasts are so undifferentiated that morphologic distinction from acute myeloid leukemia (AML) is difficult or impossible. Because antigen receptor gene rearrangements are not entirely lineage specific, immunophenotype plays a key role in the diagnosis of precursor B",
"    <span class=\"nowrap\">",
"     LBL/ALL.",
"    </span>",
"   </p>",
"   <p>",
"    Precursor B cell",
"    <span class=\"nowrap\">",
"     LBL/ALL",
"    </span>",
"    (like precursor T cell",
"    <span class=\"nowrap\">",
"     LBL/ALL)",
"    </span>",
"    is distinguished from AML by its positivity for TdT and lack of staining for myeloperoxidase. The B cell lineage is then identified by expression of B cell antigens (eg, CD19, CD22, CD20 and CD79a) and lack of expression of T cell antigens (eg, CD3). In more primitive precursor B cell",
"    <span class=\"nowrap\">",
"     LBL/ALLs,",
"    </span>",
"    CD19 may be the only B lineage marker present, whereas more mature tumors tend to express CD20. Surface immunoglobulin, the hallmark of a mature B cell, is absent, but cytoplasmic Ig mu heavy chain may be detected in more mature tumors.",
"   </p>",
"   <p>",
"    The term precursor B cell acute lymphoblastic leukemia (B-ALL) is used if there are &gt;25 percent bone marrow blasts, with or without a mass lesion. For cases with a mass lesion and less than 25 percent bone marrow involvement, the term precursor B cell lymphoblastic lymphoma (B-LBL) is used.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Precursor B cell",
"    <span class=\"nowrap\">",
"     LBL/ALL",
"    </span>",
"    must be differentiated from other forms of lymphoma and leukemia and from the presence of increased numbers of normal maturing B cell precursors, known as hematogones. Most notably, precursor B cell",
"    <span class=\"nowrap\">",
"     LBL/ALL",
"    </span>",
"    is differentiated from precursor T cell",
"    <span class=\"nowrap\">",
"     LBL/ALL",
"    </span>",
"    by immunophenotypic analysis, which demonstrates B cell antigens and the absence of T cell antigens. In addition, precursor B and T cell",
"    <span class=\"nowrap\">",
"     LBL/ALL",
"    </span>",
"    are differentiated from AML by their positivity for TdT and lack of staining for myeloperoxidase. Although hematogones may be suggested by findings on immunohistochemical staining of bone marrow biopsy specimens [",
"    <a class=\"abstract\" href=\"UTD.htm?25/25/26007/abstract/22\">",
"     22",
"    </a>",
"    ], they can be most easily distinguished from precursor B cell",
"    <span class=\"nowrap\">",
"     LBL/ALL",
"    </span>",
"    by multicolor flow cytometry [",
"    <a class=\"abstract\" href=\"UTD.htm?25/25/26007/abstract/23\">",
"     23",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/20/30023?source=see_link\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of precursor T cell acute lymphoblastic leukemia/lymphoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/58/20393?source=see_link\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of acute myeloid leukemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both tumor and patient characteristics can be used to predict treatment outcomes in precursor B cell",
"    <span class=\"nowrap\">",
"     ALL/LBL.",
"    </span>",
"    In particular, age at diagnosis and",
"    <span class=\"nowrap\">",
"     cytogenetic/genetic",
"    </span>",
"    findings appear to be the strongest predictors of survival. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The outcome is less favorable in infants less than one year of age and in adults and more favorable in children.",
"     </li>",
"     <li>",
"      In infants, many cases have translocations involving the MLL gene at 11q23, which is associated with a poor prognosis at any age [",
"      <a class=\"abstract\" href=\"UTD.htm?25/25/26007/abstract/19\">",
"       19",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Adult precursor B-ALL is more often associated with the poor-prognosis t(9;22) or t(v11q23) abnormalities, and survival is much poorer than in childhood cases [",
"      <a class=\"abstract\" href=\"UTD.htm?25/25/26007/abstract/11,24\">",
"       11,24",
"      </a>",
"      ]. Other poor prognostic factors include hypodiploidy and Ikaros mutations.",
"     </li>",
"     <li>",
"      Older children more often have hyperdiploidy and the t(12;21), which confer a better prognosis (85 to 90 percent long-term survival) [",
"      <a class=\"abstract\" href=\"UTD.htm?25/25/26007/abstract/20\">",
"       20",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Myeloid antigen expression does not seem to be an independent prognostic factor in ALL [",
"      <a class=\"abstract\" href=\"UTD.htm?25/25/26007/abstract/12,25\">",
"       12,25",
"      </a>",
"      ]. Overall, the prognosis for these patients may be worse than that for adults with T cell",
"      <span class=\"nowrap\">",
"       LBL/ALL.",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The relationship between prognosis and cytogenetic abnormalities in ALL is discussed in more detail elsewhere. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Genetic features'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/25/22938?source=see_link\">",
"     \"Cytogenetics in acute lymphoblastic leukemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?15/15/15602?source=see_link\">",
"       \"Patient information: Acute lymphoblastic leukemia (ALL) (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?17/34/17955?source=see_link\">",
"       \"Patient information: Acute lymphoblastic leukemia (ALL) treatment in adults (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Precursor B-lymphoblastic",
"      <span class=\"nowrap\">",
"       leukemia/lymphoma,",
"      </span>",
"      also called precursor B cell acute lymphoblastic leukemia (precursor B cell ALL) is postulated to arise from precursor B cells at varying stages of differentiation.",
"     </li>",
"     <li>",
"      The term precursor B cell acute lymphoblastic leukemia (B-ALL) is used if there are &gt;25 percent bone marrow blasts, with or without a mass lesion. For cases with a mass lesion and less than 25 percent bone marrow involvement, the term precursor B cell lymphoblastic lymphoma (B-LBL) is used. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/20/30023?source=see_link&amp;anchor=H733536#H733536\">",
"       \"Clinical manifestations, pathologic features, and diagnosis of precursor T cell acute lymphoblastic leukemia/lymphoma\", section on 'Introduction'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Precursor",
"      <span class=\"nowrap\">",
"       B-ALL/LBL,",
"      </span>",
"      which accounts for approximately 2 percent of the lymphoid neoplasms, occurs most frequently in childhood, but can also be seen in adults. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Peripheral blood smear, bone marrow biopsy, and tissue biopsy can demonstrate lymphoblasts with varying morphology. Precursor B",
"      <span class=\"nowrap\">",
"       LBL/ALL",
"      </span>",
"      is morphologically indistinguishable from precursor T",
"      <span class=\"nowrap\">",
"       ALL/LBL.",
"      </span>",
"      (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Morphology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Key diagnostic studies include histochemical stains, immunocytochemistry, and flow cytometry. These are required to differentiate between precursor",
"      <span class=\"nowrap\">",
"       B-ALL/LBL,",
"      </span>",
"      precursor",
"      <span class=\"nowrap\">",
"       T-ALL/LBL,",
"      </span>",
"      and other acute leukemias. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Histochemistry and immunophenotype'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Although not specifically used in the diagnosis of precursor B cell",
"      <span class=\"nowrap\">",
"       LBL/ALL,",
"      </span>",
"      cytogenetic analysis is of prognostic importance in B lineage tumors. Some centers screen for Ikaros (IKZF1) mutations, which confer a poor prognosis. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Genetic features'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/25/22938?source=see_link\">",
"       \"Cytogenetics in acute lymphoblastic leukemia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The diagnosis of precursor B-lymphoblastic",
"      <span class=\"nowrap\">",
"       leukemia/lymphoma",
"      </span>",
"      is made based upon the results of a bone marrow biopsy with or without biopsy of other involved tissues, such as lymph nodes or skin. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Both tumor and patient characteristics can be used to predict treatment outcomes in precursor B cell",
"      <span class=\"nowrap\">",
"       ALL/LBL.",
"      </span>",
"      In particular, age at diagnosis and chromosomal changes appear to be the strongest predictors of survival. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Prognosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/25/26007/abstract/1\">",
"      Harris NL, Jaffe ES, Stein H, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994; 84:1361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/25/26007/abstract/2\">",
"      Harris NL, Jaffe ES, Diebold J, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol 1999; 17:3835.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/25/26007/abstract/3\">",
"      Brouet JC, Rabian C, Gisselbrecht C, Flandrin G. Clinical and immunological study of non-Hodgkin T-cell lymphomas (cutaneous and lymphoblastic lymphomas excluded). Br J Haematol 1984; 57:315.",
"     </a>",
"    </li>",
"    <li>",
"     World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues, Swerdlow SH, Campo E, Harris NL, et al. (Eds), IARC Press, Lyon 2008.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/25/26007/abstract/5\">",
"      Han X, Kilfoy B, Zheng T, et al. Lymphoma survival patterns by WHO subtype in the United States, 1973-2003. Cancer Causes Control 2008; 19:841.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/25/26007/abstract/6\">",
"      Soslow RA, Baergen RN, Warnke RA. B-lineage lymphoblastic lymphoma is a clinicopathologic entity distinct from other histologically similar aggressive lymphomas with blastic morphology. Cancer 1999; 85:2648.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/25/26007/abstract/7\">",
"      Dores GM, Devesa SS, Curtis RE, et al. Acute leukemia incidence and patient survival among children and adults in the United States, 2001-2007. Blood 2012; 119:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/25/26007/abstract/8\">",
"      Laurini JA, Perry AM, Boilesen E, et al. Classification of non-Hodgkin lymphoma in Central and South America: a review of 1028 cases. Blood 2012; 120:4795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/25/26007/abstract/9\">",
"      Shafer D, Wu H, Al-Saleem T, et al. Cutaneous precursor B-cell lymphoblastic lymphoma in 2 adult patients: clinicopathologic and molecular cytogenetic studies with a review of the literature. Arch Dermatol 2008; 144:1155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/25/26007/abstract/10\">",
"      Ducassou S, Ferlay C, Bergeron C, et al. Clinical presentation, evolution, and prognosis of precursor B-cell lymphoblastic lymphoma in trials LMT96, EORTC 58881, and EORTC 58951. Br J Haematol 2011; 152:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/25/26007/abstract/11\">",
"      Khalidi HS, Chang KL, Medeiros LJ, et al. Acute lymphoblastic leukemia. Survey of immunophenotype, French-American-British classification, frequency of myeloid antigen expression, and karyotypic abnormalities in 210 pediatric and adult cases. Am J Clin Pathol 1999; 111:467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/25/26007/abstract/12\">",
"      Pui CH, Rubnitz JE, Hancock ML, et al. Reappraisal of the clinical and biologic significance of myeloid-associated antigen expression in childhood acute lymphoblastic leukemia. J Clin Oncol 1998; 16:3768.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/25/26007/abstract/13\">",
"      Kitchingman GR, Rovigatti U, Mauer AM, et al. Rearrangement of immunoglobulin heavy chain genes in T cell acute lymphoblastic leukemia. Blood 1985; 65:725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/25/26007/abstract/14\">",
"      Tawa A, Hozumi N, Minden M, et al. Rearrangement of the T-cell receptor beta-chain gene in non-T-cell, non-B-cell acute lymphoblastic leukemia of childhood. N Engl J Med 1985; 313:1033.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/25/26007/abstract/15\">",
"      Felix CA, Poplack DG, Reaman GH, et al. Characterization of immunoglobulin and T-cell receptor gene patterns in B-cell precursor acute lymphoblastic leukemia of childhood. J Clin Oncol 1990; 8:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/25/26007/abstract/16\">",
"      Nachman JB, Heerema NA, Sather H, et al. Outcome of treatment in children with hypodiploid acute lymphoblastic leukemia. Blood 2007; 110:1112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/25/26007/abstract/17\">",
"      Mullighan CG, Miller CB, Radtke I, et al. BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros. Nature 2008; 453:110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/25/26007/abstract/18\">",
"      Mullighan CG, Su X, Zhang J, et al. Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. N Engl J Med 2009; 360:470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/25/26007/abstract/19\">",
"      Pui CH, Behm FG, Downing JR, et al. 11q23/MLL rearrangement confers a poor prognosis in infants with acute lymphoblastic leukemia. J Clin Oncol 1994; 12:909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/25/26007/abstract/20\">",
"      Rubnitz JE, Pui CH, Downing JR. The role of TEL fusion genes in pediatric leukemias. Leukemia 1999; 13:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/25/26007/abstract/21\">",
"      Harvey RC, Mullighan CG, Chen IM, et al. Rearrangement of CRLF2 is associated with mutation of JAK kinases, alteration of IKZF1, Hispanic/Latino ethnicity, and a poor outcome in pediatric B-progenitor acute lymphoblastic leukemia. Blood 2010; 115:5312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/25/26007/abstract/22\">",
"      Al-Shieban S, Byrne E, Trivedi P, et al. Immunohistochemical distinction of haematogones from B lymphoblastic leukaemia/lymphoma or B-cell acute lymphoblastic leukaemia (B-ALL) on bone marrow trephine biopsies: a study on 62 patients. Br J Haematol 2011; 154:466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/25/26007/abstract/23\">",
"      Kroft SH, Asplund SL, McKenna RW, Karandikar NJ. Haematogones in the peripheral blood of adults: a four-colour flow cytometry study of 102 patients. Br J Haematol 2004; 126:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/25/26007/abstract/24\">",
"      Boucheix C, David B, Sebban C, et al. Immunophenotype of adult acute lymphoblastic leukemia, clinical parameters, and outcome: an analysis of a prospective trial including 562 tested patients (LALA87). French Group on Therapy for Adult Acute Lymphoblastic Leukemia. Blood 1994; 84:1603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/25/26007/abstract/25\">",
"      Uckun FM, Sather HN, Gaynon PS, et al. Clinical features and treatment outcome of children with myeloid antigen positive acute lymphoblastic leukemia: a report from the Children's Cancer Group. Blood 1997; 90:28.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4686 Version 13.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-115.66.252.144-6720EAAD2F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_25_26007=[""].join("\n");
var outline_f25_25_26007=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H22\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CELL OF ORIGIN",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H498317\">",
"      PATHOLOGIC FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Morphology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Histochemistry and immunophenotype",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Genetic features",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Numerical changes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Translocations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/4686\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/4686|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?43/6/44131\" title=\"figure 1\">",
"      Flow B cell ALL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/4686|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?11/16/11526\" title=\"picture 1\">",
"      Peripheral blood B cell ALL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?30/13/30936\" title=\"picture 2\">",
"      BM biopsy B cell ALL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?4/18/4390\" title=\"picture 3\">",
"      BM aspirate B cell ALL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?29/25/30103\" title=\"picture 4\">",
"      TdT staining ALL",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/53/21337?source=related_link\">",
"      Classification of the hematopoietic neoplasms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/58/20393?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of acute myeloid leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/20/30023?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of precursor T cell acute lymphoblastic leukemia/lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/25/22938?source=related_link\">",
"      Cytogenetics in acute lymphoblastic leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/11/9400?source=related_link\">",
"      General principles of hematopoietic cell transplantation for acute lymphoblastic leukemia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/5/23642?source=related_link\">",
"      Induction therapy for Philadelphia chromosome negative acute lymphoblastic leukemia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?15/15/15602?source=related_link\">",
"      Patient information: Acute lymphoblastic leukemia (ALL) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?17/34/17955?source=related_link\">",
"      Patient information: Acute lymphoblastic leukemia (ALL) treatment in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f25_25_26008="Alemtuzumab: Drug information";
var content_f25_25_26008=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Alemtuzumab: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?7/55/8053?source=see_link\">",
"    see \"Alemtuzumab: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block spa drugH1Div\" id=\"F14933039\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Special Alerts",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Campath&reg; Being Withdrawn From Market to be Relaunched as Lemtrada&trade;",
"     </span>",
"     <span class=\"collapsible-date\">",
"      August 2012",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       Sanofi is withdrawing its leukemia therapy Campath&reg; (alemtuzumab) from the U.S. market to prepare for a relaunch (under the name Lemtrada&trade;) at a lower dose to treat relapsing-remitting multiple sclerosis (MS). The withdrawal from the commercial market, designed to prevent the off-label use of Campath&reg; in the MS indication, will be effective September 4, 2012. After this date, Campath&reg; will remain accessible free of charge through the Campath&reg; Distribution Program for the treatment of B-cell chronic lymphocytic leukemia and select unlabeled uses. Regulatory applications for Lemtrada&trade; were filed with the U.S. Food and Drug Administration (FDA) in June and, if approved, the product could be launched in 2013.",
"      </p>",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       For additional information, please refer to file://www.campath.com.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708604\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F12807845\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Campath&reg; [DSC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F4663229\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      MabCampath&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F131201\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antineoplastic Agent, Monoclonal Antibody;",
"     </li>",
"     <li>",
"      Monoclonal Antibody",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F131179\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     <b>",
"      Dose escalation is required;",
"     </b>",
"     usually accomplished in 3-7 days. Single doses &gt;30 mg or cumulative doses &gt;90 mg/week increase the incidence of pancytopenia. Pretreatment (with acetaminophen 500-1000 mg and diphenhydramine 50 mg) is recommended prior to the first dose, with dose escalations, and as clinically indicated; I.V. hydrocortisone may be used for severe infusion-related reactions. Reinitiate with gradual dose escalation if treatment is withheld &ge;7 days.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Dose escalation:",
"     </b>",
"     Initial: 3 mg daily beginning on day 1; if tolerated (infusion reaction &le;grade 2), increase to 10 mg daily; if tolerated (infusion reaction &le;grade 2), may increase to maintenance of 30 mg per dose 3 times weekly if required for maintenance dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      B-cell chronic lymphocytic leukemia (B-CLL):",
"     </b>",
"     I.V.: Gradually escalate  to a maintenance of 30 mg per dose 3 times weekly on alternate days for a total duration of therapy of up to 12 weeks (Hillmen, 2007; Keating, 2002)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      B-CLL (unlabeled route):",
"     </b>",
"     SubQ: Initial: 3 mg on day 1; if tolerated 10 mg on day 3; if tolerated increase to 30 mg on day 5; maintenance: 30 mg per dose 3 times weekly for a maximum of 18 weeks (Lundin, 2002)",
"     <b>",
"      or",
"     </b>",
"     3 mg on day 1; if tolerated 10 mg on day 2; if tolerated 30 mg on day 3, followed by 30 mg per dose 3 times weekly for 4-12 weeks (Stilgenbauer, 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Autoimmune cytopenias, CLL-induced, refractory (unlabeled use):",
"     </b>",
"     I.V., SubQ: Gradually escalate to a maintenance of 10-30 mg per dose 3 times weekly for 4-12 weeks (Karlsson, 2007; Osterborg, 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Graft versus host disease (GVHD), acute, steroid refractory, treatment (unlabeled use):",
"     </b>",
"     I.V.: 10 mg daily for 5 consecutive days, then 10 mg weekly on days 8, 15, and 22 if CR not achieved (Martinez, 2009)",
"     <b>",
"      or",
"     </b>",
"     10 mg weekly until symptom resolution (Schnitzler, 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Multiple sclerosis, relapsed-remitting (RRMS; unlabeled use):",
"     </b>",
"     I.V.: 12 mg daily for 5 consecutive days, followed 12 months later by 12 mg daily for 3 consecutive days; may receive an additional 12 mg daily for 3 consecutive days 12 months later (CAMMS223, 2008; Coles, 2012)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Renal transplant, induction (unlabeled use):",
"     </b>",
"     I.V.: 30 mg as a single dose at the time of transplant (Hanaway, 2011)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Stem cell transplant (allogeneic) conditioning regimen (unlabeled use):",
"     </b>",
"     I.V.: 20 mg daily for 5 days (in combination with fludarabine and melphalan) beginning 8 days prior to transplant (Mead, 2010)",
"     <b>",
"      or",
"     </b>",
"     beginning 7 days prior to transplant (Van Besien, 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      T-cell prolymphocytic leukemia (T-PLL; unlabeled use):",
"     </b>",
"     I.V.: Initial test dose 3 mg or 10 mg, followed by dose escalation to 30 mg per dose 3 times weekly as tolerated until maximum response (Dearden, 2001)",
"     <b>",
"      or",
"     </b>",
"     Initial dose: 3 mg day 1, if tolerated increase to 10 mg day 2, if tolerated increase to 30 mg on day 3 (days 1, 2, and 3 are consecutive days), followed by 30 mg per dose every Monday, Wednesday, Friday for a total of 4-12 weeks (Keating, 2002)",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F131180\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F15671340\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in the manufacturer&rsquo;s labeling (has not been studied).",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15671341\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in the manufacturer&rsquo;s labeling (has not been studied).",
"    </p>",
"   </div>",
"   <div class=\"block dot drugH1Div\" id=\"F131202\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adjustment for Toxicity",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Dosage adjustment for nonhematologic toxicity:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     If treatment is withheld &ge;7 days, reinitiate at 3 mg with re-escalation to 10 mg and then 30 mg.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Grade 3 or 4 infusion reaction: Withhold infusion",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Serious infection or other serious adverse reaction: Withhold alemtuzumab until resolution",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Autoimmune anemia or autoimmune thrombocytopenia: Discontinue alemtuzumab",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Dosage adjustment for hematologic toxicity (severe neutropenia or thrombocytopenia, not autoimmune):",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     If treatment is withheld &ge;7 days, reinitiate at 3 mg with re-escalation to 10 mg and then 30 mg.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     ANC &lt;250/mm",
"     <sup>",
"      3",
"     </sup>",
"     and/or platelet count &le;25,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     :",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     First occurrence: Withhold treatment; resume at 30 mg per dose when ANC &ge;500/mm",
"     <sup>",
"      3",
"     </sup>",
"     and platelet count &ge;50,000/mm",
"     <sup>",
"      3",
"     </sup>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Second occurrence: Withhold treatment; resume at 10 mg per dose when ANC &ge;500/mm",
"     <sup>",
"      3",
"     </sup>",
"     and platelet count &ge;50,000/mm",
"     <sup>",
"      3",
"     </sup>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Third occurrence: Discontinue alemtuzumab.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Patients with a baseline ANC &le;250/mm",
"     <sup>",
"      3",
"     </sup>",
"     and/or a baseline platelet count &le;25,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     at initiation of therapy: If ANC and/or platelet counts decrease to &le;50% of the baseline value:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     First occurrence: Withhold treatment; resume at 30 mg per dose upon return to baseline values",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Second occurrence: Withhold treatment; resume at 10 mg per dose upon return to baseline values",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Third occurrence: Discontinue  alemtuzumab.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F131158\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution [preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Campath&reg;: 30 mg/mL (1 mL [DSC]) [contains edetate disodium, polysorbate 80]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F131144\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block accres drugH1Div\" id=\"F14944659\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Prescribing and Access Restrictions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     As of September 4, 2012, alemtuzumab (Campath&reg;) is no longer commercially available in the United States (or Europe); a restricted distribution program will allow access (free of charge) for appropriate patients. Information on necessary documentation and requirements is available at Campath Distribution Program (1-877-422-6728) or Genzyme Medical Information (1-800-745-4447, option 2).",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F131160\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer by I.V. infusion over 2 hours. Premedicate with diphenhydramine 50 mg and acetaminophen 500-1000 mg 30 minutes before each infusion. Hydrocortisone (I.V.) has been effective in decreasing severe infusion-related events. Start anti-infective prophylaxis. Other drugs should not be added to or simultaneously infused through the same I.V. line. Do not give I.V. push or bolus. Compatible in polyvinylchloride (PVC) or polyethylene lined administration sets.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     SubQ (unlabeled route): SubQ administration has been studied (Lundin, 2002; Stilgenbauer, 2009); an increased rate of injection site reactions has been observed, with only rare incidences of chills or infusion-like reactions typically observed with I.V. infusion. A longer dose escalation time (1-2 weeks) may be needed due to injection site reactions (Lundin, 2002). Premedicate with diphenhydramine 50 mg and acetaminophen 500-1000 mg 30 minutes before dose. The subQ route should",
"     <b>",
"      NOT",
"     </b>",
"     be used for the treatment of T-PLL (Deardon, 2011).",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F131208\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     W, NS. Medications should not be added to the solution or simultaneously infused through the same I.V. line.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F131159\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Campath&reg;: Treatment (as a single agent) of B-cell chronic lymphocytic leukemia (B-CLL)",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F131197\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Conditioning regimen in stem cell transplant; prophylaxis of graft-versus-host disease (GVHD); treatment of steroid-refractory GVHD; treatment of T-cell prolymphocytic leukemia; treatment of autoimmune hemolytic anemia (CLL-induced); immunosuppressant in solid organ transplant (induction and steroid-refractory rejection); treatment of relapsed-remitting multiple sclerosis",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F3401548\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F131199\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse reactions reported with Campath&reg;:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Hypotension (16%), hypertension (14%), dysrhythmia (14%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Fever (69%), chills (53%), headache (14%), dysthesias, fatigue",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Urticaria (16%), rash (13%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, anorexia, mucositis, nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Lymphopenia (grades 3/4: 97%), neutropenia (77%; grade 3/4: 42% to 64% [median onset: 31 days, median duration: 28-37 days]), anemia (76%; grade 3/4: 12% to 38% [median onset: 31 days, median duration 8 days]), thrombocytopenia (71%; grade 3/4: 13% to 52% [median onset: 9 days; median duration: 14-21 days])",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Local: Injection site reaction (SubQ administration: 90%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Musculoskeletal pain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Dyspnea (14%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Infection (50% to 74%; grades 3/4: 5% to 21%; includes bacterial, fungal, protozoan, viral), CMV viremia (55%), infusion reactions (grades 3/4: 10% to 35%), CMV infection (16%), sepsis (grades 3/4/5: 3% to 10%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Tachycardia (10%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Insomnia (10%), anxiety (8%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Erythema (4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Diarrhea (10%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Neutropenic fever (grades 3/4: 5% to 10%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Tremor (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Bronchospasm",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Acute respiratory distress syndrome,  anaphylactoid shock, angioedema, aplastic anemia, arrhythmia, bleeding, bone marrow aplasia, bone marrow hypoplasia, bruising, cardiac arrest, cardiac insufficiency, cardiomyopathy, chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), ejection fraction decreased, Epstein-Barr virus, Epstein-Barr virus-associated lymphoproliferative disorder, Goodpasture&rsquo;s syndrome, Graves' disease, Guillain-Barr&eacute; syndrome, hemolytic anemia, HF, idiopathic thrombocytopenic purpura (ITP), MI, optic neuropathy, pallor, petechia,",
"     <i>",
"      Pneumocystis jirovecii",
"     </i>",
"     pneumonia (PCP), progressive multifocal leukoencephalopathy (PML), pulmonary infiltrates, pure red cell aplasia, purpura, respiratory arrest, serum sickness, syncope, transfusion-associated GVHD, tumor lysis syndrome, virus reactivation (latent), weakness",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F131163\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no contraindications listed in the manufacturer's labeling",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F131148\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bone marrow suppression:",
"     <b>",
"      [U.S. Boxed Warning]: Serious and fatal cytopenias (including pancytopenia, bone marrow hypoplasia, autoimmune hemolytic anemia, and autoimmune idiopathic thrombocytopenia) have occurred. Single doses &gt;30 mg or cumulative weekly doses &gt;90 mg are associated with an increased incidence of pancytopenia.",
"     </b>",
"     Severe prolonged myelosuppression, hemolytic anemia, pure red cell aplasia,  bone marrow aplasia, and bone marrow hypoplasia have also been reported with use at the normal dose for the treatment of B-CLL. Discontinue for serious hematologic or other serious toxicity (except lymphopenia) until the event resolves. Permanently discontinue if autoimmune anemia or autoimmune thrombocytopenia occurs. Patients receiving blood products should only receive irradiated blood products due to the potential for transfusion-associated GVHD during lymphopenia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Immune thrombocytopenia: Immune thrombocytopenia (ITP) or idiopathic thrombocytopenic purpura has been reported in 6 patients receiving alemtuzumab for the treatment of relapsed-remitting multiple sclerosis; some cases were severe, with 1 fatality (Cuker, 2011). The median time to onset was 24.5 months from initial alemtuzumab exposure and 10.5 months from the last dose. In 4 cases, ITP was treated with standard therapy and responses were observed within 1 week. After the initial case was discovered, patients were instructed to report abnormal bleeding, bruising or petechial rash and blood counts were monitored monthly.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Infections:",
"     <b>",
"      [U.S. Boxed Warning]: Serious and potentially fatal infections (bacterial, viral, fungal, and protozoan) have been reported. Administer prophylactic medications against PCP pneumonia and herpes viral infections during treatment",
"     </b>",
"     and for at least 2 months following last dose or until CD4",
"     <sup>",
"      +",
"     </sup>",
"     counts are &ge;200 cells/&mu;L (whichever is later). Severe and prolonged lymphopenia may occur; CD4",
"     <sup>",
"      +",
"     </sup>",
"     counts usually return to &ge;200 cells/&mu;L within 2-6 months; however, CD4",
"     <sup>",
"      +",
"     </sup>",
"     and CD8",
"     <sup>",
"      +",
"     </sup>",
"     lymphocyte counts may not return to baseline levels for more than 1 year. Withhold treatment during serious infections; may be reinitiated upon resolution of infection. Monitor for CMV infection (during and for at least 2 months after completion of therapy); initiate appropriate antiviral treatment and withhold alemtuzumab for CMV infection or confirmed CMV viremia (withhold alemtuzumab during CMV antiviral treatment).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Infusion reactions:",
"     <b>",
"      [U.S. Boxed Warning]: Serious and potentially fatal infusion-related reactions may occur; monitor for infusion reaction; withhold treatment for grade 3 or 4 infusion reactions. Gradual escalation to the recommended maintenance dose is required at initiation and with treatment interruptions (for &ge;7 days) to minimize infusion-related reactions.",
"     </b>",
"     Infusion reaction symptoms may include acute respiratory distress syndrome, anaphylactic shock, angioedema, bronchospasm, cardiac arrest, cardiac arrhythmias, chills, dyspnea, fever, hypotension, myocardial infarction, pulmonary infiltrates, rash, rigors, syncope, or urticaria. The incidence of infusion reaction is highest during the first week of treatment. Premedicate with acetaminophen and an oral antihistamine. Medications for the treatment of reactions should be available for immediate use. Use caution and carefully monitor blood pressure in patients with ischemic heart disease and patients on antihypertensive therapy. Reinitiate with gradual dose escalation if treatment is withheld &ge;7 days.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Immunizations: Patients should not be immunized with live, viral vaccines during or recently after treatment. The ability to respond to any vaccine following therapy is unknown.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298700\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F2139162\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Abciximab: May enhance the potential for allergic or hypersensitivity reactions to Monoclonal Antibodies. Also may cause thrombocytopenia or diminished therapeutic effects.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Immunosuppressants may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Belimumab: Monoclonal Antibodies may enhance the adverse/toxic effect of Belimumab.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for agranulocytosis may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Coccidioidin Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioidin Skin Test.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Echinacea: May diminish the therapeutic effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or other non-disease modifying antirheumatic drugs (non-DMARDs) is permitted, and this warning seems to particularly focused on more potent immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Vaccinial infections may develop. Immunosuppressants may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F4151275\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Herb/Nutraceutical: Echinacea may diminish the therapeutic effect of alemtuzumab.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F131154\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F131165\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Human IgG is known to cross the placental barrier; therefore, alemtuzumab may also cross the barrier and cause fetal B- and T-lymphocyte depletion. Use during pregnancy only if the benefit to the mother outweighs the potential risk to the fetus. Effective contraception is recommended during and for at least 6 months after treatment for women of childbearing potential and men of reproductive potential.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F131186\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F131166\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Human IgG is excreted in breast milk; therefore, alemtuzumab may also be excreted in milk. Due to the potential for serious adverse reactions in the nursing infant, the decision to discontinue alemtuzumab or to discontinue breast-feeding should take into account the importance of treatment to the mother and the half-life of alemtuzumab.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F131156\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Vital signs; carefully monitor BP especially in patients with ischemic heart disease or on antihypertensive medications; CBC with differential and platelets (weekly, more frequent if worsening); signs and symptoms of infection; CD4+ lymphocyte counts (after treatment until recovery); CMV antigen (routinely during and for 2 months after treatment). Monitor closely for infusion reactions (including hypotension, rigors, fever, shortness of breath, bronchospasm, chills, and/or rash); consider TSH at baseline and then every 2-3 months during alemtuzumab treatment (Hamnvik, 2011).",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F131167\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Campath (AR, PE, UY);",
"     </li>",
"     <li>",
"      MabCampath (AT, AU, BE, BG, CH, CO, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HK, HN, ID, IE, IL, IT, KP, MT, MY, NL, NO, NZ, PL, PT, RU, SE, SG, SK, TH, TR, ZA)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F131147\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Binds to CD52, a nonmodulating antigen present on the surface of B and T lymphocytes, a majority of monocytes, macrophages, NK cells, and a subpopulation of granulocytes. After binding to CD52",
"     <sup>",
"      +",
"     </sup>",
"     cells, an antibody-dependent lysis of malignant cells occurs.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F131162\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : I.V.: 0.18 L/kg (range: 0.1-0.4 L/kg)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Clearance decreases with repeated dosing (due to loss of CD52 receptors in periphery), resulting in a sevenfold increase in AUC after 12 weeks of therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: I.V.: 11 hours (following first 30 mg dose; range: 2-32 hours); 6 days (following the last 30 mg dose; range: 1-14 days)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Basu A, Ramkumar M, Tan HP, et al, &ldquo;Reversal of Acute Cellular Rejection After Renal Transplantation With Campath-1H,&rdquo;",
"      <i>",
"       Transplant Proc",
"      </i>",
"      , 2005, 37(2):923-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/25/26008/abstract-text/15848576/pubmed\" id=\"15848576\" target=\"_blank\">",
"        15848576",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Berger JR and Houff S, &ldquo;Opportunistic Infections and Other Risks With Newer Multiple Sclerosis Therapies,&rdquo;",
"      <i>",
"       Ann Neurol",
"      </i>",
"      , 2009, 65(4):367-77.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/25/26008/abstract-text/19399841/pubmed\" id=\"19399841\" target=\"_blank\">",
"        19399841",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      CAMMS223 Trial Investigators: Coles AJ, Compston DA, Selmaj KW, et al, &ldquo;Alemtuzumab vs Interferon Beta-1a in Early Multiple \Sclerosis,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2008, 359(17):1786-801.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/25/26008/abstract-text/18946064/pubmed\" id=\"18946064\" target=\"_blank\">",
"        18946064",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ciancio G, Burke GW, Gaynor JJ, et al, &ldquo;A Randomized Trial of Three Renal Transplant Induction Antibodies: Early Comparison of Tacrolimus, Mycophenolate Mofetil, and Steroid Dosing, and Newer Immune-Monitoring,&rdquo;",
"      <i>",
"       Transplantation",
"      </i>",
"      , 2005, 80(4):457-65.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/25/26008/abstract-text/16123718/pubmed\" id=\"16123718\" target=\"_blank\">",
"        16123718",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Coles AJ, Fox E, Vladic A, et al, &ldquo;Alemtuzumab More Effective Than Interferon &Beta;-1a at 5-Year Follow-Up of CAMMS223 Clinical Trial,&rdquo; Neurology, 2012, 78(14):1069-78.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/25/26008/abstract-text/22442431/pubmed\" id=\"22442431\" target=\"_blank\">",
"        22442431",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cuker A, Coles AJ, Sullivan H, et al, &ldquo;A Distinctive Form of Immune Thrombocytopenia in a Phase 2 Study of Alemtuzumab for the Treatment of Relapsing-Remitting Multiple Sclerosis,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 2011, 118(24):6299-305.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/25/26008/abstract-text/21960587/pubmed\" id=\"21960587\" target=\"_blank\">",
"        21960587",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dearden CE, Johnson R, Pettengell R, et al, &ldquo;Guidelines for the Management of Mature T-Cell and NK-Cell Neoplasms (Excluding Cutaneous T-Cell Lymphoma),&rdquo;",
"      <i>",
"       Br J Haematol",
"      </i>",
"      , 2011, 153(4):451-85.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/25/26008/abstract-text/21480860/pubmed\" id=\"21480860\" target=\"_blank\">",
"        21480860",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dearden CE, Matutes E, Cazin B, et al, &ldquo;High Remission Rate in T-Cell Prolymphocytic Leukemia With CAMPATH-1H,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 2001, 98(6):1721-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/25/26008/abstract-text/11535503/pubmed\" id=\"11535503\" target=\"_blank\">",
"        11535503",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Enblad G, Hagberg H, Erlanson M, et al, &ldquo;A Pilot Study of Alemtuzumab (Anti-CD52 Monoclonal Antibody) Therapy for Patients With Relapsed or Chemotherapy-Refractory Peripheral T-cell Lymphomas,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 2003, 103(8):2920-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/25/26008/abstract-text/15070664/pubmed\" id=\"15070664\" target=\"_blank\">",
"        15070664",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Farney A, Sundberg A, Moore P, et al, &ldquo;A Randomized Trial of Alemtuzumab vs Anti-Thymocyte Globulin Induction in Renal and Pancreas Transplantation,&rdquo;",
"      <i>",
"       Clin Transplant",
"      </i>",
"      , 2008, 22(1):41-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/25/26008/abstract-text/18217904/pubmed\" id=\"18217904\" target=\"_blank\">",
"        18217904",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ferrajoli A, O'Brien SM, Cortes JE, et al, &ldquo;Phase II Study of Alemtuzumab in Chronic Lymphoproliferative Disorders,&rdquo;",
"      <i>",
"       Cancer",
"      </i>",
"      , 2003, 98(4):773-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/25/26008/abstract-text/12910522/pubmed\" id=\"12910522\" target=\"_blank\">",
"        12910522",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hale G, Rebello P, Brettman LR, et al, &ldquo;Blood Concentrations of Alemtuzumab and Antiglobulin Responses in Patients With Chronic Lymphocytic Leukemia Following Intravenous or Subcutaneous Routes of Administration,",
"      <i>",
"       Blood",
"      </i>",
"      , 2004, 104(4):948-55.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/25/26008/abstract-text/15090452/pubmed\" id=\"15090452\" target=\"_blank\">",
"        15090452",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hamnvik OP, Larsen PR, and Marqusee E, &ldquo;Thyroid Dysfunction From Antineoplastic Agents,&rdquo;",
"      <i>",
"       J Natl Cancer Inst",
"      </i>",
"      , 2011, 103(21):1572-87.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/25/26008/abstract-text/22010182/pubmed\" id=\"22010182\" target=\"_blank\">",
"        22010182",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hanaway MJ, Woodle ES, Mulgaonkar S, et al, &ldquo;Alemtuzumab Induction In Renal Transplantation,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2011, 364(20):1909-19.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/25/26008/abstract-text/21591943/pubmed\" id=\"21591943\" target=\"_blank\">",
"        21591943",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hillmen P, Skotnicki A, Robak T, et al, &ldquo;Alemtuzumab Compared With Chlorambucil as First-Line Therapy for Chronic Lymphocytic Leukemia,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2007, 25(35):5616-23.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/25/26008/abstract-text/17984186/pubmed\" id=\"17984186\" target=\"_blank\">",
"        17984186",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kanda J, Lopez RD, and Rizzieri DA, \"Alemtuzumab for the Prevention and Treatment of Graft-Versus-Host Disease,\"",
"      <i>",
"       Int J Hematol",
"      </i>",
"      , 2011, 93(5):586-93.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/25/26008/abstract-text/21369856/pubmed\" id=\"21369856\" target=\"_blank\">",
"        21369856",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Karlsson C, Hansson L, Celsing F, et al, &ldquo;Treatment of Severe Refractory Autoimmune Hemolytic Anemia in B-Cell Chronic Lymphocytic Leukemia With Alemtuzumab (Humanized CD52 Monoclonal Antibody),&rdquo;",
"      <i>",
"       Leukemia",
"      </i>",
"      , 2007, 21(3):511-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/25/26008/abstract-text/17215854/pubmed\" id=\"17215854\" target=\"_blank\">",
"        17215854",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Keating MJ, Cazin B, Coutr&eacute; S, et al, &ldquo;Campath-1H Treatment of T-Cell Prolymphocytic Leukemia in Patients for Whom at Least One Prior Chemotherapy Regimen Has Failed,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2002, 20(1):205-13.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/25/26008/abstract-text/11773171/pubmed\" id=\"11773171\" target=\"_blank\">",
"        11773171",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Keating MJ, Flinn I, Jain V, et al, &ldquo;Therapeutic Role of Alemtuzumab (Campath-1H) in Patients Who Have Failed Fludarabine: Results of a Large International Study,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 2002, 99(10):3554-61.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/25/26008/abstract-text/11986207/pubmed\" id=\"11986207\" target=\"_blank\">",
"        11986207",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kennedy B and Hillmen P, &ldquo;Immunological Effects and Safe Administration of Alemtuzumab (MabCampath) in Advanced B-cLL,&rdquo;",
"      <i>",
"       Med Oncol",
"      </i>",
"      , 2002, 19(Suppl):49-55.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lepretre S, Aurran T, Mah&eacute; B, et al, &ldquo;Excess Mortality After Treatment With Fludarabine and Cyclophosphamide in Combination With Alemtuzumab in Previously Untreated Patients With Chronic Lymphocytic Leukemia in a Randomized Phase 3 Trial,\"",
"      <i>",
"       Blood",
"      </i>",
"      , 2012, 119(22):5104-10.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/25/26008/abstract-text/22337714/pubmed\" id=\"22337714\" target=\"_blank\">",
"        22337714",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lundin J, Hagberg H, Repp R, et al, &ldquo;Phase 2 Study of Alemtuzumab (Anti-CD52 Monoclonal Antibody) in Patients With Advanced Mycosis Fungoides/S&eacute;zary Syndrome,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 2003, 101(11):4267-72.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/25/26008/abstract-text/12543862/pubmed\" id=\"12543862\" target=\"_blank\">",
"        12543862",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lundin J, Kimby E, Bjorkholm M, et al, &ldquo;Phase II Trial of Subcutaneous Anti-CD52 Monoclonal Antibody Alemtuzumab (Campath-1H) as First-Line Treatment for Patients With B-Cell Chronic Lymphocytic Leukemia (B-CLL),&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 2002, 100(3):768-73.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/25/26008/abstract-text/12130484/pubmed\" id=\"12130484\" target=\"_blank\">",
"        12130484",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lundin J, Osterborg A, Brittinger G, et al, &ldquo;CAMPATH-1H Monoclonal Antibody in Therapy for Previously Treated Low-Grade Non-Hodgkin's Lymphomas: A Phase II Multicenter Study. European Study Group of CAMPATH-1H Treatment in Low-Grade Non-Hodgkin's Lymphoma,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 1998, 16(10):3257-63.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/25/26008/abstract-text/9779699/pubmed\" id=\"9779699\" target=\"_blank\">",
"        9779699",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Magliocca JF and Knechtle SJ, &ldquo;The Evolving Role of Alemtuzumab (Campath-1H) for Immunosuppressive Therapy in Organ Transplantation,&rdquo;",
"      <i>",
"       Transpl Int",
"      </i>",
"      , 2006, 19(9):705-14.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/25/26008/abstract-text/16918530/pubmed\" id=\"16918530\" target=\"_blank\">",
"        16918530",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Marcos A, Eghtesad B, Fung JJ, et al, &ldquo;Use of Alemtuzumab and Tacrolimus Monotherapy for Cadaveric Liver Transplantation: With Particular Reference to Hepatitis C Virus,&rdquo;",
"      <i>",
"       Transplantation",
"      </i>",
"      , 2004, 78(7):966-71.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/25/26008/abstract-text/15480160/pubmed\" id=\"15480160\" target=\"_blank\">",
"        15480160",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Margreiter R, Klempnauer J, Neuhaus P, et al, &ldquo;Alemtuzumab (Campath-1H) and Tacrolimus Monotherapy After Renal Transplantation: Results of a Prospective Randomized Trial,&rdquo;",
"      <i>",
"       Am J Transplant",
"      </i>",
"      , 2008, 8(7):1480-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/25/26008/abstract-text/18510632/pubmed\" id=\"18510632\" target=\"_blank\">",
"        18510632",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Martinez C, Solano C, Ferr&aacute; C, et al, &ldquo;Alemtuzumab as Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease: Results From a Phase II Study,&rdquo;",
"      <i>",
"       Biol Blood Marrow Transplant",
"      </i>",
"      , 2009, 15(5):639-42.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/25/26008/abstract-text/19361757/pubmed\" id=\"19361757\" target=\"_blank\">",
"        19361757",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mead AJ, Thomson KJ, Morris EC, et al, &ldquo;HLA-Mismatched Unrelated Donors are a Viable Alternate Graft Source for Allogeneic Transplantation Following Alemtuzumab-Based Reduced-Intensity Conditioning,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 2010, 115(25):5147-53.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/25/26008/abstract-text/20371745/pubmed\" id=\"20371745\" target=\"_blank\">",
"        20371745",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Osterborg A, Dyer MJ, Bunjes D, et al, &ldquo;Phase II Multicenter Study of Human CD52 Antibody in Previously Treated Chronic Lymphocytic Leukemia. European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 1997, 15(4):1567-74.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/25/26008/abstract-text/9193354/pubmed\" id=\"9193354\" target=\"_blank\">",
"        9193354",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Osterborg A, Fassas AS, Anagnostopoulos A, et al, &ldquo;Humanifed CD52 Monoclonal Antibody Campath-1H as First-Line Treatment in Chronic Lymphocytic Leukaemia,&rdquo;",
"      <i>",
"       Br J Haematol",
"      </i>",
"      , 1996, 93(1):151-3.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/25/26008/abstract-text/8611450/pubmed\" id=\"8611450\" target=\"_blank\">",
"        8611450",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Osterborg A, Karlsson C, and Lundin J, &ldquo;Alemtuzumab to Treat Refractory Autoimmune Hemolytic Anemia or Thrombocytopenia in Chronic Lymphocytic Leukemia,&rdquo;",
"      <i>",
"       Curr Hematol Malig Rep",
"      </i>",
"      , 2009, 4(1):47-53.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/25/26008/abstract-text/20425438/pubmed\" id=\"20425438\" target=\"_blank\">",
"        20425438",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pawson R, Dyer MJ, Barge R, et al, &ldquo;Treatment of T-Cell Prolymphocytic Leukemia With Human CD52 Antibody,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 1997, 15(7):2667-72.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/25/26008/abstract-text/9215839/pubmed\" id=\"9215839\" target=\"_blank\">",
"        9215839",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rai KR, Freter CE, Mercier RJ, et al, &ldquo;Alemtuzumab in Previously Treated Chronic Lymphocytic Leukemia Patients Who Also Had Received Fludarabine,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2002, 20(18):3891-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/25/26008/abstract-text/12228210/pubmed\" id=\"12228210\" target=\"_blank\">",
"        12228210",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Scheinberg P, Nunez O, Weinstein B, et al, &ldquo;Activity of Alemtuzumab Monotherapy in Treatment-Naive, Relapsed, and Refractory Severe Acquired Aplastic Anemia,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 2012, 119(2):345-54.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/25/26008/abstract-text/22067384/pubmed\" id=\"22067384\" target=\"_blank\">",
"        22067384",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Schnitzler M, Hasskerl J, Egger M, et al, &ldquo;Successful Treatment of Severe Acute Intestinal Graft-Versus-Host Resistant to Systemic and Topical Steroids With Alemtuzumab,&rdquo;",
"      <i>",
"       Biol Blood Marrow Transplant",
"      </i>",
"      , 2009, 15(8):910-18.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/25/26008/abstract-text/19589480/pubmed\" id=\"19589480\" target=\"_blank\">",
"        19589480",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Schweighofer CD, Ritgen M, Eichhorst BF, et al, &ldquo;Consolidation With Alemtuzumab Improves Progression-Free Survival in Patients With Chronic Lymphocytic Leukaemia (CLL) in First Remission: Long-Term Follow-Up of a Randomized Phase III Trial of the German CLL Study Group (GCLLSG),&rdquo;",
"      <i>",
"       Br J Haematol",
"      </i>",
"      , 2009, 144(1):95-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/25/26008/abstract-text/19016732/pubmed\" id=\"19016732\" target=\"_blank\">",
"        19016732",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Stilgenbauer S, Zenz T, Winkler D, et al, &ldquo;Subcutaneous Alemtuzumab in Fludarabine-Refractory Chronic Lymphocytic Leukemia: Clinical Results and Prognostic Marker Analyses from the CLL2H Study of the German Chronic Lymphocytic Leukemia Study Group,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2009, 27(24):3994-4001.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/25/26008/abstract-text/19597025/pubmed\" id=\"19597025\" target=\"_blank\">",
"        19597025",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Treon SP, Soumerai JD, Hunter ZR, et al, &ldquo;Long-Term Follow-Up of Symptomatic Patients With Lymphoplasmacytic Lymphoma/Waldenstr&ouml;m Macroglobulinemia Treated With the Anti-CD52 Monoclonal Antibody Alemtuzumab,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 2011, 118(2):276-81.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/25/26008/abstract-text/21566092/pubmed\" id=\"21566092\" target=\"_blank\">",
"        21566092",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      van Besien K, Artz A, Smith S, et al, &ldquo;Fludarabine, Melphalan, and Alemtuzumab Conditioning in Adults With Standard-Risk Advanced Acute Myeloid Leukemia and Myelodysplastic Syndrome,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2005, 23(24):5728-38.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/25/26008/abstract-text/16009946/pubmed\" id=\"16009946\" target=\"_blank\">",
"        16009946",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      van Besien K, Kunavakkam R, Rondon G, et al, &ldquo;Fludarabine-Melphalan Conditioning for AML and MDS: Alemtuzumab Reduces Acute and Chronic GVHD Without Affecting Long-term Outcomes,&rdquo;",
"      <i>",
"       Biol Blood Marrow Transplant",
"      </i>",
"      , 2009, 15(5):610-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/25/26008/abstract-text/19361753/pubmed\" id=\"19361753\" target=\"_blank\">",
"        19361753",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Vo AA, Wechsler EA, Wang J, et al, &ldquo;Analysis of Subcutaneous (SQ) Alemtuzumab Induction Therapy in Highly Sensitized Patients Desensitized With  IVIG and Rituximab,&rdquo;",
"      <i>",
"       Am J Transplant",
"      </i>",
"      , 2008, 8(1):144-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/25/26008/abstract-text/17973966/pubmed\" id=\"17973966\" target=\"_blank\">",
"        17973966",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Willis F, Marsh JC, Bevan DH, et al, &ldquo;The Effect of Treatment With Campath-1H in Patients With Autoimmune Cytopenias,&rdquo;",
"      <i>",
"       Br J Haematol",
"      </i>",
"      , 2001, 114(4):891-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/25/26008/abstract-text/11564082/pubmed\" id=\"11564082\" target=\"_blank\">",
"        11564082",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wolff D, Schleuning M, von Harsdorf S, et al, &ldquo;Consensus Conference on Clinical Practice in Chronic GVHD: Second-Line Treatment of Chronic Graft-Versus-Host Disease,&rdquo;",
"      <i>",
"       Biol Blood Marrow Transplant",
"      </i>",
"      , 2011, 17(1):1-17.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/25/26008/abstract-text/20685255/pubmed\" id=\"20685255\" target=\"_blank\">",
"        20685255",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8725 Version 45.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-109.224.62.197-C12E3FDE9F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_25_26008=[""].join("\n");
var outline_f25_25_26008=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14933039\">",
"      Special Alerts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708604\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12807845\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4663229\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131201\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131179\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131180\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15671340\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15671341\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131202\">",
"      Dosing: Adjustment for Toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131158\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131144\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14944659\">",
"      Prescribing and Access Restrictions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131160\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131208\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131159\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131197\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3401548\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131199\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131163\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131148\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298700\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2139162\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4151275\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131154\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131165\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131186\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131166\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131156\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131167\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131147\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131162\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8725\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8725|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?7/55/8053?source=related_link\">",
"      Alemtuzumab: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f25_25_26009="Hepatitis B virus reactivation associated with immunosuppression";
var content_f25_25_26009=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Hepatitis B virus reactivation associated with immunosuppression",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/25/26009/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/25/26009/contributors\">",
"     Anna SF Lok, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/25/26009/contributors\">",
"     Peter A L Bonis, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/25/26009/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/25/26009/contributors\">",
"     Rafael Esteban, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/25/26009/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/25/26009/contributors\">",
"     Shilpa Grover, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?25/25/26009/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 5, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The natural course of hepatitis B virus (HBV) infection is determined by the interplay between virus replication and the host's immune response. HBV persists in the body even after serological recovery from acute hepatitis B. Thus, individuals who have been exposed to HBV are at risk for reactivation of infection (which may result in an increase in serum aminotransferases or a flare) when the immune response is suppressed [",
"    <a class=\"abstract\" href=\"UTD.htm?25/25/26009/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An HBV flare refers to an abrupt increase in serum aminotransferase (AST or ALT) levels with or without symptoms of hepatitis in a patient with underlying chronic liver disease. It is often preceded by an increase in serum HBV DNA levels. Flares may represent a spontaneous intensification of the immune response against HBV (eg, around the time of HBeAg seroconversion), a \"rebound in immune response\" to HBV upon withdrawal of immunosuppressive therapy, or exposure to other causes of liver injury such as alcohol, drugs, or other hepatitis viruses.",
"   </p>",
"   <p>",
"    Hepatitis flares can also occur in liver diseases other than hepatitis B, such as during tapering of immunosuppressive therapy in patients with autoimmune hepatitis. Hepatitis flares are more common in patients with chronic HBV infection than those with chronic HCV infection. The reason for the difference is not clear but may be related to a more central role of the immune response on disease activity in hepatitis B.",
"   </p>",
"   <p>",
"    This topic review will summarize clinical issues related to hepatitis B flares, focusing on flares associated with immunosuppressive therapy and an increasing body of evidence supporting a role for preventive antiviral treatment in high-risk patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS AND DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;An HBV flare is characterized by an abrupt elevation of the serum ALT level, although there is no consensus definition or diagnostic criterion. A proposed definition is an abrupt increase in serum ALT to &gt;5 times the upper limit of normal or &gt;3 times the baseline level, whichever was higher [",
"    <a class=\"abstract\" href=\"UTD.htm?25/25/26009/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most patients are asymptomatic, and flares are detected through regular monitoring. Because many flares are transient, the detection of hepatitis flares increases with more frequent monitoring.",
"   </p>",
"   <p>",
"    Some patients have symptoms of hepatitis (fatigue, anorexia, nausea) during a flare, and severe flares can be associated with jaundice, hepatic decompensation, and death. Severe outcomes are more likely when flares develop in patients who have underlying cirrhosis.",
"   </p>",
"   <p>",
"    Flares that are directly related to hepatitis B are usually preceded by an increase in serum HBV DNA levels. Because the increase in serum ALT levels lags behind the increase in HBV DNA levels, serum HBV DNA levels may be declining or undetectable when patients with flares are evaluated.",
"   </p>",
"   <p>",
"    Severe flares may be accompanied by an increase in the IgM anti-HBc titer, leading to misdiagnosis of acute hepatitis B in patients who are not previously known to be HBsAg positive. In addition to the clinical history, acute hepatitis B can be distinguished from a flare of chronic hepatitis B by higher titers of IgM anti-HBc and a lower HBV viral load [",
"    <a class=\"abstract\" href=\"UTD.htm?25/25/26009/abstract/3\">",
"     3",
"    </a>",
"    ]. Hepatitis flares can also be associated with an increase in alpha fetoprotein levels, raising concerns about the development of hepatocellular carcinoma; AFP levels &gt;5000",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?25/25/26009/abstract/4,5\">",
"     4,5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most hepatitis flares in patients with chronic HBV infection are related to perturbation in the balance between the immune response to HBV and HBV replication [",
"    <a class=\"abstract\" href=\"UTD.htm?25/25/26009/abstract/6\">",
"     6",
"    </a>",
"    ]. However, other causes of hepatic injury should also be sought, in particular, alcohol, drugs, and superinfection with other hepatitis viruses A, C, D, or E. In immunosuppressed patients, radiation toxicity, graft versus host disease, sinusoidal obstruction syndrome (hepatic veno-occlusive disease), acalculous cholecystitis, tumor infiltration, ischemia, other viruses such as CMV and herpes virus, and systemic infection should also be considered.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     SETTINGS IN WHICH FLARES HAVE BEEN DESCRIBED",
"    </span>",
"    &nbsp;&mdash;&nbsp;HBV flares have been described in a variety of settings (",
"    <a class=\"graphic graphic_table graphicRef86868 \" href=\"UTD.htm?14/52/15180\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/25/26009/abstract/7\">",
"     7",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      HIV infection, particularly after immune reconstitution",
"     </li>",
"     <li>",
"      Superinfection with other hepatitis viruses such as hepatitis A, C, D, or E",
"     </li>",
"     <li>",
"      Immune clearance phase of chronic HBV infection or HBeAg-positive chronic hepatitis. These flares are frequently but not invariably associated with spontaneous hepatitis B e antigen seroconversion. Some flares are associated with transient virus suppression without HBeAg clearance (abortive flares)",
"     </li>",
"     <li>",
"      Reactivation phase of chronic HBV infection or HBeAg-negative chronic hepatitis. Flares are usually associated with fluctuations in serum HBV DNA levels",
"     </li>",
"     <li>",
"      Interferon therapy (particularly in HBeAg-positive patients who undergo HBeAg seroconversion)",
"     </li>",
"     <li>",
"      Nucleoside and nucleotide therapy (when treatment is discontinued, in association with emergence of drug-resistance mutation or HBeAg seroconversion)",
"     </li>",
"     <li>",
"      Glucocorticoids (particularly upon abrupt withdrawal)",
"     </li>",
"     <li>",
"      Cancer chemotherapy",
"     </li>",
"     <li>",
"      Immunosuppressive therapy",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Immunosuppression",
"    </span>",
"    &nbsp;&mdash;&nbsp;HBV flares have been associated with immunosuppression. However, the precise relationship between the intensity or type of immunosuppression, viral and host characteristics, and the risk of reactivation are not well understood. Although most reports of hepatitis flares in association with immunosuppression are in the setting of cancer chemotherapy, any form of immunosuppressive therapy can theoretically lead to reactivation of HBV replication and a flare of hepatitis. The tumor response may be negatively impacted due to the need to interrupt or withhold cancer chemotherapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Cancer chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple reports have described HBV reactivation in patients who were undergoing chemotherapy or chemoradiation therapy for a variety of hematologic and solid tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?25/25/26009/abstract/8-26\">",
"     8-26",
"    </a>",
"    ]. As a general rule, the risk is greatest upon withdrawal of chemotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?25/25/26009/abstract/12,13,27-29\">",
"     12,13,27-29",
"    </a>",
"    ]. The risk has ranged from approximately 20 to 50 percent among HBsAg-positive carriers in various studies as illustrated by the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One study focused on 78 patients who were HBsAg positive prior to undergoing cancer chemotherapy for various malignancies [",
"      <a class=\"abstract\" href=\"UTD.htm?25/25/26009/abstract/18\">",
"       18",
"      </a>",
"      ]. Elevated serum aminotransferase levels developed in 34 patients (44 percent); the cause was considered to be due to HBV reactivation in 15 (19 percent). The risk was increased in men, with younger age, those who were HBeAg positive, and those with lymphoma; there was no association with pretreatment serum ALT, bilirubin, or HBV DNA. A later report from the same group identified use of anthracyclines as an additional risk factor [",
"      <a class=\"abstract\" href=\"UTD.htm?25/25/26009/abstract/19\">",
"       19",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Another report included 100 Chinese patients receiving induction chemotherapy for lymphoma [",
"      <a class=\"abstract\" href=\"UTD.htm?25/25/26009/abstract/12\">",
"       12",
"      </a>",
"      ]. Clinical hepatitis developed in 18 of 27 patients who were HBsAg positive and 10 of 72 who were HBsAg negative (67 versus 14 percent). Hepatitis could be attributed to exacerbation or reactivation of chronic hepatitis B in 13 HBsAg-positive patients compared with only two HBsAg-negative patients. Among the HBsAg-positive patients, reactivation of HBV was associated with the development of jaundice, nonfatal hepatic failure, and death in 22, 4, and 4 percent, respectively. Male sex was the only risk factor associated with an increased risk of reactivation.",
"     </li>",
"     <li>",
"      Reactivation has also been described in the setting of bone marrow transplantation [",
"      <a class=\"abstract\" href=\"UTD.htm?25/25/26009/abstract/8,11\">",
"       8,11",
"      </a>",
"      ]. One report included 137 consecutive patients (23 positive for HBsAg, 37 positive for anti-HBs, and 77 negative for HBV) who underwent hematopoietic cell transplantation [",
"      <a class=\"abstract\" href=\"UTD.htm?25/25/26009/abstract/11\">",
"       11",
"      </a>",
"      ]. Hepatitis developed in 32 patients (23 percent) with a mean onset at 136 days after transplantation; it was considered to be due to hepatitis B reactivation in 13 of the 32 patients. Hepatitis due to HBV reactivation was more common in HBsAg-positive patients than HBsAg-negative patients (11 of 23 versus 2 of 114). The most important risk factor for reactivation was an HBV DNA level of &gt;10(5)",
"      <span class=\"nowrap\">",
"       copies/mL",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?25/25/26009/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    While any chemotherapy regimen can potentially lead to reactivation of HBV replication, the risk may be decreased with steroid-free chemotherapy, implicating the use of glucocorticoids as a risk factor [",
"    <a class=\"abstract\" href=\"UTD.htm?25/25/26009/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several reports have described severe hepatitis flares with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    , causing the manufacturer to issue a warning regarding its use in patients who are at increased risk for HBV infection [",
"    <a class=\"abstract\" href=\"UTD.htm?25/25/26009/abstract/16,17,20,31,32\">",
"     16,17,20,31,32",
"    </a>",
"    ]. Reactivation with rituximab has been described in patients who were HBsAg negative but anti-HBc positive [",
"    <a class=\"abstract\" href=\"UTD.htm?25/25/26009/abstract/31,33\">",
"     31,33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An illustrative report included 80 HBsAg-negative patients with CD20(+) diffuse large B-cell lymphoma who were treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/29/1498?source=see_link\">",
"     vincristine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    (CHOP) alone or with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?25/25/26009/abstract/31\">",
"     31",
"    </a>",
"    ]. Of the 80 patients, 46 were HBsAg",
"    <span class=\"nowrap\">",
"     negative/anti-HBc",
"    </span>",
"    positive; of these patients, 25 were treated with CHOP, and none had reactivation following treatment. By contrast, of the remaining 21 patients treated with rituximab plus CHOP, five developed reactivation. In an exploratory analysis, the authors found that male sex, absence of anti-HBs, and use of rituximab were predictive of HBV reactivation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Crohn's disease treated with infliximab or adalimumab",
"    </span>",
"    &nbsp;&mdash;&nbsp;Case series have demonstrated reactivation of HBV in patients with Crohn's disease undergoing treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    . In a study of 80 patients with Crohn's disease who were receiving infliximab, three were identified as being HBsAg positive [",
"    <a class=\"abstract\" href=\"UTD.htm?25/25/26009/abstract/34\">",
"     34",
"    </a>",
"    ]. Of these, two developed severe hepatitis (leading to one death) after withdrawal of infliximab therapy. Reactivation was not observed in three patients who were anti-HBs and anti-HBc positive with normal aminotransferases. Similar issues probably apply with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39303?source=see_link\">",
"     adalimumab",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Rheumatalogic disorders treated with anti-TNF agents, methotrexate, and other biologics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Flares of hepatitis have been described in a variety of rheumatologic conditions treated with biological response modifiers including:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Anti-tumor necrosis factor (anti-TNF) agents in patients with rheumatoid arthritis with chronic HBV [",
"      <a class=\"abstract\" href=\"UTD.htm?25/25/26009/abstract/35-39\">",
"       35-39",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       Methotrexate",
"      </a>",
"      , particularly following its withdrawal [",
"      <a class=\"abstract\" href=\"UTD.htm?25/25/26009/abstract/40-42\">",
"       40-42",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/14/18662?source=see_link\">",
"       Abatacept",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?25/25/26009/abstract/43\">",
"       43",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/46/742?source=see_link\">",
"       Ustekinumab",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?25/25/26009/abstract/44\">",
"       44",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The incidence of HBV reactivation with each of these agents is unclear because of the lack of systematic studies. Thus, while HBV screening before treatment is suggested, whether prophylactic antiviral should be recommended for all HBsAg positive patients is unclear. We generally offer antiviral prophylaxis to patients who require biological response modifiers. A reasonable alternative is close monitoring of liver chemistries and testing for HBV DNA in those with an elevated ALT and prompt initiation of antiviral therapy in those with reactivation of hepatitis B.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Solid organ transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Numerous reports have described reactivation of HBV replication in patients who underwent solid organ transplantation. Reactivation has occurred not only in patients who were HBsAg positive but also in those who had markers for past HBV infection",
"    <span class=\"nowrap\">",
"     (anti-HBs/anti-HBc",
"    </span>",
"    positive). Reactivation of HBV replication is an important cause of morbidity and mortality in HBsAg positive patients undergoing renal transplantation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/28/44488?source=see_link\">",
"     \"Renal disease associated with hepatitis B virus infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/2/15402?source=see_link\">",
"     \"Liver transplantation for chronic hepatitis B virus infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/29/10714?source=see_link\">",
"     \"Prophylaxis of infections in solid organ transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Glucocorticoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;HBV replication increases in the presence of glucocorticoids. Despite the increase in viral replication, serum aminotransferases tend to decline. The opposite occurs once glucocorticoids are withdrawn; viral replication declines while aminotransferases increase [",
"    <a class=\"abstract\" href=\"UTD.htm?25/25/26009/abstract/45-48\">",
"     45-48",
"    </a>",
"    ]. The peak rise in aminotransferases typically occurs four to six weeks after withdrawal [",
"    <a class=\"abstract\" href=\"UTD.htm?25/25/26009/abstract/7,49\">",
"     7,49",
"    </a>",
"    ]. One report found that a steroid-free chemotherapy regimen reduced the risk of HBV reactivation in patients with lymphoma; however, a steroid-free regimen appeared to decrease tumor response [",
"    <a class=\"abstract\" href=\"UTD.htm?25/25/26009/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The viral and immunologic underpinnings of these events are incompletely understood. The increased viral replication may at least in part be due to a glucocorticoid responsive element in the HBV genome that stimulates viral replication and transcriptional activity [",
"    <a class=\"abstract\" href=\"UTD.htm?25/25/26009/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Deliberate introduction of a short course of glucocorticoids (typically four to eight weeks) followed by abrupt withdrawal (glucocorticoid \"priming\") has been evaluated as a strategy for improving the efficacy of antiviral therapy. The immune rebound following withdrawal of glucocorticoids is likely to be related to increased activation of lymphocytes that promote a Th-1 immune response while there is increased viral antigen expression [",
"    <a class=\"abstract\" href=\"UTD.htm?25/25/26009/abstract/50\">",
"     50",
"    </a>",
"    ]. It was hoped that this immunologic setting may increase the efficacy of antiviral treatments, an approach that has been best studied with interferon. Unfortunately, controlled trials have suggested that a benefit, if it exists at all, is observed in only a small subset of patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/60/14281?source=see_link&amp;anchor=H13#H13\">",
"     \"Standard and pegylated interferon for chronic hepatitis B virus infection\", section on 'Prednisone priming'",
"    </a>",
"    .) In addition, the post-steroid flare had been reported to result in hepatic decompensation in some patients. Thus, this treatment strategy is no longer used.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Superinfection with other viruses",
"    </span>",
"    &nbsp;&mdash;&nbsp;Superinfection with hepatitis A, C, D, or E in patients who are chronic carriers of HBV can be associated with severe hepatitis, sometimes leading to fulminant hepatic failure. (See appropriate topic reviews).",
"   </p>",
"   <p>",
"    The degree to which superinfection should be suspected appears to depend in part upon the host's immunologic status [",
"    <a class=\"abstract\" href=\"UTD.htm?25/25/26009/abstract/51\">",
"     51",
"    </a>",
"    ]. In a study of 76 Asian patients who were HBsAg positive and developed a flare, the flare was mostly due to spontaneous HBeAg seroconversion in those who were initially HBeAg positive. By contrast, in those who were anti-HBe positive, one-half had delta superinfection, while approximately 20 percent were thought to have acute non-A, non-B (presumably hepatitis C) virus infection, and only 25 percent were felt to have reactivation of HBV.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     HIV coinfection",
"    </span>",
"    &nbsp;&mdash;&nbsp;HBV flares have been described during the course of HIV infection, particularly following immune reconstitution with antiretroviral therapy and discontinuation of antiretroviral drugs that have anti-HBV activity. In HIV coinfected patients, hepatitis flares may also be related to drug-induced liver injury as well as superinfection with other hepatitis viruses. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/55/7033?source=see_link\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of hepatitis B in the HIV-infected patient\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/35/23098?source=see_link\">",
"     \"Immune reconstitution inflammatory syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     RISK FACTORS FOR REACTIVATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;As described above, the following risk factors for reactivation have been identified, although the magnitude of risk is incompletely understood.",
"   </p>",
"   <p>",
"    Among HBsAg positive persons:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      HBeAg positive or high levels of HBV DNA",
"     </li>",
"     <li>",
"      Possibly male sex",
"     </li>",
"     <li>",
"      Use of glucocorticoids",
"     </li>",
"     <li>",
"      Use of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"     </li>",
"     <li>",
"      Treatment for hematologic malignancies",
"     </li>",
"     <li>",
"      Preparative therapy for bone marrow or stem cell transplant",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Among HBsAg-negative, anti-HBc-positive persons:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Use of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"     </li>",
"     <li>",
"      Treatment for hematologic malignancies",
"     </li>",
"     <li>",
"      Preparative therapy for bone marrow or stem cell transplant",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple reports have suggested a benefit from prophylactic use of antiviral treatments in patients at risk for HBV reactivation [",
"    <a class=\"abstract\" href=\"UTD.htm?25/25/26009/abstract/52-60\">",
"     52-60",
"    </a>",
"    ]. The greatest experience has been with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    . A meta-analysis of 14 studies involving a total of 275 patients receiving chemotherapy who received lamivudine found that preventive lamivudine therapy reduced the risk of HBV reactivation and HBV-related hepatitis by 80 to 100 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?25/25/26009/abstract/61\">",
"     61",
"    </a>",
"    ]. The following illustrate the range of findings in the individual studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One of the few controlled trials compared outcomes in 65 HBsAg-positive patients (11 percent positive for HBeAg) undergoing chemotherapy who received prophylactic",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"       lamivudine",
"      </a>",
"      (beginning seven days before chemotherapy) with 193 historical HBsAg-positive controls [",
"      <a class=\"abstract\" href=\"UTD.htm?25/25/26009/abstract/62\">",
"       62",
"      </a>",
"      ]. Patients who received lamivudine experienced significantly fewer episodes of HBV reactivation (5 versus 25 percent), less severe hepatitis during reactivation, and less disruption of chemotherapy.",
"     </li>",
"     <li>",
"      Another study included 30 consecutive HBsAg-positive patients with lymphoma who were randomly assigned to receive",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"       lamivudine",
"      </a>",
"      (100 mg daily) prior to intensive chemotherapy or to have treatment deferred until there was serologic evidence of HBV reactivation (ie, preemptive antiviral therapy) [",
"      <a class=\"abstract\" href=\"UTD.htm?25/25/26009/abstract/54\">",
"       54",
"      </a>",
"      ]. Reactivation after chemotherapy was observed significantly less often in the prophylactic group (0 versus 53 percent). A subsequent economic analysis found lamivudine prophylaxis to be cost-effective in patients undergoing chemotherapy for lymphoma [",
"      <a class=\"abstract\" href=\"UTD.htm?25/25/26009/abstract/63\">",
"       63",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A third trial included 73 patients with hepatocellular carcinoma and chronic HBV infection who were undergoing transarterial chemoembolization [",
"      <a class=\"abstract\" href=\"UTD.htm?25/25/26009/abstract/64\">",
"       64",
"      </a>",
"      ]. Patients were randomly assigned to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"       lamivudine",
"      </a>",
"      (100 mg daily beginning at the start of therapy) or observation. A flare of hepatitis due to HBV reactivation was observed significantly more often in the observation group (30 versus 3 percent). The frequency of flares and their severity were significantly greater in the observation group. An HBV DNA level of more than 10(4)",
"      <span class=\"nowrap\">",
"       copies/mL",
"      </span>",
"      was the only independent predictor of a flare.",
"     </li>",
"     <li>",
"      A fourth trial compared prophylactic",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"       lamivudine",
"      </a>",
"      with therapeutic lamivudine only in patients who developed evidence of HBV reactivation in patients undergoing chemotherapy for non-Hodgkin lymphoma [",
"      <a class=\"abstract\" href=\"UTD.htm?25/25/26009/abstract/65\">",
"       65",
"      </a>",
"      ]. Prophylactic antiviral therapy significantly reduced the incidence and severity of HBV-related hepatitis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There have been no controlled trials of preemptive therapy in other settings involving the use of immunosuppressive drugs.",
"   </p>",
"   <p>",
"    A potential concern related to the use of prophylactic",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    is the development of antiviral drug resistance mutants. However, resistance appears to be uncommon, probably because of the short course of antiviral therapy used and the low level of HBV DNA in many patients receiving prophylaxis [",
"    <a class=\"abstract\" href=\"UTD.htm?25/25/26009/abstract/66\">",
"     66",
"    </a>",
"    ]. With the availability of antiviral agents such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/55/29557?source=see_link\">",
"     entecavir",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    , which are associated with very low risk of drug resistance, lamivudine should not be used unless cost is a limiting factor.",
"   </p>",
"   <p>",
"    The optimal duration of prophylactic therapy is unclear. We suggest that treatment should be maintained for at least six months after withdrawal of chemotherapy; longer duration of treatment may be necessary in patients who had high serum HBV DNA prior to treatment. Because of the lag in recovery of B cell function, antiviral prophylaxis should be maintained for at least 12 months after stopping",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    The natural history of patients who stopped prophylactic therapy has not been well studied. The largest report included 46 patients in whom",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    was started before chemotherapy and continued for a median of 3.1 months after completion [",
"    <a class=\"abstract\" href=\"UTD.htm?25/25/26009/abstract/67\">",
"     67",
"    </a>",
"    ]. HBV reactivation was observed in 11 patients (24 percent) after withdrawal of therapy. The likelihood of reactivation was most strongly correlated with the prechemotherapy HBV DNA titer (RR 16, 95% CI 3-87). Reactivation was observed in 50 percent of patients with an HBV DNA level greater than 10(4)",
"    <span class=\"nowrap\">",
"     copies/mL",
"    </span>",
"    (approximately 2000 int.",
"    <span class=\"nowrap\">",
"     unit/mL)",
"    </span>",
"    compared with only 10 percent of those with lower levels. Reactivation was also significantly more likely in patients who were HBeAg positive (46 versus 17 percent). Whether a longer period of consolidation could reduce the risk of reactivation in patients with these risk factors is unclear. As noted below, the duration of therapy should also consider the need for HBV therapy independent of the issues surrounding immunosuppression. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Summary and recommendations'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;A flare of HBV should be suspected in the clinical settings described above with appropriate serologic testing and evaluation for other (or contributing) causes of liver disease. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Clinical manifestations and diagnosis'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Several reports have demonstrated clinical improvement with antiviral treatment in patients who developed a flare of HBV [",
"    <a class=\"abstract\" href=\"UTD.htm?25/25/26009/abstract/68-70\">",
"     68-70",
"    </a>",
"    ]. Thus, it is reasonable to begin antiviral therapy once a flare is recognized. Although flares may resolve spontaneously, it may not be possible to predict the clinical course. Furthermore, a flare may lead to unnecessary interruption of therapy. Antiviral treatment should be initiated as soon as a flare is determined to be related to hepatitis B, as the effects of antiviral therapy take time and may not prevent progression to hepatic decompensation if treatment is delayed until the patient is jaundiced.",
"   </p>",
"   <p>",
"    Patients should be monitored closely with determination of liver biochemical tests and prothrombin time. Early referral to a transplant center should be considered in patients who appear to have a severe and progressive course, although transplant may not be feasible in patients with a malignancy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/17/2330?source=see_link\">",
"     \"Acute liver failure in adults: Etiology, clinical manifestations, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     MAJOR SOCIETY GUIDELINES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     American Association for the Study of Liver Diseases",
"    </span>",
"    &nbsp;&mdash;&nbsp;2009 guidelines issued by the American Association for the Study of Liver Diseases (AASLD) suggest the following [",
"    <a class=\"abstract\" href=\"UTD.htm?25/25/26009/abstract/71\">",
"     71",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients at high risk of HBV should undergo testing for HBsAg and anti-HBc before chemotherapy or immunosuppressive therapy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/51/24378?source=see_link&amp;anchor=H4#H4\">",
"       \"Overview of the management of hepatitis B and case examples\", section on 'Who should be tested'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Prophylactic antiviral therapy is recommended for HBV carriers at the onset of cancer chemotherapy or of a finite course of immunosuppressive therapy.",
"     </li>",
"     <li>",
"      Patients with baseline HBV DNA &lt;2000 int.",
"      <span class=\"nowrap\">",
"       unit/mL",
"      </span>",
"      should continue treatment for six months after completion of chemotherapy or immunosuppressive therapy. Patients with high baseline HBV DNA (&gt;2000 int.",
"      <span class=\"nowrap\">",
"       unit/mL)",
"      </span>",
"      should continue treatment until they reach treatment endpoints as in immunocompetent patients.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"       Lamivudine",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?3/15/3317?source=see_link\">",
"       telbivudine",
"      </a>",
"      can be used if the anticipated duration of treatment is short (&le;12 months) and baseline serum HBV DNA is not detectable.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"       Tenofovir",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/55/29557?source=see_link\">",
"       entecavir",
"      </a>",
"      is preferred if a longer duration of treatment is anticipated.",
"     </li>",
"     <li>",
"      Interferon alpha should be avoided in view of the bone marrow suppressive effect.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     American Society of Clinical Oncology",
"    </span>",
"    &nbsp;&mdash;&nbsp;In 2010, the American Society of Clinical Oncology (ASCO) published provisional clinical opinions regarding HBV screening in patients receiving cytotoxic chemotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?25/25/26009/abstract/72\">",
"     72",
"    </a>",
"    ]. The opinion statement notes the insufficient evidence to determine the net benefits and harms of routine screening for chronic HBV in individuals with cancer who are about to receive cytotoxic or immunosuppressive therapy, or who are already receiving it.",
"   </p>",
"   <p>",
"    As a result, ASCO suggests that HBV screening requires clinical judgment. It may be considered in patients with an increased risk for chronic HBV or if highly immunosuppressive therapy is planned. Highly immunosuppressive treatments include, but are not limited to, hematopoietic cell transplantation and regimens that include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    In patients with evidence of chronic HBV infection, antiviral therapy before and throughout the course of chemotherapy can be considered to reduce the risk of HBV reactivation, although evidence from controlled trials of this approach is limited. Screening",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    treating HBV infection should not delay the initiation of chemotherapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2072035\">",
"    <span class=\"h2\">",
"     European Association for the Study of the Liver",
"    </span>",
"    &nbsp;&mdash;&nbsp;The European Association for the Study of the Liver (EASL) recommends that HBsAg-positive patients receiving chemotherapy or immunosuppressive therapy (including the established and emerging range of biological response modifiers) be screened for HBsAg and anti-HBc prior to the initiation of treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?25/25/26009/abstract/73\">",
"     73",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1320917\">",
"    <span class=\"h1\">",
"     NATIONAL INSTITUTES OF HEALTH",
"    </span>",
"    &nbsp;&mdash;&nbsp;A 2009 consensus conference from the United States National Institutes of Health recommended that all patients who undergo cancer chemotherapy, marked immunosuppressive treatments, or solid organ or bone marrow transplantation be screened for evidence of ongoing or previous hepatitis B (with HBsAg and anti-HBc) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/25/26009/abstract/74\">",
"     74",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Those found to be HBsAg positive should be evaluated for indications for HBV treatment and started on appropriate therapy before starting chemotherapy or immune suppression. Therapy should continue for as long as required for management of underlying chronic HBV.",
"     </li>",
"     <li>",
"      Those found to be an inactive HBsAg carrier or in the immune-tolerance phase should receive antiviral prophylaxis before starting chemotherapy or immune suppression.",
"     </li>",
"     <li>",
"      Patients found to be anti-HBc positive without HBsAg should be considered for antiviral prophylaxis if they are scheduled for organ or bone marrow transplantation or if aggressive or prolonged chemotherapy is planned.",
"     </li>",
"     <li>",
"      Prophylaxis should continue for at least six months after stopping chemotherapy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1320949\">",
"    <span class=\"h1\">",
"     CENTERS FOR DISEASE CONTROL AND PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;In 2008, the United States Centers for Disease Control and Prevention recommended that patients needing immunosuppressive therapy (chemotherapy, immunosuppression related to organ transplantation and immunosuppression for rheumatologic or gastroenterologic disorders) should undergo serologic testing for markers of HBV infection (HBsAg, anti-HBc, and anti-HBs) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/25/26009/abstract/75\">",
"     75",
"    </a>",
"    ]. All persons who are HBsAg positive should receive antiviral prophylaxis, while those who are HBsAg negative, anti-HBc positive should be monitored closely for signs of liver disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The preceding discussion provides the basis for the following recommendations, which are consistent with the AASLD guidelines described above.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We suggest that patients who have risk factors for HBV infection be tested for exposure to HBV prior to initiation of immunosuppressive therapy (",
"      <a class=\"grade\" href=\"._grade_4?title=Grade 2A\">",
"       Grade 2A",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/51/24378?source=see_link&amp;anchor=H4#H4\">",
"       \"Overview of the management of hepatitis B and case examples\", section on 'Who should be tested'",
"      </a>",
"      .) However, given the inaccuracies in ascertaining risks for HBV infection, we concur with the CDC recommendation and the EASL recommendation that all patients should be tested prior to initiation of long-term immunosuppressive therapy. (See",
"      <a class=\"local\" href=\"#H2072035\">",
"       'European Association for the Study of the Liver'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H1320949\">",
"       'Centers for disease control and prevention'",
"      </a>",
"      above.) Serologic testing should include assessment of HBsAg and anti-HBc; further testing should include HBeAg, anti-HBe, and an HBV DNA level if the patient is HBsAg positive.",
"     </li>",
"     <li>",
"      Preemptive therapy has been best studied in the setting of chemotherapy. Furthermore, most reports have described use of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"       lamivudine",
"      </a>",
"      , although it is likely that a similar degree of benefit would be observed with other nucleoside(tide) analogues:",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/44/10949?source=see_link\">",
"       adefovir",
"      </a>",
"      dipivoxil,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/55/29557?source=see_link\">",
"       entecavir",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?3/15/3317?source=see_link\">",
"       telbivudine",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"       tenofovir",
"      </a>",
"      . Interferon should not be used in this setting to avoid further bone marrow suppression or exacerbation of hepatitis. Entecavir or tenofovir is preferred if the anticipated duration of treatment is longer than 12 months.",
"     </li>",
"     <li>",
"      We suggest initiating antiviral therapy as soon as possible in HBsAg-positive patients who are scheduled to undergo myelosuppressive chemotherapy, immunotherapy for cancer, or intrahepatic artery chemoembolization for hepatocellular carcinoma, and treatment regimens that include",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      or corticosteroids regardless of HBeAg and HBV DNA status (",
"      <a class=\"grade\" href=\"._grade_4?title=Grade 2A\">",
"       Grade 2A",
"      </a>",
"      ). The evidence to support benefit is strongest in patients being treated for lymphoma, especially those receiving rituximab and in patients undergoing hematopoietic stem cell transplantation.",
"     </li>",
"     <li>",
"      We also suggest antiviral prophylaxis for all HBsAg-positive patients receiving concomitant chemoradiotherapy with the potential for myelosuppression (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Treatment should be maintained for at least six months after withdrawal of chemotherapy. Treatment should be continued until a therapeutic endpoint is achieved in patients who have a high baseline serum HBV DNA (ie, &gt;2000 int.",
"      <span class=\"nowrap\">",
"       unit/mL).",
"      </span>",
"      Treatment should be continued for at least 12 months after withdrawal of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      . Although most studies used",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"       lamivudine",
"      </a>",
"      , newer therapies such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/55/29557?source=see_link\">",
"       entecavir",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"       tenofovir",
"      </a>",
"      , which are more potent and have lower rates of drug resistance, are preferred except for patients with undetectable or low baseline serum HBV DNA and a short anticipated duration of treatment. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/51/24378?source=see_link\">",
"       \"Overview of the management of hepatitis B and case examples\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The benefit of preemptive therapy in patients with serological markers of HBV exposure is less well established. It may be reasonable to monitor such patients closely and to initiate treatment when serum HBV DNA level becomes detectable or when a hepatitis flare is diagnosed. On the other hand, we suggest preemptive therapy in HBsAg-negative, anti-HBc-positive patients who are at high-risk for HBV reactivation (eg, those receiving steroid-containing cancer chemotherapy or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      and those receiving treatment for hematologic malignancies or preparative therapy for hematopoietic stem cell transplantation) (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Reactivation has also been described following therapy with other forms of immunosuppression, particularly with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"       infliximab",
"      </a>",
"      therapy for Crohn's disease and rheumatoid arthritis, or long-term steroid therapy. Although there are no direct data from which to derive recommendations, we suggest prophylaxis in HBsAg-positive patients receiving anti-TNF therapy and in those who require long-term treatment with other potent immunosuppressive therapies (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      We suggest antiviral treatment be instituted upon recognition in HBsAg-positive patients who develop a hepatitis flare considered to be due to HBV in the setting of immunosuppression (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/25/26009/abstract/1\">",
"      Gupta S, Govindarajan S, Fong TL, Redeker AG. Spontaneous reactivation in chronic hepatitis B: patterns and natural history. J Clin Gastroenterol 1990; 12:562.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/25/26009/abstract/2\">",
"      Lok AS, Lai CL, Wu PC, et al. Spontaneous hepatitis B e antigen to antibody seroconversion and reversion in Chinese patients with chronic hepatitis B virus infection. Gastroenterology 1987; 92:1839.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/25/26009/abstract/3\">",
"      Dao DY, Hynan LS, Yuan HJ, et al. Two distinct subtypes of hepatitis B virus-related acute liver failure are separable by quantitative serum immunoglobulin M anti-hepatitis B core antibody and hepatitis B virus DNA levels. Hepatology 2012; 55:676.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/25/26009/abstract/4\">",
"      Lok AS, Lai CL. alpha-Fetoprotein monitoring in Chinese patients with chronic hepatitis B virus infection: role in the early detection of hepatocellular carcinoma. Hepatology 1989; 9:110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/25/26009/abstract/5\">",
"      Liaw YF, Tai DI, Chen TJ, et al. Alpha-fetoprotein changes in the course of chronic hepatitis: relation to bridging hepatic necrosis and hepatocellular carcinoma. Liver 1986; 6:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/25/26009/abstract/6\">",
"      Lok AS, Lai CL. Acute exacerbations in Chinese patients with chronic hepatitis B virus (HBV) infection. Incidence, predisposing factors and etiology. J Hepatol 1990; 10:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/25/26009/abstract/7\">",
"      Perrillo RP. Acute flares in chronic hepatitis B: the natural and unnatural history of an immunologically mediated liver disease. Gastroenterology 2001; 120:1009.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/25/26009/abstract/8\">",
"      Dh&eacute;din N, Douvin C, Kuentz M, et al. Reverse seroconversion of hepatitis B after allogeneic bone marrow transplantation: a retrospective study of 37 patients with pretransplant anti-HBs and anti-HBc. Transplantation 1998; 66:616.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/25/26009/abstract/9\">",
"      Cheng JC, Liu MC, Tsai SY, et al. Unexpectedly frequent hepatitis B reactivation by chemoradiation in postgastrectomy patients. Cancer 2004; 101:2126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/25/26009/abstract/10\">",
"      Jang JW, Choi JY, Bae SH, et al. Transarterial chemo-lipiodolization can reactivate hepatitis B virus replication in patients with hepatocellular carcinoma. J Hepatol 2004; 41:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/25/26009/abstract/11\">",
"      Lau GK, Leung YH, Fong DY, et al. High hepatitis B virus (HBV) DNA viral load as the most important risk factor for HBV reactivation in patients positive for HBV surface antigen undergoing autologous hematopoietic cell transplantation. Blood 2002; 99:2324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/25/26009/abstract/12\">",
"      Lok AS, Liang RH, Chiu EK, et al. Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study. Gastroenterology 1991; 100:182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/25/26009/abstract/13\">",
"      Markovic S, Drozina G, Vovk M, Fidler-Jenko M. Reactivation of hepatitis B but not hepatitis C in patients with malignant lymphoma and immunosuppressive therapy. A prospective study in 305 patients. Hepatogastroenterology 1999; 46:2925.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/25/26009/abstract/14\">",
"      Nakamura Y, Motokura T, Fujita A, et al. Severe hepatitis related to chemotherapy in hepatitis B virus carriers with hematologic malignancies. Survey in Japan, 1987-1991. Cancer 1996; 78:2210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/25/26009/abstract/15\">",
"      Shimizu D, Nomura K, Matsumoto Y, et al. Hepatitis B virus reactivation in a patient undergoing steroid-free chemotherapy. World J Gastroenterol 2004; 10:2301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/25/26009/abstract/16\">",
"      Soong YL, Lee KM, Lui HF, et al. Hepatitis B reactivation in a patient receiving radiolabeled rituximab. Ann Hematol 2005; 84:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/25/26009/abstract/17\">",
"      Tsutsumi Y, Kawamura T, Saitoh S, et al. Hepatitis B virus reactivation in a case of non-Hodgkin's lymphoma treated with chemotherapy and rituximab: necessity of prophylaxis for hepatitis B virus reactivation in rituximab therapy. Leuk Lymphoma 2004; 45:627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/25/26009/abstract/18\">",
"      Yeo W, Chan PK, Zhong S, et al. Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors. J Med Virol 2000; 62:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/25/26009/abstract/19\">",
"      Yeo W, Lam KC, Zee B, et al. Hepatitis B reactivation in patients with hepatocellular carcinoma undergoing systemic chemotherapy. Ann Oncol 2004; 15:1661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/25/26009/abstract/20\">",
"      Zell JA, Yoon EJ, Ignatius Ou SH, et al. Precore mutant hepatitis B reactivation after treatment with CHOP-rituximab. Anticancer Drugs 2005; 16:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/25/26009/abstract/21\">",
"      Kim MK, Ahn JH, Kim SB, et al. Hepatitis B reactivation during adjuvant anthracycline-based chemotherapy in patients with breast cancer: a single institution's experience. Korean J Intern Med 2007; 22:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/25/26009/abstract/22\">",
"      Peng JW, Lin GN, Xiao JJ, Jiang XM. Hepatitis B virus reactivation in hepatocellular carcinoma patients undergoing transcatheter arterial chemoembolization therapy. Asia Pac J Clin Oncol 2012; 8:356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/25/26009/abstract/23\">",
"      Wang YD, Cui GH, Li M, et al. Hepatitis B virus reactivation in a chronic myeloid leukemia patient treated with imatinib mesylate. Chin Med J (Engl) 2012; 125:2636.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/25/26009/abstract/24\">",
"      Tanaka H, Sakuma I, Hashimoto S, et al. Hepatitis B reactivation in a multiple myeloma patient with resolved hepatitis B infection during bortezomib therapy : case report. J Clin Exp Hematop 2012; 52:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/25/26009/abstract/25\">",
"      Tsutsumi Y, Ogasawara R, Miyashita N, et al. HBV reactivation in malignant lymphoma patients treated with rituximab and bendamustine. Int J Hematol 2012; 95:588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/25/26009/abstract/26\">",
"      Ohno M, Narita Y, Miyakita Y, et al. Reactivation of hepatitis B virus after glioblastoma treatment with temozolomide--case report. Neurol Med Chir (Tokyo) 2011; 51:728.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/25/26009/abstract/27\">",
"      Hoofnagle JH, Dusheiko GM, Schafer DF, et al. Reactivation of chronic hepatitis B virus infection by cancer chemotherapy. Ann Intern Med 1982; 96:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/25/26009/abstract/28\">",
"      Lau JY, Lai CL, Lin HJ, et al. Fatal reactivation of chronic hepatitis B virus infection following withdrawal of chemotherapy in lymphoma patients. Q J Med 1989; 73:911.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/25/26009/abstract/29\">",
"      Thung SN, Gerber MA, Klion F, Gilbert H. Massive hepatic necrosis after chemotherapy withdrawal in a hepatitis B virus carrier. Arch Intern Med 1985; 145:1313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/25/26009/abstract/30\">",
"      Cheng AL, Hsiung CA, Su IJ, et al. Steroid-free chemotherapy decreases risk of hepatitis B virus (HBV) reactivation in HBV-carriers with lymphoma. Hepatology 2003; 37:1320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/25/26009/abstract/31\">",
"      Yeo W, Chan TC, Leung NW, et al. Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab. J Clin Oncol 2009; 27:605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/25/26009/abstract/32\">",
"      Evens AM, Jovanovic BD, Su YC, et al. Rituximab-associated hepatitis B virus (HBV) reactivation in lymphoproliferative diseases: meta-analysis and examination of FDA safety reports. Ann Oncol 2011; 22:1170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/25/26009/abstract/33\">",
"      Ji D, Cao J, Hong X, et al. Low incidence of hepatitis B virus reactivation during chemotherapy among diffuse large B-cell lymphoma patients who are HBsAg-negative/ HBcAb-positive: a multicenter retrospective study. Eur J Haematol 2010; 85:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/25/26009/abstract/34\">",
"      Esteve M, Saro C, Gonz&aacute;lez-Huix F, et al. Chronic hepatitis B reactivation following infliximab therapy in Crohn's disease patients: need for primary prophylaxis. Gut 2004; 53:1363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/25/26009/abstract/35\">",
"      Michel M, Duvoux C, Hezode C, Cherqui D. Fulminant hepatitis after infliximab in a patient with hepatitis B virus treated for an adult onset still's disease. J Rheumatol 2003; 30:1624.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/25/26009/abstract/36\">",
"      Ostuni P, Botsios C, Punzi L, et al. Hepatitis B reactivation in a chronic hepatitis B surface antigen carrier with rheumatoid arthritis treated with infliximab and low dose methotrexate. Ann Rheum Dis 2003; 62:686.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/25/26009/abstract/37\">",
"      Lee YH, Bae SC, Song GG. Hepatitis B virus (HBV) reactivation in rheumatic patients with hepatitis core antigen (HBV occult carriers) undergoing anti-tumor necrosis factor therapy. Clin Exp Rheumatol 2013; 31:118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/25/26009/abstract/38\">",
"      Kim PS, Ho GY, Prete PE, Furst DE. Safety and efficacy of abatacept in eight rheumatoid arthritis patients with chronic hepatitis B. Arthritis Care Res (Hoboken) 2012; 64:1265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/25/26009/abstract/39\">",
"      Ryu HH, Lee EY, Shin K, et al. Hepatitis B virus reactivation in rheumatoid arthritis and ankylosing spondylitis patients treated with anti-TNF&alpha; agents: a retrospective analysis of 49 cases. Clin Rheumatol 2012; 31:931.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/25/26009/abstract/40\">",
"      Ito S, Nakazono K, Murasawa A, et al. Development of fulminant hepatitis B (precore variant mutant type) after the discontinuation of low-dose methotrexate therapy in a rheumatoid arthritis patient. Arthritis Rheum 2001; 44:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/25/26009/abstract/41\">",
"      Narv&aacute;ez J, Rodriguez-Moreno J, Martinez-Aguil&aacute; MD, Clavaguera MT. Severe hepatitis linked to B virus infection after withdrawal of low dose methotrexate therapy. J Rheumatol 1998; 25:2037.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/25/26009/abstract/42\">",
"      Hagiyama H, Kubota T, Komano Y, et al. Fulminant hepatitis in an asymptomatic chronic carrier of hepatitis B virus mutant after withdrawal of low-dose methotrexate therapy for rheumatoid arthritis. Clin Exp Rheumatol 2004; 22:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/25/26009/abstract/43\">",
"      Germanidis G, Hytiroglou P, Zakalka M, Settas L. Reactivation of occult hepatitis B virus infection, following treatment of refractory rheumatoid arthritis with abatacept. J Hepatol 2012; 56:1420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/25/26009/abstract/44\">",
"      Navarro R, Vilarrasa E, Herranz P, et al. Safety and effectiveness of ustekinumab and antitumour necrosis factor therapy in patients with psoriasis and chronic viral hepatitis B or C: a retrospective, multicentre study in a clinical setting. Br J Dermatol 2013; 168:609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/25/26009/abstract/45\">",
"      Chou CK, Wang LH, Lin HM, Chi CW. Glucocorticoid stimulates hepatitis B viral gene expression in cultured human hepatoma cells. Hepatology 1992; 16:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/25/26009/abstract/46\">",
"      Sagnelli E, Manzillo G, Maio G, et al. Serum levels of hepatitis B surface and core antigens during immunosuppressive treatment of HBsAg-positive chronic active hepatitis. Lancet 1980; 2:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/25/26009/abstract/47\">",
"      Nair PV, Tong MJ, Stevenson D, et al. Effects of short-term, high-dose prednisone treatment of patients with HBsAg-positive chronic active hepatitis. Liver 1985; 5:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/25/26009/abstract/48\">",
"      Scullard GH, Smith CI, Merigan TC, et al. Effects of immunosuppressive therapy on viral markers in chronic active hepatitis B. Gastroenterology 1981; 81:987.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/25/26009/abstract/49\">",
"      Sheen IS, Liaw YF, Lin SM, Chu CM. Severe clinical rebound upon withdrawal of corticosteroid before interferon therapy: incidence and risk factors. J Gastroenterol Hepatol 1996; 11:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/25/26009/abstract/50\">",
"      Liaw YF, Tsai SL, Chien RN, et al. Prednisolone priming enhances Th1 response and efficacy of subsequent lamivudine therapy in patients with chronic hepatitis B. Hepatology 2000; 32:604.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/25/26009/abstract/51\">",
"      Chu CM, Liaw YF, Pao CC, Huang MJ. The etiology of acute hepatitis superimposed upon previously unrecognized asymptomatic HBsAg carriers. Hepatology 1989; 9:452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/25/26009/abstract/52\">",
"      Ahmed A, Keeffe EB. Lamivudine therapy for chemotherapy-induced reactivation of hepatitis B virus infection. Am J Gastroenterol 1999; 94:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/25/26009/abstract/53\">",
"      Dai MS, Wu PF, Lu JJ, et al. Preemptive use of lamivudine in breast cancer patients carrying hepatitis B virus undergoing cytotoxic chemotherapy: a longitudinal study. Support Care Cancer 2004; 12:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/25/26009/abstract/54\">",
"      Lau GK, Yiu HH, Fong DY, et al. Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy. Gastroenterology 2003; 125:1742.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/25/26009/abstract/55\">",
"      Leaw SJ, Yen CJ, Huang WT, et al. Preemptive use of interferon or lamivudine for hepatitis B reactivation in patients with aggressive lymphoma receiving chemotherapy. Ann Hematol 2004; 83:270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/25/26009/abstract/56\">",
"      Nagamatsu H, Itano S, Nagaoka S, et al. Prophylactic lamivudine administration prevents exacerbation of liver damage in HBe antigen positive patients with hepatocellular carcinoma undergoing transhepatic arterial infusion chemotherapy. Am J Gastroenterol 2004; 99:2369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/25/26009/abstract/57\">",
"      Rossi G, Pelizzari A, Motta M, Puoti M. Primary prophylaxis with lamivudine of hepatitis B virus reactivation in chronic HbsAg carriers with lymphoid malignancies treated with chemotherapy. Br J Haematol 2001; 115:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/25/26009/abstract/58\">",
"      Yeo W, Ho WM, Hui P, et al. Use of lamivudine to prevent hepatitis B virus reactivation during chemotherapy in breast cancer patients. Breast Cancer Res Treat 2004; 88:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/25/26009/abstract/59\">",
"      Li YH, He YF, Jiang WQ, et al. Lamivudine prophylaxis reduces the incidence and severity of hepatitis in hepatitis B virus carriers who receive chemotherapy for lymphoma. Cancer 2006; 106:1320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/25/26009/abstract/60\">",
"      Kohrt HE, Ouyang DL, Keeffe EB. Systematic review: lamivudine prophylaxis for chemotherapy-induced reactivation of chronic hepatitis B virus infection. Aliment Pharmacol Ther 2006; 24:1003.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/25/26009/abstract/61\">",
"      Loomba R, Rowley A, Wesley R, et al. Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy. Ann Intern Med 2008; 148:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/25/26009/abstract/62\">",
"      Yeo W, Chan PK, Ho WM, et al. Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis B s-antigen seropositive cancer patients undergoing cytotoxic chemotherapy. J Clin Oncol 2004; 22:927.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/25/26009/abstract/63\">",
"      Saab S, Dong MH, Joseph TA, Tong MJ. Hepatitis B prophylaxis in patients undergoing chemotherapy for lymphoma: a decision analysis model. Hepatology 2007; 46:1049.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/25/26009/abstract/64\">",
"      Jang JW, Choi JY, Bae SH, et al. A randomized controlled study of preemptive lamivudine in patients receiving transarterial chemo-lipiodolization. Hepatology 2006; 43:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/25/26009/abstract/65\">",
"      Hsu C, Hsiung CA, Su IJ, et al. A revisit of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in non-Hodgkin's lymphoma: a randomized trial. Hepatology 2008; 47:844.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/25/26009/abstract/66\">",
"      Pelizzari AM, Motta M, Cariani E, et al. Frequency of hepatitis B virus mutant in asymptomatic hepatitis B virus carriers receiving prophylactic lamivudine during chemotherapy for hematologic malignancies. Hematol J 2004; 5:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/25/26009/abstract/67\">",
"      Hui CK, Cheung WW, Au WY, et al. Hepatitis B reactivation after withdrawal of pre-emptive lamivudine in patients with haematological malignancy on completion of cytotoxic chemotherapy. Gut 2005; 54:1597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/25/26009/abstract/68\">",
"      Liao CA, Lee CM, Wu HC, et al. Lamivudine for the treatment of hepatitis B virus reactivation following chemotherapy for non-Hodgkin's lymphoma. Br J Haematol 2002; 116:166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/25/26009/abstract/69\">",
"      Clark FL, Drummond MW, Chambers S, et al. Successful treatment with lamivudine for fulminant reactivated hepatitis B infection following intensive therapy for high-grade non-Hodgkin's lymphoma. Ann Oncol 1998; 9:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/25/26009/abstract/70\">",
"      Picardi M, Selleri C, De Rosa G, et al. Lamivudine treatment for chronic replicative hepatitis B virus infection after allogeneic bone marrow transplantation. Bone Marrow Transplant 1998; 21:1267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/25/26009/abstract/71\">",
"      Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009; 50:661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/25/26009/abstract/72\">",
"      Artz AS, Somerfield MR, Feld JJ, et al. American Society of Clinical Oncology provisional clinical opinion: chronic hepatitis B virus infection screening in patients receiving cytotoxic chemotherapy for treatment of malignant diseases. J Clin Oncol 2010; 28:3199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/25/26009/abstract/73\">",
"      European Association For The Study Of The Liver. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol 2012; 57:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/25/26009/abstract/74\">",
"      Hoofnagle JH. Reactivation of hepatitis B. Hepatology 2009; 49:S156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/25/26009/abstract/75\">",
"      Weinbaum CM, Williams I, Mast EE, et al. Recommendations for identification and public health management of persons with chronic hepatitis B virus infection. MMWR Recomm Rep 2008; 57:1.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3649 Version 14.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-203.80.222.8-E31ECE9AB0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_25_26009=[""].join("\n");
var outline_f25_25_26009=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H18\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLINICAL MANIFESTATIONS AND DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      SETTINGS IN WHICH FLARES HAVE BEEN DESCRIBED",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Immunosuppression",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Cancer chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Crohn's disease treated with infliximab or adalimumab",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Rheumatalogic disorders treated with anti-TNF agents, methotrexate, and other biologics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Solid organ transplantation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Superinfection with other viruses",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      HIV coinfection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      RISK FACTORS FOR REACTIVATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      MAJOR SOCIETY GUIDELINES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      American Association for the Study of Liver Diseases",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      American Society of Clinical Oncology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2072035\">",
"      European Association for the Study of the Liver",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1320917\">",
"      NATIONAL INSTITUTES OF HEALTH",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1320949\">",
"      CENTERS FOR DISEASE CONTROL AND PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/3649\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/3649|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?14/52/15180\" title=\"table 1\">",
"      Risk of severe reactivation of HBV",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/17/2330?source=related_link\">",
"      Acute liver failure in adults: Etiology, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/55/7033?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of hepatitis B in the HIV-infected patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/35/23098?source=related_link\">",
"      Immune reconstitution inflammatory syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/2/15402?source=related_link\">",
"      Liver transplantation for chronic hepatitis B virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/51/24378?source=related_link\">",
"      Overview of the management of hepatitis B and case examples",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/29/10714?source=related_link\">",
"      Prophylaxis of infections in solid organ transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/28/44488?source=related_link\">",
"      Renal disease associated with hepatitis B virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/60/14281?source=related_link\">",
"      Standard and pegylated interferon for chronic hepatitis B virus infection",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f25_25_26010="Chronic asthma in children younger than 12 years: Evaluation and diagnosis";
var content_f25_25_26010=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Chronic asthma in children younger than 12 years: Evaluation and diagnosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/25/26010/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/25/26010/contributors\">",
"     Gregory Sawicki, MD, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/25/26010/contributors\">",
"     Kenan Haver, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/25/26010/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/25/26010/contributors\">",
"     Robert A Wood, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/25/26010/contributors\">",
"     Gregory Redding, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/25/26010/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/25/26010/contributors\">",
"     Elizabeth TePas, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?25/25/26010/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 3, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Asthma is the most common chronic disease of childhood, affecting more than seven million children in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?25/25/26010/abstract/1\">",
"     1",
"    </a>",
"    ]. Establishing a diagnosis of asthma involves a careful process of history taking, physical examination, and diagnostic studies. The differential diagnosis of wheezing must be carefully considered, particularly in infants and young children, for whom testing for reversible airflow obstruction is technically difficult.",
"   </p>",
"   <p>",
"    The evaluation and monitoring of childhood asthma will be reviewed here. The epidemiology, pathology, and pathophysiology of childhood asthma and the use of specific medications are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/61/15319?source=see_link\">",
"     \"Chronic asthma in children younger than 12 years: Definition, epidemiology, and pathophysiology\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/30/37354?source=see_link\">",
"     \"Chronic asthma in children younger than 12 years: Controller medications\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/47/39670?source=see_link\">",
"     \"Chronic asthma in children younger than 12 years: Quick-relief agents\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     HISTORY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The history in a child with suspected asthma centers on the presence of symptoms, precipitating factors or conditions (ie, atopy), typical symptom patterns, and asthma risk factors (",
"    <a class=\"graphic graphic_table graphicRef79182 \" href=\"UTD.htm?0/29/476\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Additional history that should be obtained in a child with established asthma who presents for disease monitoring includes previous and current therapy (controller and quick-relief medication use), exposure to triggers, utilization of health care services (emergency department, hospital, unscheduled clinic visits), school attendance and performance, and participation in physical activity. The evaluation of a child who presents with an acute asthma exacerbation is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/16/33034?source=see_link\">",
"     \"Acute asthma exacerbations in children: Outpatient management\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 80 percent of children with asthma develop symptoms before five years of age, but the disease is frequently misdiagnosed or not suspected, particularly in infants and toddlers [",
"    <a class=\"abstract\" href=\"UTD.htm?25/25/26010/abstract/2\">",
"     2",
"    </a>",
"    ]. Evaluating the presence of asthma symptoms is an important first step in establishing a proper diagnosis.",
"   </p>",
"   <p>",
"    Coughing and wheezing are the most common symptoms of childhood asthma. Breathlessness, chest tightness or pressure, and chest pain also are reported. Poor school performance and fatigue may indicate sleep deprivation from nocturnal symptoms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Cough",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of a nocturnal cough, a cough that recurs seasonally, a cough in response to specific exposures, or a cough that lasts more than three weeks should raise the suspicion for asthma [",
"    <a class=\"abstract\" href=\"UTD.htm?25/25/26010/abstract/3\">",
"     3",
"    </a>",
"    ]. Although wheezing is considered the hallmark of childhood asthma, cough is frequently the sole presenting complaint [",
"    <a class=\"abstract\" href=\"UTD.htm?25/25/26010/abstract/4\">",
"     4",
"    </a>",
"    ]. The most common cause of chronic cough in children older than three years is asthma, even if it is not accompanied by wheezing. The cough is typically dry and hacking; when the cough is productive, clear or whitish sputum may be expectorated (which often contains eosinophils). It is not unusual for chronic cough lasting more than three weeks to be labeled \"bronchitis\" and to be treated with ineffective medications, such as cough suppressants, decongestants, or antibiotics. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/9/17561?source=see_link\">",
"     \"Approach to chronic cough in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Wheeze",
"    </span>",
"    &nbsp;&mdash;&nbsp;Wheezing is a high-pitched sound produced when air is forced through narrow airways. The wheezing of asthma tends to be polyphonic (varied in pitch), reflecting the heterogeneous distribution of affected airways. When airflow obstruction becomes severe, wheezing can be heard on both inspiration and expiration. Central airway obstruction may cause a harsh expiratory monophonic wheeze, as occurs with tracheomalacia. Upper airway obstruction (eg, vocal cord dysfunction) should be suspected if an inspiratory monophonic (of single pitch) wheeze (typically called stridor) is the only audible sound during an attack. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/61/21464?source=see_link\">",
"     \"Assessment of stridor in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A silent chest in the context of an asthma exacerbation implies airflow limitation of such severity that audible wheezes cannot be produced; this represents a medical emergency. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/16/33034?source=see_link\">",
"     \"Acute asthma exacerbations in children: Outpatient management\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Seasonal symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Symptoms that are worse in certain pollen seasons are characteristic of atopic asthma. Trees pollinate in early spring, grasses in summer, and weeds in the fall. Children who are sensitive to molds tend to wheeze or cough during rainy seasons or if they are exposed to flooding or indoor dampness. Other allergic symptoms, such as rhinitis, conjunctivitis, or eczema may flare concurrently with the chest complaints. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/34/35370?source=see_link\">",
"     \"Clinical manifestations, pathophysiology, and diagnosis of chronic rhinosinusitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/2/34856?source=see_link\">",
"     \"Allergic conjunctivitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/40/42631?source=see_link\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of atopic dermatitis (eczema)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Symptom patterns",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic asthma symptoms assume several typical patterns:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Intermittent exacerbations superimposed upon an asymptomatic baseline",
"     </li>",
"     <li>",
"      Chronic symptoms punctuated by periods of worsening symptoms",
"     </li>",
"     <li>",
"      Morning \"dipping\" (an accentuation of the physiologic cycle of pulmonary function in normal individuals, characterized by worsening of symptoms and decreased peak flow in the early morning, with improvement as the day progresses)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Precipitating factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Wheezing or cough may occur at any time, but certain patterns and precipitating factors are typical (",
"    <a class=\"graphic graphic_table graphicRef52199 \" href=\"UTD.htm?25/35/26171\">",
"     table 2",
"    </a>",
"    ). Depending upon the type and intensity of the provocative agent, most acute asthma attacks have a slow onset over several days. Uncommonly, severe attacks may occur suddenly and with minimal warning, resulting in life-threatening exacerbations [",
"    <a class=\"abstract\" href=\"UTD.htm?25/25/26010/abstract/5-9\">",
"     5-9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/53/854?source=see_link\">",
"     \"Peak expiratory flow rate monitoring in asthma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/16/33034?source=see_link\">",
"     \"Acute asthma exacerbations in children: Outpatient management\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/9/44184?source=see_link\">",
"     \"Trigger control to enhance asthma management\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Viral URI",
"    </span>",
"    &nbsp;&mdash;&nbsp;Viral upper respiratory illnesses are an important triggering factor for asthma in infants and young children [",
"    <a class=\"abstract\" href=\"UTD.htm?25/25/26010/abstract/10\">",
"     10",
"    </a>",
"    ]. VURIs are common triggers for patients with asthma of all ages. Clustering of asthma attacks between fall and spring suggests viral illness-induced phenomena [",
"    <a class=\"abstract\" href=\"UTD.htm?25/25/26010/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. Among children who are hospitalized for wheezing, respiratory syncytial virus, influenza virus, and rhinovirus are most common in those younger than three years (depending upon the season); rhinovirus is most common among older children [",
"    <a class=\"abstract\" href=\"UTD.htm?25/25/26010/abstract/11\">",
"     11",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/15/2298?source=see_link\">",
"     \"Virus-induced wheezing and asthma: An overview\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    One study found that clusters of asthma hospitalizations in school aged children in Canada occurred predictably after they returned to school following summer vacation and other breaks [",
"    <a class=\"abstract\" href=\"UTD.htm?25/25/26010/abstract/13\">",
"     13",
"    </a>",
"    ]. Specifically, there was a \"September asthma epidemic\" approximately 18 days after Labor Day (the first Monday of September), with a lesser increase in attacks two days later in preschool children, and six days later in adults. Viral infections were the presumed cause, although a reduction in daily asthma medication use (eg, therapeutic holiday) during the summer months has also been implicated.",
"   </p>",
"   <p>",
"    It is unusual for bacterial respiratory infections to trigger asthma, even when pneumonia occurs; however, chronic sinusitis (which is often bacterial), and respiratory infections due to Mycoplasma pneumoniae and Chlamydophila (Chlamydia) pneumoniae may precipitate worsening of asthma [",
"    <a class=\"abstract\" href=\"UTD.htm?25/25/26010/abstract/14-18\">",
"     14-18",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/18/33062?source=see_link\">",
"     \"Pneumonia caused by Chlamydophila (Chlamydia) species in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/35/6713?source=see_link&amp;anchor=H5#H5\">",
"     \"Mycoplasma pneumoniae infection in children\", section on 'Clinical features'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Exercise",
"    </span>",
"    &nbsp;&mdash;&nbsp;Exercise-induced bronchospasm (EIB) may be the only manifestation of asthma in children [",
"    <a class=\"abstract\" href=\"UTD.htm?25/25/26010/abstract/19\">",
"     19",
"    </a>",
"    ]. Typical symptoms are shortness of breath, chest tightness, and cough. Exercise-triggered symptoms typically develop 10 to 15 minutes after a brief episode of exercise or about 15 minutes into prolonged exercise. Symptoms usually resolve with rest over 30 to 60 minutes. A subset of patients does not have symptoms until cooling down after exercise.",
"   </p>",
"   <p>",
"    Certain types of exertion (eg, swimming) appear to be less provocative of asthma than others (eg, running, skating), probably because they produce less airway cooling and drying, which are thought to be provocative of EIB [",
"    <a class=\"abstract\" href=\"UTD.htm?25/25/26010/abstract/19\">",
"     19",
"    </a>",
"    ]. However, there is an ongoing debate about potential lung damage caused by repeated respiratory exposure to chlorine by-products in recreational swimmers [",
"    <a class=\"abstract\" href=\"UTD.htm?25/25/26010/abstract/20-23\">",
"     20-23",
"    </a>",
"    ]. Short bursts of activity tend to be better tolerated than prolonged exercise. Repeated short periods of exercise tend to result in diminishing EIB with each episode. Nonetheless, children with asthma do not need to be steered toward particular sports, since they can typically tolerate any particular activity with proper treatment, and improved exercise tolerance leads to lower respiratory rates with the same level of activity.",
"   </p>",
"   <p>",
"    If untreated, long-standing EIB results in poor overall fitness, decreased exercise stamina, a preference for a sedentary lifestyle, and exercise avoidance due to the distress brought on by physical activity. Further, although exercise can be the major trigger for some children with asthma, it is usually not the only trigger and EIB that is difficult to control often indicates inadequately controlled underlying asthma. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/30/1513?source=see_link\">",
"     \"Exercise-induced bronchoconstriction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Weather",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cold air; hot, humid air; changes in barometric pressure; rain; or wind may be provocative factors for asthma in individual patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/9/44184?source=see_link&amp;anchor=H11#H11\">",
"     \"Trigger control to enhance asthma management\", section on 'Temperature and weather'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Tobacco smoke",
"    </span>",
"    &nbsp;&mdash;&nbsp;Exposure to secondhand cigarette smoke is the single most common external risk factor for the development and progression of asthma symptoms in children [",
"    <a class=\"abstract\" href=\"UTD.htm?25/25/26010/abstract/24-26\">",
"     24-26",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/4/5194?source=see_link\">",
"     \"Secondhand smoke exposure: Effects in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Allergens",
"    </span>",
"    &nbsp;&mdash;&nbsp;Indoor and outdoor allergens are an important trigger of childhood asthma, particularly for children older than three years of age (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/48/34569?source=see_link\">",
"     \"Allergen avoidance in the treatment of asthma and allergic rhinitis\"",
"    </a>",
"    ). These include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      House dust mites, cockroaches, and rodents [",
"      <a class=\"abstract\" href=\"UTD.htm?25/25/26010/abstract/27-30\">",
"       27-30",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Animal exposures; cats and dogs are especially provocative, but other furry animals (gerbils, rabbits, hamsters, etc) may be suspect, especially if symptoms only occur in settings where these animals reside [",
"      <a class=\"abstract\" href=\"UTD.htm?25/25/26010/abstract/31\">",
"       31",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Pollens [",
"      <a class=\"abstract\" href=\"UTD.htm?25/25/26010/abstract/32\">",
"       32",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Molds",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Other exposures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Asthma symptoms that occur after prolonged time indoors (eg, winter months or during periods of inclement weather) should raise a suspicion of sensitivity to indoor exposures to inhaled airway irritants, such as [",
"    <a class=\"abstract\" href=\"UTD.htm?25/25/26010/abstract/33\">",
"     33",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Nitrogen dioxide (from gas stoves) [",
"      <a class=\"abstract\" href=\"UTD.htm?25/25/26010/abstract/34\">",
"       34",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Particulates and smoke from wood fires or kerosene space heaters",
"     </li>",
"     <li>",
"      Propellant cleaning sprays",
"     </li>",
"     <li>",
"      Perfumes, hair sprays",
"     </li>",
"     <li>",
"      Paint",
"     </li>",
"     <li>",
"      Room deodorizers",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Additional history",
"    </span>",
"    &nbsp;&mdash;&nbsp;Additional history that should be obtained in children with suspected asthma includes a personal history of other atopic diseases, family history of asthma or other atopic diseases, environmental history, past medical history, medication use, medical utilization, school attendance, physical activity, and psychosocial factors.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Allergic history",
"    </span>",
"    &nbsp;&mdash;&nbsp;Allergic disease is associated with the development, severity, and persistence of asthma. As an example, up to 80 percent of children with atopic dermatitis develop asthma",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    allergic rhinitis later in childhood [",
"    <a class=\"abstract\" href=\"UTD.htm?25/25/26010/abstract/35\">",
"     35",
"    </a>",
"    ]. Approximately 30 percent of children with food allergy have asthma and respiratory allergy, compared with 10 percent of children without food allergy [",
"    <a class=\"abstract\" href=\"UTD.htm?25/25/26010/abstract/36\">",
"     36",
"    </a>",
"    ]. Food allergy is also a risk factor for life-threatening asthma, as evidenced by a substantially higher rate of food allergy in children requiring intubation for asthma compared to a control group of asthmatic children [",
"    <a class=\"abstract\" href=\"UTD.htm?25/25/26010/abstract/37\">",
"     37",
"    </a>",
"    ]. Sensitivity to many mold allergens is associated with increased asthma severity and persistence [",
"    <a class=\"abstract\" href=\"UTD.htm?25/25/26010/abstract/38,39\">",
"     38,39",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/59/26551?source=see_link\">",
"     \"Role of allergy in atopic dermatitis (eczema)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/48/34569?source=see_link\">",
"     \"Allergen avoidance in the treatment of asthma and allergic rhinitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/12/20682?source=see_link&amp;anchor=H7#H7\">",
"     \"Risk factors for asthma\", section on 'Atopy and allergens'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In a study of children who were hospitalized for wheezing (cases), total serum IgE concentrations in the subgroup &lt;3 years of age were similar to hospitalized children without wheezing (controls), but were significantly elevated among the cases in the subgroup &gt;3 years old [",
"    <a class=\"abstract\" href=\"UTD.htm?25/25/26010/abstract/11\">",
"     11",
"    </a>",
"    ]. In addition, a higher percentage of cases were sensitized to at least one inhaled allergen (84 versus 33 percent).",
"   </p>",
"   <p>",
"    In atopic infants, sensitization to common foods, such as egg white and cow's milk may occur, and peaks at approximately eight months of age [",
"    <a class=\"abstract\" href=\"UTD.htm?25/25/26010/abstract/40\">",
"     40",
"    </a>",
"    ]. IgE antibodies to inhalant allergens generally appear beginning at two years of age and increase throughout childhood [",
"    <a class=\"abstract\" href=\"UTD.htm?25/25/26010/abstract/40\">",
"     40",
"    </a>",
"    ]. Food allergy and eczema are the most common manifestations of atopy in early life, whereas asthma and allergic rhinitis are more common in older children. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/40/42631?source=see_link\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of atopic dermatitis (eczema)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/29/14808?source=see_link\">",
"     \"Clinical manifestations of food allergy: An overview\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/28/12746?source=see_link\">",
"     \"The natural history of childhood food allergy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Family history",
"    </span>",
"    &nbsp;&mdash;&nbsp;The influence of genetics in the development of asthma has not been fully defined [",
"    <a class=\"abstract\" href=\"UTD.htm?25/25/26010/abstract/26,41-47\">",
"     26,41-47",
"    </a>",
"    ]. Because families also share environments, determining the influence of the genetic contribution to asthma is complicated. Nonetheless, a family history of asthma or other atopic disease (ie, allergic rhinitis, atopic dermatitis, or food allergy) certainly strengthens the likelihood that a child with a compatible history has asthma.",
"   </p>",
"   <p>",
"    Children with one asthmatic parent are 2.6 times more likely to have asthma; with two asthmatic parents, the odds ratio rises to 5.2 [",
"    <a class=\"abstract\" href=\"UTD.htm?25/25/26010/abstract/41\">",
"     41",
"    </a>",
"    ]. Maternal asthma appears to make a bigger contribution than paternal asthma to asthma in offspring, although this finding is inconsistent [",
"    <a class=\"abstract\" href=\"UTD.htm?25/25/26010/abstract/43-45\">",
"     43-45",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Environment",
"    </span>",
"    &nbsp;&mdash;&nbsp;A thorough review of all regular environments, including home, school, daycare, and relatives' homes, is essential to evaluate possible provocative situations in the asthmatic child. The table outlines some questions that may be helpful in obtaining this history (",
"    <a class=\"graphic graphic_table graphicRef59599 \" href=\"UTD.htm?6/48/6923\">",
"     table 3",
"    </a>",
"    ). A strategy to avoid asthma triggers is one of the essential elements for managing the disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/9/44184?source=see_link\">",
"     \"Trigger control to enhance asthma management\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/48/34569?source=see_link\">",
"     \"Allergen avoidance in the treatment of asthma and allergic rhinitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Past medical history",
"    </span>",
"    &nbsp;&mdash;&nbsp;A careful survey of all aspects of the child's medical history is critical to formulate a differential diagnosis of the child's complaint. Questions about the neonatal course, early respiratory symptoms, the coexistence of systemic symptoms (failure to thrive, fever, developmental delay, recurrent infections) may point toward other diagnoses. (See",
"    <a class=\"local\" href=\"#H26\">",
"     'Differential diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Sleep disordered breathing was associated with a 3.6-fold increased risk of severe asthma in one study [",
"    <a class=\"abstract\" href=\"UTD.htm?25/25/26010/abstract/48\">",
"     48",
"    </a>",
"    ]. Results are conflicting regarding the relationship between obesity and asthma severity [",
"    <a class=\"abstract\" href=\"UTD.htm?25/25/26010/abstract/48-52\">",
"     48-52",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Medications",
"    </span>",
"    &nbsp;&mdash;&nbsp;A careful review of prior and present medications (including over-the-counter and alternative remedies) provides information on adherence to therapy, drug efficacy, accuracy of diagnosis, and control of asthma. Common reasons for poor response to asthma medications include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Nonadherence to the prescribed regimen. Parents and children often overreport adherence with controller medications; objective measures (eg, an inhaler with a dose counter) may be necessary to verify adherence [",
"      <a class=\"abstract\" href=\"UTD.htm?25/25/26010/abstract/53\">",
"       53",
"      </a>",
"      ]. Overuse of quick-relief medications (eg, short acting beta agonists) with resultant tolerance can also be an issue. Tolerance to beta agonists may also occur with chronic use of long acting beta agonists [",
"      <a class=\"abstract\" href=\"UTD.htm?25/25/26010/abstract/54\">",
"       54",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/31/12789?source=see_link\">",
"       \"Enhancing patient adherence to asthma therapy\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/26/8618?source=see_link&amp;anchor=H12#H12\">",
"       \"Beta agonists in asthma: Acute administration and prophylactic use\", section on 'Tolerance'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Inadequate inhaler technique. Since the efficacy of many asthma medications depends upon their deposition in the lung, inhalation technique figures strongly in the success or failure of inhaled therapies. Metered dose inhalers (MDIs) require a significant degree of coordination for optimal drug delivery, and there is considerable evidence that most individuals do not regularly perform proper inhalation technique [",
"      <a class=\"abstract\" href=\"UTD.htm?25/25/26010/abstract/55\">",
"       55",
"      </a>",
"      ]. Errors also can be made with dry powder inhalers (DPIs). Patient education materials, use of spacers (with MDIs), and frequent reappraisal of technique contribute to greater success with this form of therapy. Spacers with masks are especially helpful to the very young child with asthma and are probably superior to the use of nebulizers. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/18/31014?source=see_link\">",
"       \"Delivery of inhaled medication in children\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/57/36760?source=see_link\">",
"       \"The use of inhaler devices in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Ineffective drug dose or dosing interval. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/30/37354?source=see_link\">",
"       \"Chronic asthma in children younger than 12 years: Controller medications\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Complicating medical problems (eg, chronic sinusitis, vocal cord dysfunction, gastroesophageal reflux, ongoing allergic stimulation) [",
"      <a class=\"abstract\" href=\"UTD.htm?25/25/26010/abstract/56,57\">",
"       56,57",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/34/35370?source=see_link\">",
"       \"Clinical manifestations, pathophysiology, and diagnosis of chronic rhinosinusitis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/11/16567?source=see_link\">",
"       \"Paradoxical vocal cord motion\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/41/41625?source=see_link\">",
"       \"Clinical manifestations and diagnosis of gastroesophageal reflux disease in children and adolescents\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Complicating psychosocial factors.",
"     </li>",
"     <li>",
"      Inappropriate treatment (eg, antibiotics, antitussives, over-the-counter or alternative medications).",
"     </li>",
"     <li>",
"      Different response to controller medications depending upon the child's baseline characteristics [",
"      <a class=\"abstract\" href=\"UTD.htm?25/25/26010/abstract/58-61\">",
"       58-61",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Medical utilization",
"    </span>",
"    &nbsp;&mdash;&nbsp;The degree of asthma control is usually linked to healthcare utilization, such that more severe or poorly controlled patients with asthma tend to be treated more often in emergency departments (EDs) or doctors' offices. A history of more than a few such interventions is indicative of poorly controlled asthma, regardless of the level of chronic symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?25/25/26010/abstract/62\">",
"     62",
"    </a>",
"    ]. In addition, a history of prior hospitalizations, ED visits, or exacerbations requiring oral glucocorticoids confers an increased risk for future asthma exacerbations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     School attendance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Interference with regular school attendance or achievement is a good measure of disability from childhood asthma. A pattern of significant numbers of lost days from school and a deteriorating academic performance should prompt more aggressive asthma management.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Physical activity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most children with asthma can have symptoms brought on by intensive activity, therefore many children limit their level of exertion. In one study, children with newly diagnosed, untreated asthma were less fit and spent less time in vigorous activity than their healthy peers [",
"    <a class=\"abstract\" href=\"UTD.htm?25/25/26010/abstract/63\">",
"     63",
"    </a>",
"    ]. However, physical activities need not be restricted. Rather, appropriate treatment should allow full participation, which should be encouraged.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Psychosocial profile",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic asthma may create or exacerbate psychosocial problems for patients and their families. Conversely, psychosocial factors can affect asthma symptoms and health behaviors [",
"    <a class=\"abstract\" href=\"UTD.htm?25/25/26010/abstract/64\">",
"     64",
"    </a>",
"    ]. Stressors surrounding asthma can include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Anxiety about the often sudden, life-threatening nature of attacks",
"     </li>",
"     <li>",
"      Fear of dying",
"     </li>",
"     <li>",
"      Fear of peer rejection because of being \"different\"",
"     </li>",
"     <li>",
"      Concern regarding the adverse effects of asthma drugs (particularly glucocorticoids, also called corticosteroids)",
"     </li>",
"     <li>",
"      Sleep deprivation due to nocturnal symptoms",
"     </li>",
"     <li>",
"      Poor school performance",
"     </li>",
"     <li>",
"      Financial consequences",
"     </li>",
"     <li>",
"      Difficulty obtaining health insurance because of a \"preexisting condition\" or having benefits terminated because of excessive utilization or job changes",
"     </li>",
"     <li>",
"      Disruption in family routines",
"     </li>",
"     <li>",
"      Siblings' resentment of the patient's special status within the family",
"     </li>",
"     <li>",
"      Limitation of social or geographic venues because of potential triggering of asthma (eg, cannot visit places where environmental tobacco smoke or allergen exposure is likely)",
"     </li>",
"     <li>",
"      Family discord over asthma treatment",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     PHYSICAL EXAMINATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Physical examination of an asthmatic child is generally normal if performed in the absence of an acute exacerbation. Abnormal findings may suggest severe disease, suboptimal control or associated atopic conditions. Abnormalities that may be observed include [",
"    <a class=\"abstract\" href=\"UTD.htm?25/25/26010/abstract/65\">",
"     65",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      An increased anterior-posterior diameter of the chest due to air trapping",
"     </li>",
"     <li>",
"      Decreased air entry or wheezing on auscultation",
"     </li>",
"     <li>",
"      A prolonged expiratory phase on auscultation",
"     </li>",
"     <li>",
"      Dry cough",
"     </li>",
"     <li>",
"      Signs of rhinitis, conjunctivitis, and sinusitis (nasal discharge, inflamed nasal mucosa, sinus tenderness, dark circles under the eyes) (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/34/35370?source=see_link\">",
"       \"Clinical manifestations, pathophysiology, and diagnosis of chronic rhinosinusitis\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      A transverse nasal crease due to frequent itching (allergic salute)",
"     </li>",
"     <li>",
"      Halitosis, due to chronic rhinitis, sinusitis, and mouth breathing",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       Eczema/atopic",
"      </span>",
"      dermatitis",
"     </li>",
"     <li>",
"      Nasal polyps (glistening, gray, mucoid masses within the nasal cavities, which may be associated with asthma and",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/10/19624?source=see_link\">",
"       aspirin",
"      </a>",
"      sensitivity in adolescents and adults, but should prompt evaluation for cystic fibrosis) (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/49/28442?source=see_link\">",
"       \"Cystic fibrosis: Clinical manifestations and diagnosis\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Obesity and higher percent body fat are more commonly seen in children with newly diagnosed, untreated asthma than their healthy peers [",
"    <a class=\"abstract\" href=\"UTD.htm?25/25/26010/abstract/63\">",
"     63",
"    </a>",
"    ]. Higher BMI is also associated with greater asthma severity [",
"    <a class=\"abstract\" href=\"UTD.htm?25/25/26010/abstract/49\">",
"     49",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/12/20682?source=see_link&amp;anchor=H22#H22\">",
"     \"Risk factors for asthma\", section on 'Obesity'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Examination findings during an acute exacerbation include tachypnea, hypoxia, wheezing, accessory muscle use, retractions, and prolonged expiratory phase. These findings are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/16/33034?source=see_link\">",
"     \"Acute asthma exacerbations in children: Outpatient management\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although wheezing is most commonly caused by asthma, it is not necessarily a pathognomonic finding. The lack of objective measures of pulmonary function in young children and the relatively high prevalence of congenital and inherited disorders that present with wheezing make it imperative to consider the differential diagnosis of wheezing illnesses before making a diagnosis of asthma solely on the basis of wheezing (",
"    <a class=\"graphic graphic_table graphicRef67370 \" href=\"UTD.htm?23/40/24204\">",
"     table 4",
"    </a>",
"    ). Clinical features suggestive of a diagnosis other than asthma are seen in the table (",
"    <a class=\"graphic graphic_table graphicRef70442 \" href=\"UTD.htm?4/41/4764\">",
"     table 5",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/45/30424?source=see_link\">",
"     \"Approach to wheezing in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Establishing a diagnosis of asthma involves a careful process of history taking, physical examination, and diagnostic studies [",
"    <a class=\"abstract\" href=\"UTD.htm?25/25/26010/abstract/65-67\">",
"     65-67",
"    </a>",
"    ]. For an individual patient, this process first involves obtaining a history of episodic or chronic symptoms of airflow obstruction. Response to treatment with",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?38/54/39782?source=see_link\">",
"     albuterol",
"    </a>",
"    (decreased respiratory rate, diminished retractions, increased aeration, decreased cough or wheezing) can be very helpful. The onset of action is rapid and the benefits should last four to six hours. Spirometry and other pulmonary function testing should be undertaken to establish the presence of airflow obstruction and to establish reversibility. Finally, alternative diagnoses may need to be excluded. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Symptoms'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/27/29112?source=see_link\">",
"     \"Overview of pulmonary function testing in children\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H26\">",
"     'Differential diagnosis'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Spirometry",
"    </span>",
"    &nbsp;&mdash;&nbsp;The medical history and physical examination may suggest the diagnosis of asthma. However, to establish the diagnosis and to facilitate assessment of severity, one should demonstrate, when possible, reversible airflow obstruction using spirometry (",
"    <a class=\"graphic graphic_figure graphicRef73165 \" href=\"UTD.htm?17/61/18399\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/25/26010/abstract/65\">",
"     65",
"    </a>",
"    ]. The National Asthma Education and Prevention Program (NAEPP) expert panel recommends that spirometry be performed in patients older than five years if a diagnosis of asthma is being considered [",
"    <a class=\"abstract\" href=\"UTD.htm?25/25/26010/abstract/65\">",
"     65",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Spirometry measurements include forced vital capacity (FVC) and the forced expiratory volume in one second (FEV1). Airflow obstruction is defined as FEV1 reduced to less than 80 percent predicted and an",
"    <span class=\"nowrap\">",
"     FEV1/FVC",
"    </span>",
"    ratio of less than 0.85 (85 percent) (",
"    <a class=\"graphic graphic_table graphicRef51579 \" href=\"UTD.htm?14/35/14909\">",
"     table 6A",
"    </a>",
"    ). Reference values are based on age, height, sex, and race [",
"    <a class=\"abstract\" href=\"UTD.htm?25/25/26010/abstract/68\">",
"     68",
"    </a>",
"    ].",
"    <span class=\"nowrap\">",
"     FEV1/FVC",
"    </span>",
"    appears to be a more sensitive measure of impairment than FEV1, whereas FEV1 may be a more useful measure of risk for future exacerbations [",
"    <a class=\"abstract\" href=\"UTD.htm?25/25/26010/abstract/65,69-72\">",
"     65,69-72",
"    </a>",
"    ]. Forced expiratory flow between 25 and 75 percent of vital capacity (FEF25-75) less than 65 percent correlates with reversible airflow obstruction in children with normal FEV1 and may be a useful measure in this subgroup, although further studies are needed [",
"    <a class=\"abstract\" href=\"UTD.htm?25/25/26010/abstract/73\">",
"     73",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Spirometry should be performed before and after administration of a bronchodilator to assess for reversibility (bronchodilator response, BDR). Significant reversibility is indicated by an increase in FEV1 of &ge;12 percent from baseline after administration of a short-acting bronchodilator. This definition for BDR positivity was established primarily in adults; an increase in FEV1 of &gt;9 percent may be a better definition for BDR in children [",
"    <a class=\"abstract\" href=\"UTD.htm?25/25/26010/abstract/74,75\">",
"     74,75",
"    </a>",
"    ]. Spirometry is the preferred method of diagnosis of airflow obstruction. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/27/29112?source=see_link\">",
"     \"Overview of pulmonary function testing in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Evidence of airway obstruction on spirometry, especially if acutely reversible with a bronchodilator, strongly supports the diagnosis of asthma. However, normal spirometry, or the lack of acute reversibility of obstruction, does not exclude the diagnosis.",
"   </p>",
"   <p>",
"    There is some evidence from cross-sectional studies to suggest that the NAEPP criteria for percent predicted FEV1 (",
"    <a class=\"graphic graphic_table graphicRef51579 graphicRef73634 \" href=\"UTD.htm?21/62/22510\">",
"     table 6A-B",
"    </a>",
"    ) do not accurately categorize asthma severity in children, and that symptom frequency and rescue medication use may be more sensitive measures [",
"    <a class=\"abstract\" href=\"UTD.htm?25/25/26010/abstract/69,70,76-78\">",
"     69,70,76-78",
"    </a>",
"    ]. In the Childhood Asthma Management Program (CAMP) study, the mean FEV1 of all children studied was 94 percent predicted [",
"    <a class=\"abstract\" href=\"UTD.htm?25/25/26010/abstract/70\">",
"     70",
"    </a>",
"    ]. Nonetheless, percent predicted FEV1 remains a useful measure because it is strongly associated with the risk of asthma exacerbation in the 12 months after measurement [",
"    <a class=\"abstract\" href=\"UTD.htm?25/25/26010/abstract/71,72\">",
"     71,72",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/27/29112?source=see_link\">",
"     \"Overview of pulmonary function testing in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Measurements of peak expiratory flow using a peak flow meter are more variable and effort dependent. In addition, there is wide variability in the published predicted peak expiratory flow reference values and in the reference values from brand to brand [",
"    <a class=\"abstract\" href=\"UTD.htm?25/25/26010/abstract/65\">",
"     65",
"    </a>",
"    ]. Thus, peak flow measurements alone should not be used to diagnose asthma. Peak flow measurements may be more useful in monitoring a patient's symptoms and response to therapy over time (",
"    <a class=\"graphic graphic_table graphicRef73634 \" href=\"UTD.htm?6/11/6333\">",
"     table 6B",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/25/26010/abstract/65\">",
"     65",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/53/854?source=see_link\">",
"     \"Peak expiratory flow rate monitoring in asthma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Impulse oscillometry (IOS) is an alternative to spirometry in younger children, since it only requires passive cooperation [",
"    <a class=\"abstract\" href=\"UTD.htm?25/25/26010/abstract/79\">",
"     79",
"    </a>",
"    ]. IOS measurements at baseline and postbronchodilator differed significantly between children aged three to six years with and without asthma, whereas no significant differences were seen with traditional spirometry. IOS may detect alterations in respiratory mechanics not seen with spirometry even in older children [",
"    <a class=\"abstract\" href=\"UTD.htm?25/25/26010/abstract/80-82\">",
"     80-82",
"    </a>",
"    ]. However, IOS is not readily available to most clinicians treating children with asthma. In such circumstances, a trial of asthma medications may help to establish the diagnosis in young children, and other tools can be used to assess control in older children, including traditional spirometry and questionnaires. (See",
"    <a class=\"local\" href=\"#H32\">",
"     'Assessment of Control'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Children &lt;5 years",
"    </span>",
"    &nbsp;&mdash;&nbsp;In infants and children younger than five years of age, the diagnostic steps should remain the same as described above, except that spirometry often cannot be performed in this age group. (See",
"    <a class=\"local\" href=\"#H27\">",
"     'Diagnosis'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Debate is ongoing regarding how to best classify infants and young children with recurrent wheezing; the terms asthma, reactive airway disease, wheezy bronchitis, bronchiolitis, asthmatic bronchitis, wheezing-associated respiratory illness, and post-infectious bronchial hyperreactivity have all been employed.",
"   </p>",
"   <p>",
"    This jargon reflects an attempt to describe and define a subgroup of wheezing children with a more benign prognosis than is implied by \"asthma&rdquo;, which is, by definition, chronic. &ldquo;Wheezy bronchitis\" usually defines nonatopic babies or toddlers with recurrent, virus-induced wheezing (the majority of this group of wheezing young children) that tends to disappear by five years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?25/25/26010/abstract/83,84\">",
"     83,84",
"    </a>",
"    ]. Asthma, on the other hand, has been taken to mean a chronic condition, frequently associated with atopy, provoked by a number of triggers in addition to viruses, and carrying a poorer prognosis for spontaneous resolution. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/13/7383?source=see_link&amp;anchor=H2#H2\">",
"     \"Natural history of asthma\", section on 'Infants and children'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/6/34920?source=see_link\">",
"     \"Wheezing phenotypes and prediction of asthma in young children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/15/2298?source=see_link\">",
"     \"Virus-induced wheezing and asthma: An overview\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/45/30424?source=see_link\">",
"     \"Approach to wheezing in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Ancillary studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;The history and physical examination, in conjunction with spirometry are usually adequate to establish the diagnosis of asthma. Ancillary studies are most helpful to exclude competing diagnoses.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Bronchoprovocation testing &mdash; In a patient with symptoms suggestive of asthma but with normal or near-normal spirometry, a trial of asthma medication is warranted. If such treatment fails to improve symptoms, bronchoprovocation testing with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/32/10756?source=see_link\">",
"       methacholine",
"      </a>",
"      , histamine, cold air, or exercise may be warranted. A negative bronchoprovocation study may also be useful in excluding a diagnosis of asthma. For safety reasons, these tests should be conducted in a specialized facility with trained technicians and should not be performed if a patient has severe airflow limitation (FEV1 &lt;50 percent predicted) [",
"      <a class=\"abstract\" href=\"UTD.htm?25/25/26010/abstract/85\">",
"       85",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/27/29112?source=see_link\">",
"       \"Overview of pulmonary function testing in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Chest radiograph &mdash; The chest radiograph may display findings suggestive of congenital malformations (eg, a right aortic arch suggestive of a vascular ring); evidence of airspace disease consistent with aspiration or cystic fibrosis; or findings consistent with asthma, such as hyperinflation, peribronchial thickening, and mucoid impaction with atelectasis.",
"     </li>",
"     <li>",
"      Sweat chloride test &mdash; A negative sweat chloride test reduces the likelihood of the diagnosis of cystic fibrosis in children with respiratory complaints in association with diarrhea, recurrent pneumonia, edema,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      failure to thrive. There should be a low threshold to perform this test in children with this clinical picture, even if prenatal maternal screening or newborn screening was negative, since identifying a patient with cystic fibrosis has major implications for the patient, the family, and future reproductive decisions. Mutation analysis should be performed even if the sweat chloride is negative if the suspicion for CF remains high. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/49/28442?source=see_link\">",
"       \"Cystic fibrosis: Clinical manifestations and diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/17/12564?source=see_link\">",
"       Barium",
"      </a>",
"      swallow &mdash; A barium swallow may be helpful in patients who have a history of reflux symptoms or in infants younger than one year of age with problematic asthma, because it may uncover tracheoesophageal fistulas, gastroesophageal reflux (GER), or compressive vascular anomalies. However, a barium swallow alone cannot exclude the diagnosis of GER. A modified barium swallow should be included in the diagnostic evaluation if swallowing dysfunction is a consideration. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/41/41625?source=see_link\">",
"       \"Clinical manifestations and diagnosis of gastroesophageal reflux disease in children and adolescents\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/41/1689?source=see_link\">",
"       \"Wheezing illnesses other than asthma in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Allergy testing &mdash; Allergy testing, done either by skin or in vitro testing, is helpful when used selectively in the very young child. Specifically, when the environmental history uncovers exposure to animals, molds, cockroaches, or dust mites, it is worthwhile to test for these or other limited allergens to formulate proper avoidance strategies. Outdoor aeroallergens are unusual triggers in infants and very young children. Food allergy testing is not helpful unless there is a sound history of gastrointestinal complaints, worsening eczema, urticaria, or asthma that is temporally associated with the ingestion of certain foods. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/55/32633?source=see_link\">",
"       \"Overview of skin testing for allergic disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Exhaled nitric oxide &mdash; Fractional exhaled nitric oxide (eNO) may have a role in the diagnosis of glucocorticoid-responsive asthma, especially in patients in whom the diagnosis is unclear. Levels of eNO are typically elevated in patients with asthma. However, chronic exposure to passive smoking may decrease eNO levels in children with asthma [",
"      <a class=\"abstract\" href=\"UTD.htm?25/25/26010/abstract/86\">",
"       86",
"      </a>",
"      ]. Exhaled nitric oxide testing is currently not routinely available. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/15/7416?source=see_link&amp;anchor=H9#H9\">",
"       \"Exhaled nitric oxide analysis\", section on 'Use in asthma'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h1\">",
"     ASSESSMENT OF SEVERITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Asthma severity can be assessed using the following components when the diagnosis of asthma is made in a child who is not yet taking long-term asthma &ldquo;controller&rdquo; medications: frequency of symptoms, nighttime awakenings, use of quick-relief medications and systemic glucocorticoids, and interference with normal activity (",
"    <a class=\"graphic graphic_table graphicRef61691 graphicRef51579 \" href=\"UTD.htm?15/60/16334\">",
"     table 6A, 6C",
"    </a>",
"    ). However, this classification is difficult to use in patients who are already on daily controller asthma treatment. In this setting, it is more useful to assess degree of asthma control rather than severity.",
"   </p>",
"   <p>",
"    Thus, the Joint Task Force of the American Thoracic Society and the European Respiratory Society also recommends defining asthma severity as the degree of difficulty in achieving asthma control while on daily treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?25/25/26010/abstract/87\">",
"     87",
"    </a>",
"    ]. Severity may be influenced by the underlying phenotype, environmental and family function factors (including smoking), adherence to treatment, drug delivery technique, and comorbidities.",
"   </p>",
"   <p>",
"    Patients with severe asthma can include those who are untreated, who are difficult to treat, and who are maximally treated but resistant to therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?25/25/26010/abstract/88,89\">",
"     88,89",
"    </a>",
"    ]. As an example, children are considered to have severe asthma if they are poorly controlled on several daily medications or if they are well controlled, but require three controller medications to maintain asthma control.",
"   </p>",
"   <p>",
"    One potential tool for estimating the risk of exacerbations is the Asthma Exacerbation Clinical Score, which takes into account symptoms, current medications, healthcare utilization, and other aspects of the patient&rsquo;s medical history [",
"    <a class=\"abstract\" href=\"UTD.htm?25/25/26010/abstract/90\">",
"     90",
"    </a>",
"    ]. Another tool is the Composite Asthma Severity Index (CASI) (",
"    <a class=\"graphic graphic_table graphicRef82978 \" href=\"UTD.htm?10/52/11085\">",
"     table 7",
"    </a>",
"    ), which includes measures of impairment, risk, and medication use (both rescue and controller) required to maintain control [",
"    <a class=\"abstract\" href=\"UTD.htm?25/25/26010/abstract/91\">",
"     91",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h1\">",
"     ASSESSMENT OF CONTROL",
"    </span>",
"    &nbsp;&mdash;&nbsp;The American Thoracic Society and the European Respiratory Society recommend defining asthma control as the extent to which therapy reduces or eliminates the manifestations of asthma [",
"    <a class=\"abstract\" href=\"UTD.htm?25/25/26010/abstract/87\">",
"     87",
"    </a>",
"    ]. This includes evaluation of impairment, including measures of symptomatic control, activities of daily living and quality of life, rescue medication use, and pulmonary function testing, and assessment of risk, including number of exacerbations that require systemic oral glucocorticoids and treatment-related adverse effects (",
"    <a class=\"graphic graphic_table graphicRef52149 graphicRef73634 \" href=\"UTD.htm?7/15/7422\">",
"     table 6B, 6D",
"    </a>",
"    ). The presence of persistent asthma symptoms (impairment domain) is a risk factor for severe asthma exacerbations (risk domain), although the predictors for each are different [",
"    <a class=\"abstract\" href=\"UTD.htm?25/25/26010/abstract/92\">",
"     92",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In patients with established asthma, the history obtained at follow-up visits is helpful in determining the adequacy of control and the risk of future exacerbations with progressive loss of pulmonary function. Salient historical points include medications and other therapies, medical utilization, school attendance and performance, physical activity, and psychosocial profile.",
"   </p>",
"   <p>",
"    The use of a standardized questionnaire, such as the Asthma Control Test or Asthma Control Questionnaire, facilitates the gathering of this information [",
"    <a class=\"abstract\" href=\"UTD.htm?25/25/26010/abstract/65\">",
"     65",
"    </a>",
"    ]. The Childhood Asthma Control Test (",
"    <a class=\"graphic graphic_figure graphicRef81872 \" href=\"UTD.htm?24/11/24762\">",
"     figure 2",
"    </a>",
"    ) is validated for use in children aged 4 to 11 years [",
"    <a class=\"abstract\" href=\"UTD.htm?25/25/26010/abstract/93\">",
"     93",
"    </a>",
"    ]. The Test for Respiratory and Asthma Control in Kids (TRACK) questionnaire is validated for preschool-aged children. This tool assesses impairment of asthma control (symptom burden, activity limitations, and rescue use of bronchodilators), and is the first to also assess risk (oral glucocorticoid use in the past 12 months) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/25/26010/abstract/94-96\">",
"     94-96",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Pulmonary function testing may be a useful adjunct to assess asthma control in addition to a careful assessment of symptoms and medication use. Measurement of fractional exhaled nitric oxide (eNO) is another potentially useful tool. As an example, a model for monitoring asthma control in children with allergies and persistent asthma was developed by a machine learning approach (soft computing) using spirometry and fractional exhaled nitric oxide (eNO) measurements [",
"    <a class=\"abstract\" href=\"UTD.htm?25/25/26010/abstract/97\">",
"     97",
"    </a>",
"    ]. The model was then validated in another group of children with persistent or intermittent allergic asthma. The soft computing method was able to correctly identify all patients with uncontrolled asthma (as defined by the Global Initiative for Asthma [GINA] guidelines) and 80 percent of those with partially and completely controlled asthma when both spirometry and eNO were used together, but was not predictive of asthma control when the measures were used separately. (See",
"    <a class=\"local\" href=\"#H28\">",
"     'Spirometry'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H30\">",
"     'Ancillary studies'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Suboptimal asthma control is associated with underuse of controller medications [",
"    <a class=\"abstract\" href=\"UTD.htm?25/25/26010/abstract/98\">",
"     98",
"    </a>",
"    ]. Other potentially modifiable factors associated with poor control include parents' low expectations that controller medications will improve asthma symptoms and high levels of worry about competing household priorities, such as jobs, money, safety, relationships, and health of other family members. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/30/37354?source=see_link\">",
"     \"Chronic asthma in children younger than 12 years: Controller medications\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?13/7/13427?source=see_link\">",
"       \"Patient information: Cough in children (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?37/0/37892?source=see_link\">",
"       \"Patient information: Asthma symptoms and diagnosis in children (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?17/60/18374?source=see_link\">",
"       \"Patient information: Asthma treatment in children (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Establishing a diagnosis of asthma involves a careful process of history taking, physical examination, and diagnostic studies; other causes of wheezing must be excluded. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The history in a child with suspected asthma centers on the presence of symptoms (cough and wheeze are the most common), precipitating factors or conditions (",
"      <a class=\"graphic graphic_table graphicRef79182 \" href=\"UTD.htm?0/29/476\">",
"       table 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef52199 \" href=\"UTD.htm?25/35/26171\">",
"       table 2",
"      </a>",
"      ), typical symptom patterns, and response to asthma therapy. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'History'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Additional history that should be obtained in children with suspected asthma includes a history of atopy, family history of asthma, environmental history, and past medical history. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Additional history'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Important aspects of the history in a child with asthma who presents for monitoring include previous and current therapy, exposure to triggers, medical utilization, school attendance and performance, comorbidities, and psychosocial stressors. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Additional history'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Physical examination of an asthmatic child is generally normal if performed in the absence of an acute exacerbation. Abnormal findings may suggest severe disease, suboptimal control, or associated atopic conditions. (See",
"      <a class=\"local\" href=\"#H25\">",
"       'Physical examination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Other causes of wheezing in children must be excluded before a diagnosis of asthma can be made (",
"      <a class=\"graphic graphic_table graphicRef67370 \" href=\"UTD.htm?23/40/24204\">",
"       table 4",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef70442 \" href=\"UTD.htm?4/41/4764\">",
"       table 5",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H26\">",
"       'Differential diagnosis'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/45/30424?source=see_link\">",
"       \"Approach to wheezing in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Diagnosis of asthma requires a history on episodic symptoms of airflow obstruction or bronchial hyperresponsiveness, demonstration (with spirometry if possible) that airflow obstruction is reversible, and exclusion of alternate diagnoses. If spirometry cannot be performed, a trial of medications may help to establish reversibility. (See",
"      <a class=\"local\" href=\"#H27\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      When the diagnosis of asthma is established in children who are not taking long-term control medications, asthma severity should be assessed (",
"      <a class=\"graphic graphic_table graphicRef61691 graphicRef51579 \" href=\"UTD.htm?15/60/16334\">",
"       table 6A, 6C",
"      </a>",
"      ) so that controller medications can be initiated if necessary. (See",
"      <a class=\"local\" href=\"#H31\">",
"       'Assessment of severity'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/30/37354?source=see_link\">",
"       \"Chronic asthma in children younger than 12 years: Controller medications\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     National Health Interview Survey (NHIS 2005), National Center for Health Statistics (NCHS), Centers for Disease Control and Prevention. Hyattsville, MD 2005. www.cdc.gov/nchs/fastats/asthma.htm (Accessed on February 11, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/25/26010/abstract/2\">",
"      Speight AN, Lee DA, Hey EN. Underdiagnosis and undertreatment of asthma in childhood. Br Med J (Clin Res Ed) 1983; 286:1253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/25/26010/abstract/3\">",
"      Marchant JM, Masters IB, Taylor SM, et al. Evaluation and outcome of young children with chronic cough. Chest 2006; 129:1132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/25/26010/abstract/4\">",
"      Johnson D, Osborn LM. Cough variant asthma: a review of the clinical literature. J Asthma 1991; 28:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/25/26010/abstract/5\">",
"      Wasserfallen JB, Schaller MD, Feihl F, Perret CH. Sudden asphyxic asthma: a distinct entity? Am Rev Respir Dis 1990; 142:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/25/26010/abstract/6\">",
"      Saetta M, Thiene G, Crescioli S, Fabbri LM. Fatal asthma in a young patient with severe bronchial hyperresponsiveness but stable peak flow records. Eur Respir J 1989; 2:1008.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/25/26010/abstract/7\">",
"      Maffei FA, van der Jagt EW, Powers KS, et al. Duration of mechanical ventilation in life-threatening pediatric asthma: description of an acute asphyxial subgroup. Pediatrics 2004; 114:762.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/25/26010/abstract/8\">",
"      Br&eacute;mont F. [From asthma attack to fatal asthma in children]. Arch Pediatr 2004; 11 Suppl 2:86s.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/25/26010/abstract/9\">",
"      Schmitz T, von Kries R, Wjst M, Schuster A. A nationwide survey in Germany on fatal asthma and near-fatal asthma in children: different entities? Eur Respir J 2000; 16:845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/25/26010/abstract/10\">",
"      Gern JE. Viral respiratory infection and the link to asthma. Pediatr Infect Dis J 2008; 27:S97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/25/26010/abstract/11\">",
"      Heymann PW, Carper HT, Murphy DD, et al. Viral infections in relation to age, atopy, and season of admission among children hospitalized for wheezing. J Allergy Clin Immunol 2004; 114:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/25/26010/abstract/12\">",
"      Tarlo SM, Broder I, Corey P, et al. A case-control study of the role of cold symptoms and other historical triggering factors in asthma exacerbations. Can Respir J 2000; 7:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/25/26010/abstract/13\">",
"      Johnston NW, Johnston SL, Norman GR, et al. The September epidemic of asthma hospitalization: school children as disease vectors. J Allergy Clin Immunol 2006; 117:557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/25/26010/abstract/14\">",
"      Virant FS. Sinusitis and pediatric asthma. Pediatr Ann 2000; 29:434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/25/26010/abstract/15\">",
"      Tsao CH, Chen LC, Yeh KW, Huang JL. Concomitant chronic sinusitis treatment in children with mild asthma: the effect on bronchial hyperresponsiveness. Chest 2003; 123:757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/25/26010/abstract/16\">",
"      Biscardi S, Lorrot M, Marc E, et al. Mycoplasma pneumoniae and asthma in children. Clin Infect Dis 2004; 38:1341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/25/26010/abstract/17\">",
"      Emre U, Roblin PM, Gelling M, et al. The association of Chlamydia pneumoniae infection and reactive airway disease in children. Arch Pediatr Adolesc Med 1994; 148:727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/25/26010/abstract/18\">",
"      Webley WC, Salva PS, Andrzejewski C, et al. The bronchial lavage of pediatric patients with asthma contains infectious Chlamydia. Am J Respir Crit Care Med 2005; 171:1083.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/25/26010/abstract/19\">",
"      Guill M. Exercise-induced bronchospasm in children: effects and therapies. Pediatr Ann 1996; 25:146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/25/26010/abstract/20\">",
"      Uyan ZS, Carraro S, Piacentini G, Baraldi E. Swimming pool, respiratory health, and childhood asthma: should we change our beliefs? Pediatr Pulmonol 2009; 44:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/25/26010/abstract/21\">",
"      Font-Ribera L, Villanueva CM, Nieuwenhuijsen MJ, et al. Swimming pool attendance, asthma, allergies, and lung function in the Avon Longitudinal Study of Parents and Children cohort. Am J Respir Crit Care Med 2011; 183:582.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/25/26010/abstract/22\">",
"      Piacentini GL, Baraldi E. Pro: swimming in chlorinated pools and risk of asthma: we can now carry on sending our children to swimming pools! Am J Respir Crit Care Med 2011; 183:569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/25/26010/abstract/23\">",
"      Bernard A, Voisin C, Sardella A. Con: respiratory risks associated with chlorinated swimming pools: a complex pattern of exposure and effects. Am J Respir Crit Care Med 2011; 183:570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/25/26010/abstract/24\">",
"      Cook DG, Strachan DP. Health effects of passive smoking. 3. Parental smoking and prevalence of respiratory symptoms and asthma in school age children. Thorax 1997; 52:1081.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/25/26010/abstract/25\">",
"      Mannino DM, Moorman JE, Kingsley B, et al. Health effects related to environmental tobacco smoke exposure in children in the United States: data from the Third National Health and Nutrition Examination Survey. Arch Pediatr Adolesc Med 2001; 155:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/25/26010/abstract/26\">",
"      Young S, Le Sou&euml;f PN, Geelhoed GC, et al. The influence of a family history of asthma and parental smoking on airway responsiveness in early infancy. N Engl J Med 1991; 324:1168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/25/26010/abstract/27\">",
"      De Vera MJ, Drapkin S, Moy JN. Association of recurrent wheezing with sensitivity to cockroach allergen in inner-city children. Ann Allergy Asthma Immunol 2003; 91:455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/25/26010/abstract/28\">",
"      Matsui EC, Wood RA, Rand C, et al. Cockroach allergen exposure and sensitization in suburban middle-class children with asthma. J Allergy Clin Immunol 2003; 112:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/25/26010/abstract/29\">",
"      Perry T, Matsui E, Merriman B, et al. The prevalence of rat allergen in inner-city homes and its relationship to sensitization and asthma morbidity. J Allergy Clin Immunol 2003; 112:346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/25/26010/abstract/30\">",
"      Gruchalla RS, Pongracic J, Plaut M, et al. Inner City Asthma Study: relationships among sensitivity, allergen exposure, and asthma morbidity. J Allergy Clin Immunol 2005; 115:478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/25/26010/abstract/31\">",
"      Nelson HS, Szefler SJ, Jacobs J, et al. The relationships among environmental allergen sensitization, allergen exposure, pulmonary function, and bronchial hyperresponsiveness in the Childhood Asthma Management Program. J Allergy Clin Immunol 1999; 104:775.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/25/26010/abstract/32\">",
"      Erbas B, Akram M, Dharmage SC, et al. The role of seasonal grass pollen on childhood asthma emergency department presentations. Clin Exp Allergy 2012; 42:799.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/25/26010/abstract/33\">",
"      Samet JM, Marbury MC, Spengler JD. Health effects and sources of indoor air pollution. Part I. Am Rev Respir Dis 1987; 136:1486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/25/26010/abstract/34\">",
"      Chauhan AJ, Inskip HM, Linaker CH, et al. Personal exposure to nitrogen dioxide (NO2) and the severity of virus-induced asthma in children. Lancet 2003; 361:1939.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/25/26010/abstract/35\">",
"      Eichenfield LF, Hanifin JM, Beck LA, et al. Atopic dermatitis and asthma: parallels in the evolution of treatment. Pediatrics 2003; 111:608.",
"     </a>",
"    </li>",
"    <li>",
"     Branum AM, Lukacs SL. Food allergy among U.S. children: Trends in prevalence and hospitalizations. NCHS data brief, no 10. Hyattsville, MD: National Center for Health Statistics. 2008.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/25/26010/abstract/37\">",
"      Roberts G, Patel N, Levi-Schaffer F, et al. Food allergy as a risk factor for life-threatening asthma in childhood: a case-controlled study. J Allergy Clin Immunol 2003; 112:168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/25/26010/abstract/38\">",
"      Denning DW, O'Driscoll BR, Hogaboam CM, et al. The link between fungi and severe asthma: a summary of the evidence. Eur Respir J 2006; 27:615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/25/26010/abstract/39\">",
"      Matsuoka H, Niimi A, Matsumoto H, et al. Specific IgE response to trichophyton and asthma severity. Chest 2009; 135:898.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/25/26010/abstract/40\">",
"      Hattevig G, Kjellman B, Bj&ouml;rkst&eacute;n B. Appearance of IgE antibodies to ingested and inhaled allergens during the first 12 years of life in atopic and non-atopic children. Pediatr Allergy Immunol 1993; 4:182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/25/26010/abstract/41\">",
"      Dold S, Wjst M, von Mutius E, et al. Genetic risk for asthma, allergic rhinitis, and atopic dermatitis. Arch Dis Child 1992; 67:1018.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/25/26010/abstract/42\">",
"      Kaufman HS, Frick OL. The development of allergy in infants of allergic parents: a prospective study concerning the role of heredity. Ann Allergy 1976; 37:410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/25/26010/abstract/43\">",
"      Bjerg A, Hedman L, Perzanowski MS, et al. Family history of asthma and atopy: in-depth analyses of the impact on asthma and wheeze in 7- to 8-year-old children. Pediatrics 2007; 120:741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/25/26010/abstract/44\">",
"      Happle R, Schnyder UW. Evidence for the Carter effect in atopy. Int Arch Allergy Appl Immunol 1982; 68:90.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/25/26010/abstract/45\">",
"      Mel&eacute;n E, Kere J, Pershagen G, et al. Influence of male sex and parental allergic disease on childhood wheezing: role of interactions. Clin Exp Allergy 2004; 34:839.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/25/26010/abstract/46\">",
"      R&ouml;nmark E, J&ouml;nsson E, Platts-Mills T, Lundb&auml;ck B. Different pattern of risk factors for atopic and nonatopic asthma among children--report from the Obstructive Lung Disease in Northern Sweden Study. Allergy 1999; 54:926.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/25/26010/abstract/47\">",
"      Burke W, Fesinmeyer M, Reed K, et al. Family history as a predictor of asthma risk. Am J Prev Med 2003; 24:160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/25/26010/abstract/48\">",
"      Ross KR, Storfer-Isser A, Hart MA, et al. Sleep-disordered breathing is associated with asthma severity in children. J Pediatr 2012; 160:736.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/25/26010/abstract/49\">",
"      Michelson PH, Williams LW, Benjamin DK, Barnato AE. Obesity, inflammation, and asthma severity in childhood: data from the National Health and Nutrition Examination Survey 2001-2004. Ann Allergy Asthma Immunol 2009; 103:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/25/26010/abstract/50\">",
"      Musaad SM, Patterson T, Ericksen M, et al. Comparison of anthropometric measures of obesity in childhood allergic asthma: central obesity is most relevant. J Allergy Clin Immunol 2009; 123:1321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/25/26010/abstract/51\">",
"      Ginde AA, Santillan AA, Clark S, Camargo CA Jr. Body mass index and acute asthma severity among children presenting to the emergency department. Pediatr Allergy Immunol 2010; 21:480.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/25/26010/abstract/52\">",
"      Hom J, Morley EJ, Sasso P, Sinert R. Body mass index and pediatric asthma outcomes. Pediatr Emerg Care 2009; 25:569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/25/26010/abstract/53\">",
"      Bender BG, Bartlett SJ, Rand CS, et al. Impact of interview mode on accuracy of child and parent report of adherence with asthma-controller medication. Pediatrics 2007; 120:e471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/25/26010/abstract/54\">",
"      Weinberger M, Abu-Hasan M. Life-threatening asthma during treatment with salmeterol. N Engl J Med 2006; 355:852.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/25/26010/abstract/55\">",
"      De Blaquiere P, Christensen DB, Carter WB, Martin TR. Use and misuse of metered-dose inhalers by patients with chronic lung disease. A controlled, randomized trial of two instruction methods. Am Rev Respir Dis 1989; 140:910.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/25/26010/abstract/56\">",
"      Khoshoo V, Le T, Haydel RM Jr, et al. Role of gastroesophageal reflux in older children with persistent asthma. Chest 2003; 123:1008.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/25/26010/abstract/57\">",
"      Debley JS, Carter ER, Redding GJ. Prevalence and impact of gastroesophageal reflux in adolescents with asthma: a population-based study. Pediatr Pulmonol 2006; 41:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/25/26010/abstract/58\">",
"      Zeiger RS, Szefler SJ, Phillips BR, et al. Response profiles to fluticasone and montelukast in mild-to-moderate persistent childhood asthma. J Allergy Clin Immunol 2006; 117:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/25/26010/abstract/59\">",
"      Szefler SJ, Phillips BR, Martinez FD, et al. Characterization of within-subject responses to fluticasone and montelukast in childhood asthma. J Allergy Clin Immunol 2005; 115:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/25/26010/abstract/60\">",
"      Federico MJ, Covar RA, Brown EE, et al. Racial differences in T-lymphocyte response to glucocorticoids. Chest 2005; 127:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/25/26010/abstract/61\">",
"      Gauvreau GM, Inman MD, Kelly M, et al. Increased levels of airway neutrophils reduce the inhibitory effects of inhaled glucocorticosteroids on allergen-induced airway eosinophils. Can Respir J 2002; 9:26.",
"     </a>",
"    </li>",
"    <li>",
"     National Asthma Education and Prevention Program: Expert panel report III: Guidelines for the diagnosis and management of asthma. Bethesda, MD: National Heart, Lung, and Blood Institute, 2007. (NIH publication no. 08-4051). www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm (Accessed on February 11, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/25/26010/abstract/63\">",
"      Vahlkvist S, Pedersen S. Fitness, daily activity and body composition in children with newly diagnosed, untreated asthma. Allergy 2009; 64:1649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/25/26010/abstract/64\">",
"      Chen E, Chim LS, Strunk RC, Miller GE. The role of the social environment in children and adolescents with asthma. Am J Respir Crit Care Med 2007; 176:644.",
"     </a>",
"    </li>",
"    <li>",
"     National Asthma Education and Prevention Program: Expert panel report 3 (EPR3): Guidelines for the diagnosis and management of asthma. Bethesda, MD: National Heart, Lung, and Blood Institute, 2007. (NIH publication no. 08-4051). www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm (Accessed on February 11, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/25/26010/abstract/66\">",
"      British Thoracic Society Scottish Intercollegiate Guidelines Network. British Guideline on the Management of Asthma. Thorax 2008; 63 Suppl 4:iv1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/25/26010/abstract/67\">",
"      Papadopoulos NG, Arakawa H, Carlsen KH, et al. International consensus on (ICON) pediatric asthma. Allergy 2012; 67:976.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/25/26010/abstract/68\">",
"      Lung function testing: selection of reference values and interpretative strategies. American Thoracic Society. Am Rev Respir Dis 1991; 144:1202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/25/26010/abstract/69\">",
"      Paull K, Covar R, Jain N, et al. Do NHLBI lung function criteria apply to children? A cross-sectional evaluation of childhood asthma at National Jewish Medical and Research Center, 1999-2002. Pediatr Pulmonol 2005; 39:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/25/26010/abstract/70\">",
"      Bacharier LB, Dawson C, Bloomberg GR, et al. Hospitalization for asthma: atopic, pulmonary function, and psychological correlates among participants in the Childhood Asthma Management Program. Pediatrics 2003; 112:e85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/25/26010/abstract/71\">",
"      Fuhlbrigge AL, Kitch BT, Paltiel AD, et al. FEV(1) is associated with risk of asthma attacks in a pediatric population. J Allergy Clin Immunol 2001; 107:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/25/26010/abstract/72\">",
"      Fuhlbrigge AL, Weiss ST, Kuntz KM, et al. Forced expiratory volume in 1 second percentage improves the classification of severity among children with asthma. Pediatrics 2006; 118:e347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/25/26010/abstract/73\">",
"      Simon MR, Chinchilli VM, Phillips BR, et al. Forced expiratory flow between 25% and 75% of vital capacity and FEV1/forced vital capacity ratio in relation to clinical and physiological parameters in asthmatic children with normal FEV1 values. J Allergy Clin Immunol 2010; 126:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/25/26010/abstract/74\">",
"      Galant SP, Morphew T, Amaro S, Liao O. Value of the bronchodilator response in assessing controller na&iuml;ve asthmatic children. J Pediatr 2007; 151:457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/25/26010/abstract/75\">",
"      Dundas I, Chan EY, Bridge PD, McKenzie SA. Diagnostic accuracy of bronchodilator responsiveness in wheezy children. Thorax 2005; 60:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/25/26010/abstract/76\">",
"      Jenkins HA, Cherniack R, Szefler SJ, et al. A comparison of the clinical characteristics of children and adults with severe asthma. Chest 2003; 124:1318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/25/26010/abstract/77\">",
"      Bacharier LB, Strunk RC, Mauger D, et al. Classifying asthma severity in children: mismatch between symptoms, medication use, and lung function. Am J Respir Crit Care Med 2004; 170:426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/25/26010/abstract/78\">",
"      Spahn JD, Cherniack R, Paull K, Gelfand EW. Is forced expiratory volume in one second the best measure of severity in childhood asthma? Am J Respir Crit Care Med 2004; 169:784.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/25/26010/abstract/79\">",
"      Song TW, Kim KW, Kim ES, et al. Utility of impulse oscillometry in young children with asthma. Pediatr Allergy Immunol 2008; 19:763.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/25/26010/abstract/80\">",
"      Larsen GL, Morgan W, Heldt GP, et al. Impulse oscillometry versus spirometry in a long-term study of controller therapy for pediatric asthma. J Allergy Clin Immunol 2009; 123:861.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/25/26010/abstract/81\">",
"      Shi Y, Aledia AS, Tatavoosian AV, et al. Relating small airways to asthma control by using impulse oscillometry in children. J Allergy Clin Immunol 2012; 129:671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/25/26010/abstract/82\">",
"      Komarow HD, Skinner J, Young M, et al. A study of the use of impulse oscillometry in the evaluation of children with asthma: analysis of lung parameters, order effect, and utility compared with spirometry. Pediatr Pulmonol 2012; 47:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/25/26010/abstract/83\">",
"      Martinez FD, Wright AL, Taussig LM, et al. Asthma and wheezing in the first six years of life. The Group Health Medical Associates. N Engl J Med 1995; 332:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/25/26010/abstract/84\">",
"      Lewiston NJ. What is wheezy bronchitis? Pediatr Ann 1989; 18:792.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/25/26010/abstract/85\">",
"      Crapo RO, Casaburi R, Coates AL, et al. Guidelines for methacholine and exercise challenge testing-1999. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999. Am J Respir Crit Care Med 2000; 161:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/25/26010/abstract/86\">",
"      Laoudi Y, Nikasinovic L, Sahraoui F, et al. Passive smoking is a major determinant of exhaled nitric oxide levels in allergic asthmatic children. Allergy 2010; 65:491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/25/26010/abstract/87\">",
"      Reddel HK, Taylor DR, Bateman ED, et al. An official American Thoracic Society/European Respiratory Society statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice. Am J Respir Crit Care Med 2009; 180:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/25/26010/abstract/88\">",
"      Bousquet J, Mantzouranis E, Cruz AA, et al. Uniform definition of asthma severity, control, and exacerbations: document presented for the World Health Organization Consultation on Severe Asthma. J Allergy Clin Immunol 2010; 126:926.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/25/26010/abstract/89\">",
"      L&oslash;drup Carlsen KC, Hedlin G, Bush A, et al. Assessment of problematic severe asthma in children. Eur Respir J 2011; 37:432.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/25/26010/abstract/90\">",
"      Forno E, Fuhlbrigge A, Soto-Quir&oacute;s ME, et al. Risk factors and predictive clinical scores for asthma exacerbations in childhood. Chest 2010; 138:1156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/25/26010/abstract/91\">",
"      Wildfire JJ, Gergen PJ, Sorkness CA, et al. Development and validation of the Composite Asthma Severity Index--an outcome measure for use in children and adolescents. J Allergy Clin Immunol 2012; 129:694.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/25/26010/abstract/92\">",
"      Wu AC, Tantisira K, Li L, et al. Predictors of symptoms are different from predictors of severe exacerbations from asthma in children. Chest 2011; 140:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/25/26010/abstract/93\">",
"      Liu AH, Zeiger R, Sorkness C, et al. Development and cross-sectional validation of the Childhood Asthma Control Test. J Allergy Clin Immunol 2007; 119:817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/25/26010/abstract/94\">",
"      Murphy KR, Zeiger RS, Kosinski M, et al. Test for respiratory and asthma control in kids (TRACK): a caregiver-completed questionnaire for preschool-aged children. J Allergy Clin Immunol 2009; 123:833.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/25/26010/abstract/95\">",
"      Chipps B, Zeiger RS, Murphy K, et al. Longitudinal validation of the Test for Respiratory and Asthma Control in Kids in pediatric practices. Pediatrics 2011; 127:e737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/25/26010/abstract/96\">",
"      Zeiger RS, Mellon M, Chipps B, et al. Test for Respiratory and Asthma Control in Kids (TRACK): clinically meaningful changes in score. J Allergy Clin Immunol 2011; 128:983.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/25/26010/abstract/97\">",
"      Pifferi M, Bush A, Pioggia G, et al. Monitoring asthma control in children with allergies by soft computing of lung function and exhaled nitric oxide. Chest 2011; 139:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/25/26010/abstract/98\">",
"      Smith LA, Bokhour B, Hohman KH, et al. Modifiable risk factors for suboptimal control and controller medication underuse among children with asthma. Pediatrics 2008; 122:760.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5742 Version 20.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-118.195.65.248-72FD83CAD0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_25_26010=[""].join("\n");
var outline_f25_25_26010=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H34\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      HISTORY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Symptoms",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Cough",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Wheeze",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Seasonal symptoms",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Symptom patterns",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Precipitating factors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Viral URI",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Exercise",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Weather",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Tobacco smoke",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Allergens",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Other exposures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Additional history",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Allergic history",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Family history",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Environment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Past medical history",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Medications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Medical utilization",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - School attendance",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Physical activity",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Psychosocial profile",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      PHYSICAL EXAMINATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Spirometry",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Children &lt;5 years",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Ancillary studies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      ASSESSMENT OF SEVERITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      ASSESSMENT OF CONTROL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ALLRG/5742\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/5742|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?17/61/18399\" title=\"figure 1\">",
"      Obstructive defect on spirometry in a 9-year-old child",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?24/11/24762\" title=\"figure 2\">",
"      Childhood Asthma Control Test for children aged 4 to 11 years",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/5742|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?0/29/476\" title=\"table 1\">",
"      Dx and initial assessment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?25/35/26171\" title=\"table 2\">",
"      Triggers of asthma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?6/48/6923\" title=\"table 3\">",
"      Environmental history of asthma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/40/24204\" title=\"table 4\">",
"      Causes of wheeze in children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?4/41/4764\" title=\"table 5\">",
"      Nonasthmatic features",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?14/35/14909\" title=\"table 6A\">",
"      Asthma severity 5 to 11 yrs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?6/11/6333\" title=\"table 6B\">",
"      Asthma control 5 to 11 yrs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?40/41/41628\" title=\"table 6C\">",
"      Asthma severity 0 to 4 yrs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?28/37/29276\" title=\"table 6D\">",
"      Asthma control 0 to 4 yrs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?10/52/11085\" title=\"table 7\">",
"      Composite Asthma Severity Index",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/16/33034?source=related_link\">",
"      Acute asthma exacerbations in children: Outpatient management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/48/34569?source=related_link\">",
"      Allergen avoidance in the treatment of asthma and allergic rhinitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/2/34856?source=related_link\">",
"      Allergic conjunctivitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/9/17561?source=related_link\">",
"      Approach to chronic cough in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/45/30424?source=related_link\">",
"      Approach to wheezing in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/61/21464?source=related_link\">",
"      Assessment of stridor in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/26/8618?source=related_link\">",
"      Beta agonists in asthma: Acute administration and prophylactic use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/30/37354?source=related_link\">",
"      Chronic asthma in children younger than 12 years: Controller medications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/61/15319?source=related_link\">",
"      Chronic asthma in children younger than 12 years: Definition, epidemiology, and pathophysiology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/47/39670?source=related_link\">",
"      Chronic asthma in children younger than 12 years: Quick-relief agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/41/41625?source=related_link\">",
"      Clinical manifestations and diagnosis of gastroesophageal reflux disease in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/29/14808?source=related_link\">",
"      Clinical manifestations of food allergy: An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/34/35370?source=related_link\">",
"      Clinical manifestations, pathophysiology, and diagnosis of chronic rhinosinusitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/49/28442?source=related_link\">",
"      Cystic fibrosis: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/18/31014?source=related_link\">",
"      Delivery of inhaled medication in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/31/12789?source=related_link\">",
"      Enhancing patient adherence to asthma therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/40/42631?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of atopic dermatitis (eczema)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/30/1513?source=related_link\">",
"      Exercise-induced bronchoconstriction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/15/7416?source=related_link\">",
"      Exhaled nitric oxide analysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/35/6713?source=related_link\">",
"      Mycoplasma pneumoniae infection in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/13/7383?source=related_link\">",
"      Natural history of asthma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/27/29112?source=related_link\">",
"      Overview of pulmonary function testing in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/55/32633?source=related_link\">",
"      Overview of skin testing for allergic disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/11/16567?source=related_link\">",
"      Paradoxical vocal cord motion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?37/0/37892?source=related_link\">",
"      Patient information: Asthma symptoms and diagnosis in children (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?17/60/18374?source=related_link\">",
"      Patient information: Asthma treatment in children (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?13/7/13427?source=related_link\">",
"      Patient information: Cough in children (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/53/854?source=related_link\">",
"      Peak expiratory flow rate monitoring in asthma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/18/33062?source=related_link\">",
"      Pneumonia caused by Chlamydophila (Chlamydia) species in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/12/20682?source=related_link\">",
"      Risk factors for asthma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/59/26551?source=related_link\">",
"      Role of allergy in atopic dermatitis (eczema)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/4/5194?source=related_link\">",
"      Secondhand smoke exposure: Effects in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/28/12746?source=related_link\">",
"      The natural history of childhood food allergy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/57/36760?source=related_link\">",
"      The use of inhaler devices in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/9/44184?source=related_link\">",
"      Trigger control to enhance asthma management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/15/2298?source=related_link\">",
"      Virus-induced wheezing and asthma: An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/41/1689?source=related_link\">",
"      Wheezing illnesses other than asthma in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/6/34920?source=related_link\">",
"      Wheezing phenotypes and prediction of asthma in young children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f25_25_26011="Criteria for pulmonary metastatic disease in Ewings sarcoma";
var content_f25_25_26011=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F78727&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F78727&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Criteria for pulmonary/pleural metastatic disease as used in the EURO-E.W.I.N.G.99 Ewing sarcoma trial",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        CT chest finding",
"       </td>",
"       <td class=\"subtitle1\">",
"        Interpretation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        <p>",
"         One or more pulmonary/pleural nodule(s) &gt;1 cm",
"        </p>",
"        <p>",
"         <strong>",
"          OR",
"         </strong>",
"        </p>",
"        <p>",
"         More than one nodule &gt;0.5 cm",
"        </p>",
"       </td>",
"       <td class=\"centered\">",
"        Clear evidence of metastatic disease (in the absence of other clear medical explanation for these lesions).",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"centered\">",
"        <p>",
"         Solitary nodule of 0.5-1 cm",
"        </p>",
"        <p>",
"         <strong>",
"          OR",
"         </strong>",
"        </p>",
"        <p>",
"         Multiple nodules 0.3-0.5 cm",
"        </p>",
"       </td>",
"       <td class=\"centered\">",
"        Questionable evidence of metastatic disease; biopsy proof recommended.",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"centered\">",
"        <p>",
"         Solitary nodule &lt;0.5 cm",
"        </p>",
"        <p>",
"         <strong>",
"          OR",
"         </strong>",
"        </p>",
"        <p>",
"         Several nodules &lt;0.3 cm",
"        </p>",
"       </td>",
"       <td class=\"centered\">",
"        Not clear evidence of lung disease. Individual decision-making regarding biopsy.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_25_26011=[""].join("\n");
var outline_f25_25_26011=null;
var title_f25_25_26012="HPO axis and amenorrhea";
var content_f25_25_26012=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F73995&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F73995&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Major causes of amenorrhea due to abnormalities in the hypothalamic-pituitary-ovarian axis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Abnormality",
"       </td>",
"       <td class=\"subtitle1\">",
"        Causes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"12\">",
"        Hypothalamic dysfunction",
"       </td>",
"       <td>",
"        Congenital gonadotroph-releasing hormone deficiency",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Functional hypothalamic amenorrhea",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        - Weight loss, eating disorders",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        - Exercise",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        - Stress",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        - Severe or prolonged illness",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        - Heterozygous mutations - FGFR1, PROKR2, KAL1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Inflammatory or infiltrative diseases",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Brain tumors - eg, craniopharyngioma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cranial irradiation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Traumatic brain injury",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Other syndromes - Prader-Willi, Laurence-Moon-Biedl",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"6\">",
"        Pituitary dysfunction",
"       </td>",
"       <td>",
"        Hyperprolactinemia including lactotroph adenomas",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Other pituitary tumors - acromegaly, corticotroph adenomas (Cushing's disease)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Other tumors - meninigioma, germinoma, glioma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Genetic causes of hypopituitarism",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Empty sella syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pituitary infarct or apoplexy",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"4\">",
"        Ovarian dysfunction",
"       </td>",
"       <td>",
"        Polycystic ovary syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Premature ovarian failure (primary ovarian insufficiency)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        - Surgical",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        - Autoimmune, genetic, ovarian toxins, idiopathic",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"4\">",
"        Other",
"       </td>",
"       <td>",
"        Hyperthyroidism",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hypothyroidism",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Diabetes mellitus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Exogenous androgen use",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_25_26012=[""].join("\n");
var outline_f25_25_26012=null;
var title_f25_25_26013="Infarct size mortality MI";
var content_f25_25_26013=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F79558&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F79558&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 493px\">",
"   <div class=\"ttl\">",
"    Infarct size measured by sestamibi predicts mortality",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 473px; height: 271px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Among 274 patients with a myocardial infarction who had infarct size measured using 99m technetium sestamibi, the mortality at two years was lower in those with an infarct size &lt;12 percent of the left ventricle (0 versus 7 percent for those with infarct size &ge;12 percent).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Miller TD, Christian TF, Hopfenspirger MR, et al, Circulation 1995; 92:334.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_25_26013=[""].join("\n");
var outline_f25_25_26013=null;
var title_f25_25_26014="Thin blood smear 4";
var content_f25_25_26014=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F72364&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F72364&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Thin blood smear 4",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 359px; height: 238px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCADuAWcDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDjdnHvS7STgjA9amC0u3nGOMV4Nz0bFcrxTGjB6jrVll9aaVPQ00xNFJk9AMU0RDuBirbIR0FIBV8xPKV0TjHSpBHuAP8AKpTGOD6VKi8c0mxqJHHHgDP0qwkfGO9PRMjIqVVwayci0iJYjk5JH0qYDC/pT8YHShvlqL3KGHjHr0pcAdqEcOetO6nGOooC5DKABk9R3qBuCfX61O5UnaCCR2FVpV+YkdT2rSJDI3IJw344OKXOR0qkBJ55znFX40JArRqxC1I12OWCsrFThgDnFDQ5zVoRjrjDdM4pxTPao5iuUz/Lxx1+tQzQgj1rTMNMaHnmqUxOJhS2m7PFVpLMDLOpOPQZrojD14z9aQ24ODtFaKrYh00zI01AYsKrbfRhgitOBCq4ZSMdDUkdvtfgDFWAhBwOnrUzncqMbCRoOTjtU6c88U0AsQOn9KkGcehrFstIUhgev4Ux24qQ4xxULsM1KGODYxnpSlsYIJKn0qhfXQiiLMCdorGtNXknuArAKpPGTW0aMprmREpqOh1gkPYZP1qTzMjtWVFO4PRse9WY5GYZArGVOxpGRcJzxyKswjCjvVOIbu34VcQ4NZS2sWi0gxU54TmoE+YcVP8Aw4xXPI1RUmJLYFSqNqdfzqNl3Oc4606XOzaOtUDIJ2w645PTrTcn1pVQ/wARoYc1ppsQRuMjtVOUhtyjirLupLAMCRUDjkk4q4kyON8Q6F9ruvNijRieDlR/WiuolUEYPNFd9PFzjGxi4Ju7ECEAAseuelPxgYwMGnjqcg8GjHYdK5LmhGV456UhUdhxUuPXim4G3A4zzTTEQMM5qLaRkFelWivbvTQDtG7APcelWmJogjy2D6dferCJzigJjtUijHXP40mxpD4x0yKk2+ooQehzTgMYxx9KybGKBikIzTj05pcAj2pDIDEEPyjBNIAS+D0qzjrTSuDwM0+YLFdI0TJC8nuajeMls981adeO9NVTk+lUmS0VfJwc4zTsLHyTj3qztBHSmEByVZc59RT5u4rCKvHHSn7exp+znGBTgKi5ViBlxjjNMZATlSPerRXOf0qs8flToy52nr7U0wsIUxzijA4wOvqKtbR259DSbcf/AFqOYViogDE5BypxUgXI44qYr1xzSKuPpTvcVhm0c+4pGXnOfepto4FMdfypXGZzXreeUEZIB61JIeM/0qbywoPH4gdaoy/ulYsT6jmtVZ7EPQgvIhNGyNnDdcVRg0mJGVm3MFNaUTec3y8g+lTkCMZzmtFOUdETZPcbEjIB8wKk9cVbjxxg1nyzeTEzDAVcnjmsS38R5uAGj2oT2601RlU1QcyjuduirjsfrU4wcHPQ1n2s28BjzV+PHGK4pxsbxdydiyxkxruYdqfBK8ke6RNjelNjbD7QCABnPb6U/PQkDPUe1Ys1QoHU4qKXDYG4jnPBxT2eogAWBOAaEhsdt5FRuP8AOOlS5qJiSeaaJKM42ZK4GTzUZJxlqsTISnQMe3b6UyRABk9BW6ehm0Yup6gtqgLAnJ4AopNVsPtcYUcEHvRXbSVHl97czknc1tgVSEAA9qjAYHmrJHHAyfSkwMVxpmhH2qPdj1609iFDMxCqOpz0pHRipC4De9NCEznimKpA5OfwqXbjv7UBSOTwKdwGp97lTjPWpcen/wCuo3cBsbSe/FSIKTAEyOOgHY8VOpzTFxgU8VDGOZQR2pVXAHHGKrSLdsxMTKFHQE0sF3lvKnUJKPyNFnYZZxx7UnfpTqMZ/KoGMK55poXknk045BwRTTu34A+XHXP+faqRLFIx0oCmlzg8dKUEEcUMYh460vSjvjrSYwKQCOTt45pV+YfN1pR1oJAqhCqMCkPQ01XDdCPrTzilYLjcc4BprsF9qf1HWmOgJzimhDAd/wDEQPQd6ceR6mmiNRlQMA08CqdhEUn5DFZt7DvTHGO1ardKryrxzVRdiWrmVYxeRuU96tMpYcE5609oyenUHpntSAlYwGXOOuK0bu7k2srDHj8yMg9B1FYz6LaJOrhGzuzhehrYuLhIYyZCFQDJJPAqKxnE8okRf3ZGVY9z/hWkJTim1sJ2ehdtgyJ90p1yvWtOHOBknNVU3csx61bQ8cVy1Hc2iTj2/CnE1Fk5GOlP6isGjRMhklIJ606PJpHXd0OKljHH9M0+gXGkHrnHv6VEWz0IIqeRQ64PQ9qasQUDaOKSYyLaCd3GcYz7VE6YXC9B681aKgVBJx2FWmSyn95m7gH06UUplAbbjnOB796K0M3YlGKXGSD/AEpCMikViSR2FSUAUAnA9qdsHWgfhT8n2pgRMuMH39aUqO1OcAgdqBxQBEV9qFXFS4BYDuO1IAaLiIWYqQF/Sp0PHNN8pTwccc0/FDaBIerYHXAps0aS7dw5HQ96AB1NBzznH5UhgpPenE7QeKbn8qCaQC5yM9qQkUjN16VC8gFUkJsm3ce1G786riQE8dOtJ5vPFPlFzFsH2pT9Kro+c4qZOam1hpiom3vnmnFc8EUAE44/SlGM8jigYzYPTFOPQ9qft4OOTQRx2446UrhYrRKy7tzbsnI9vapl+70zmnBR2H1poUhzk/L2HpTbuK1iJ4zuyDjNKCFGDyalb5uCagkQE4HUfpTTvuJivyBjpUMh3DmnnpjrUUzFFyBwB0qkhMqyOdrFAQc1Tmu9gJcqFHVicAe9TyPuTd0z2rl9TuUurkwKT5EZzI44GR2HrXXSp87szGUrFqEtqdyZHLLaKcKDxvPf8K6S0jVQAvpxj0xWNYSR7FKYIPIGOa27V1eMbQAR6jFKu3t0CC7lpRnAB4q3H0qrECTuPbirKVxyOiJLjsKUZxTO/TGPSlJPc9qzZYigqxOSakU0wnA96ZHIXyMYwe/eizYbFjPXtimq4IppY4zQjccjFTYdxzetQS4wae7AYHf6VBK3HrVRRLKlxLHFy5CjPU0VheKjOsMfkjKE/MAOc0V6NHDKpHmbMZOzOmxkHNG2lBNLXCbDAPrk0/t7VEJSbloRG+AgfzMfKckjAPrx/KpRjOec0CE2jIz2p2OMjNIT37Uit9aAFHDdPxpwwfrSdR2zSFsUgHYFNJH0ppNRAkNyfeqSE2Tk80H1PH4Ui04jnv8ASkMZt2rhRz/OhjhckgY9eKe1ROKa1Exrnj8KrMvzFsn8acxbcQelROcDmtYqxEmNaTA5NZ11qSQyqjHBbmp7g8HrXP3FlLJLJLJ82OVHU100oRfxGUm+h1NtPuGRWjHyQefaue0WOZQTNuAPQGt6FsKBz+NYVYqLsi4MsxqQwJNTCo06d6fnjrXMzZCjjr6UdqY74FRpI5YArjNCVxXLGeOg9v8AP50x8YxTDIA2CaikkO4Yx+NNRC5KePrTHPB6c0M2Bz1PeoZGxkknrVJEtiEnHHOar3EihctxQ0h/i+XjOPesfV77yI+AGduETPLGtqcHJ2REpWKWqXj3FwbW35JBDnpsHFKumwizSFWKhTngdTVK4Y2+CsJE0vLknO2prAXP2tXO/YSMjtiu7laj7rsY7sIdLmF+rZIQHgjsK6u1TpwahgXccgce1aMSYHTFclaq57msI22JEXA5GKe3ABOcA05VwnT8aft4xXG2b2IxyeM0jvjuMd6SQlMYHU0CIEY5/OjzAcrBqVRtxxSRIUGD60Sdev5UupXQk60xjg/rTFcMeGzSt0zStqFyNmNQM7FwMfLUkzYPNRFckHr9K0WhLGyR+ZiipQM59fSimpNCsSD0oz61G3TGcUnTB/yKVguTbqDyeDVVpWEqAKWU8E+lSq4/Gny2FceSM/zpARnPSmlh6daj3YPPSiwrljPWjg/SoPNBPXFOU0co7kh5/wAKhZXyORx6VMgCjHWjbxx1oTsA5Bgc9qf3/WkA6AcCngc5qGykMPXpUTHI4qZhgD39qicEZ7U0Jlac7QT3x9apTzKFy2B6n1q5L1Of/wBdY+rW8ksYEXY8jpXTSSbszKQsU8VxIVRwW7jNWEiAYZx6+tY+k6fNHd7mGM9Tn9K3o7ZkYgnLYOGIrWqlF2TIjdq9iRYyuCP59atRBnQMeD34pY1+Wp0XHGOK5nI0SHgfLgU7oOtKPalI44rK5oNZQcdM0wg54HWnTBip2HB9aibOwDILD3polgQud2MEiqrlsgnG0Hj61OciqNy53dMc44rSC1JbLTSAA9OKrzSbs7T0rOmvQjbWyzdqju7gRxh2YKmPmOefp9a1jSdyOcfe3QgQs5OBxx39qpWdlLLP9pvP9d/AufuD/Gn6dFNcyLNcA+WvMUTL90/3j6n0rcghwOlaSkqa5VuSlzamXNpyTkBs5HpVy2swgChcKK0FiAPQVIsfPoKwdVtWNFEZDGAMAVbRfXFIijIFTqv6VzykapAq/hTsU4D3oyM4zUNlkbx7uCBg0bD2/lUw6DjFLj2qbjsQtwKrykdO9WZQMHgVUZSeRkc8ZpxGyOKJlmDRsoi2ncu3ksSMHPpjPHv7VOVzT4UI+lPK1TlqJIpXEbMhCYD44LDIHvTGt1IG8u2P9oj9BjNXGGaYQSpB57VSkJorLFsIEYVUHYCip0B28jFFFxctyBun+NV5s4GDz34p+8HOM1GzZ6c961ijNsRSB7j1pwkAYJ/F1qMcAZ70nQ7u9XYm5KzDHNU7+4MMLydSBU7ZzuPQVWnKTRttIZTx1qopX1E2ZWnapPPeLEwG0856V0ULk4wa5SOxnFyNq4Tdnd2xXTRHGBn2rXEKN1yiiX1OT/Spl6VUjOR3GfSrMTdADmuKSNUyXgCnAYFGM4oAxxUFoRunrUTDmpm5GByKYxx1oQmVGXqD0qFowSf51dYZ7VEyZJ7H2/rWsZGbRXiiVSDjtxVgL3PT6U5kIBKjJFKuSo4GaHK4WFVfpUqD5Vz1pqrg5I5NSLjIAqGykOApCvOQeB2qVOWxzT3j2rn1pXAq89ePeq11KII/MOAoYA59+KtPwKp3B+U4OPeritSWzOl1e0Rwhk5bjPpS3EhYEx8ntXN3mm3D3rnHyMc7s8VqR5gh2lsJGvJJ9O9dzpQik4sx5m3qRXkkUZaSYHCDqB+lMsrOW9mSe8H7pTmKLAwPQn1qKC3/ALWuRM5JtIz8gJ++fU11EEO1Rx25oqT9mrLcEuZhBBt+tWlQfhTo1BXI+tTqv51wykbKJEE9aU4RSWICgZJNSlR3qC7hSaEpJnB64qE77l2sTwsjqrIQVPQipQRUFukcUKRRjCrwKlLYFTLcaJOCOaQRjcSOM01Tnp+VPzyMDPP5VOxQ4YpT24o7UmeMVBSFI3daYYwacSAOtIDnpmhAMwF46033qQg5/wBmmleaYELDNCLzg9anCAde9O2joafMBDtFFPcd8Z/HFFFwsYDnYCeai88F9vP1qSQcZb8qqSDaOM13JJnK2SGTt3pwfIz/ADrlLu4uhcSHeV+bCgdhW3p8sr26tL949fetp0XBJkKVy3fxtc2kkKOUZxgMO1VdKsRYWnlGUysSWLGrYIPNIPveox09KzTdrFEiLhRinhTuyD/9amZB64qZOueOvapuMkQHHHNTxOQoLCooyD0IOODipFHFZy1KRdjORzTj0qCI1K27a2zaGxwTyM1lbUtBnmm9QB6UgBA5xnuRxSHOeKdgIncRggfMfTuakXkAnvUbBjIOm0c1IB1x+tUyRwOPw4pxPyngdM1GBkjPIPP+fzokbYORx0NKwx0L703Dip4xk9KrQocnB4PIFTh9gJ70n5AiQgp1ySKSRz0NRNIC2Khlbg7aEhMkd+CMce9ZOrXDxW0jRjLgcCrMk3JUg59ao3U0caFmO3Hcnit6cdTOTOa02/uDfASuzKc7gT096t4bVrgogZbNT8z4++fSnRxyag7eUghtSRubHMg9vaugsbVIY1WNQijoBXbVqRhqlqZRi3oFpbCNQFUKBwAO1X1JRkAQnPehE9hU6KQ3sK86cr6nRFWHqvqc/WpAuB07UKo7U49vpWLZohpHFRsuRzUuRTcEk+nbilcZEVPUDJ96eQSBTtuKdii47DY1xQu7zCMYFPGMU8AUrjsA4Heg5H5Uo5xig9PaoGQu4BAzgntSJuDZJpzRgsCeopduO1VfQB+716UmcVGTjjPWmsT2pJBcl3Cml89DUAJK5fimMpLqQTx6VaiK5azk+1FRAgL70VNguYj5KEgg/hUDoTnkYq6VwOPyqJxz93g967Is52jDutMSaXfvK+uKtwRCNAoPAHerpAI71AzokiRswDt91T1Nauo5KzItYVQTx+lNkYAVMqYHTNVboNsPHT9aUdWDIzdorAFgKtRS7hkc1xNwt3JdH5XJB6V02liRYY1kHzAc1vVoqCvcUZXZswOMnAUZ68datqQTjmqUKkn3q2A+eMY6YxXHLc1RYTPFTA8c1FGDihnKvjBxjOaxtcu5IeufSmONwI6enNKD60ueP/rUwGqvGKdtz061GpO35jmkDHcR29qdhXJuFIx2ppwcduKTd+HvQz9+1FhXHPx/9bvULuA3zHrStID7dqzbu/it5MSyANVwg5OyE2aTSbs9KiZsc+ozVSG6WeIPGykE4BFVr278iMmRizE4UDqauNN3sS5Bf3SwkktgE7VOM81lpavfMDcbljBzsz/OrVnbPcP50y/MVwFIBwP8a2ILdVAAFbuapKy3MrcxHawBflwBtAFaCLgHvSRIAeuKl2nGM1ySlc2SsKuM9asKBUCJ0PNWVrORaHDp701iO1OOSO9RkEDqajcsaWHfOaduO0bcEZ9e1ROrHoTipUBAxzQ7DJB2z1pKUDmj8akpCqPXr7U7ikA4PWgH3pMBwPPandR2pqEN07etOx71LZSDGaQr6U8D0pSKVx2K5TJyQMU0IMGrGP8A9VNIpqQrEG31/SmtHnI7VORTGGelUmTYqkhTyePU0VPt5OOvtRVXFYySMg4qPHy53Ag8iptgI5AI9DSkDGTjiuhMxK20nqAKbsxkE1M4OQFB7dKhnYgg8VaJeg9UH19KbPEG6U9Wzjg09ckkMpAA65GDSvYLGY1ouRt/SpY4McY4q+Y8kdKQx4zzVc9w5RsUe0n+VWUGKYhBHqR1qYcDpzWUmUkKB3paQnikJ/8A11JQE+lISKYzUxn4ppE3JCQc5phbJ+hqtLKVbriq32uKSQxCVSQecHrWsYNkORobtrFyflI6U8uCOuapxybMjO4cDNPDk8k49BQ4iUhZp0idFd1DSMVQE9TgnA98A/lXP63bGV965/2jnhQO9aV7ciMHc59QB1PsBVA2Ut/gzl4oieIx1Yf7Rrpork95kSd9Cnp19P5JtrSLzWDH5s4VRgdfc1pWOmyFxPeSGafsOip7AVpWtosKBY4wqg9BV1IwOADU1K6u+VWGodyKGMKKsxqD0FKqYGMUqZGd3UmuVu5olYeoxT1GTjv1xTQeaEX5ywJ57VDKRMMD2p4/WoC3T1xmpUJwM1LRRMAKQqOc0qdR3p1ZlkRTA4pMYNSEY7Unfmi40HNITjrQx9OlMY+9FgDeMcUscgb15qImlQ1VgLKfXipARg5qBWqRTjrWTRSZIpDD5aAc96TPpjFI8ioVVjgt0qSh56DrTHPvzT24HPHOKif86aAa3pSE4x1pCTSHtzxVWJZCWfeRj5aKkIyKKvQkzcjoDz1xS4/xpOP6in9BnvWpmREAkDv1phi3HLYOKmRQqhcEADAzzTwvHIquawrFZoznIOO9SKMjA6VIVFJ0z2ovcLDQpHuaUrTiQvJOKRjxwBmkOwAAYwfpTh270Dp/Sm59cfQ0CFzUYJyMkflTieemKY54yOnrTQhkj45qjPeRpgO6qT6mrE7ZzXP31pJLO7KCVxnr+GK6KUIyfvGbv0L19cbrSTyzuOMDHNY1tOLeQyshbuCe3vVzRLWVI380YUnjdWobKORgWRSw6HHSuhSjTvHdEavUS0kb7FG8pUMUBZtu0Z+lNPmyjbENoPVz1/KrlvaIhLDJY8Esc1djiCjoK55VIp6FKLZQtbFY/mPLnqx6n/Cr6QgDgYqZUAFTBawlUb3LUSBEIxwKeFxUgxvxwDjIHqKXjdjAzUNlpEZGMZ4qKcHadn3u31qwR6dKa6ggg9/Q4oTBojAwTk9f0pRj8KY5CqcYrHvtcgs7gROGLd8CtIQlPSJLdtzdB/egnrtOPzFWV7Vl204mCSISRj9DWjGwIyDxWc4tblJ3LCmndOajXB6jinEjGP1rFmiEkfCs2M4ycDqaTOQOMd8U0nH0ppAZlbuO4JosMUkg8AYqF2wDUjnI4qtO2AcVcUS2NaYA9afHICf8K5PxDeSwlI4mwHHIHWrPhv7Tk+dv2MAQCc811vD2p87Znza2OsQ8diKduwRt5+tQx9B61KqgNn+tcTNkToehNR30PniLbgFGzmnKTn0p3b+tZ7MtDmbkk4NRMfQ04gkYBqv8y53kdTjHpQkDHO2KYW5wDxVO5uFiGWbFNjuA6Ajoa2UHa5m5LYvbvSiqomA4JxRRysLkPJ9RTskEYJ9Mdqdt59KY2d4xn3rTcgePrTwOPWmqMetPxgdKkaGngcmk7ClIH50h4A460wGNgj5qcMD61EWO/H608EAjJGScfjTsIeeaONvWgEZ96OlADCPTNRSDqPSpzz15qN1z0/WmmJlWXBH0rA1u4MKoq7gSeceldI0akZ5rOvdNS65YZx6V00ZxjL3tjKSKmhSyTwnflgOjHvW9EntUFparEihVwAMYq9GpzUVZqTbQRjYVUwAKcXRZEiZlWRwSqk8sB1x+YqQLznvTwuSOM+ma52zVIEH41IozxSID3qYLwKhsqwzGKbt5z3xj/P51MVOKic7eSaSHYbjnIqM8etS8AZP6U1sZwOoqkxWKc4zxzXKa1pzz36ukTNwOR3rsXj646nuKiMQPaumlW9m7oylG+hm6TFLHGolGCRjHp6D/AD6VtR9KgCHaemc+mO/FWFGMelZVJczuXFWJYm654qQe1MUdsdKcOOKxZaEYU3pTmcAqNrYPtwKaT9KQxj4JxVeVcjip2PeopG4yx4FWiWY97pUN3MHfIIGOO4q/Z2ywqqooGBge1TDGNxOR61JGAcY71rKpJqzZKjqSDKpkBmPoOvWpVHFMXinA+/Fc7NUS5oJ96Zn1/CkY81Firjie+TUMv1NOLj1GaY3WqSE2UbuAS8EfpUcURj4zwKtyew71G3B71upO1jJrUbtBzxRTPlXAUYA447UUgJ8e3SkAp/HSgdeam5VgUAAYpT0pF4+lKcgUAM3qSBuBbOMZ79f5UkhAUk8AU2RRIrbeGwQrY5GfSkjUQJHE8oLtnbk4JPtTAUgdqUj/ADmlPtSE4NVckYcjnpSjpjHtijIzRnmgQ6gigc0gBPPakMbJ8qFlXcc9KVFyinGPxqUU5RnqefenfQViMLxUijH/AOulxQTtHtSvcLWJEFSqO1V4HD8j86srzUS0KQ7A4p/UUxTlQakXkDt9agqwdFI7VHtAAHXFSdBk0uKEx2ItvHtTdo5OBmp8UzFO4rEBXNNKHPXgVYxxTOvt+FNSFYgK4XnpkGpRSuu5SCODwaXGfrQ2FgFBNB6cc0w0hi5Gf1pGPHFISPqT+lQyOS3HSmlcTEd/XtUbsp4bGKjlcH/9dZuq3YgtXYkjjGR1raEOZ2RDZqFlJKgqQPQ1LGwwAOlcXpk8gulaNmbJ556/UV18Le4FaVqPs9BRlctqw3FcHIAPTin9e9RqcU/P4muVrU2Q4fWmTPhTTyR074qOSPKketJbjZXt2BO4nNTbvbt60iIAMChhzVu1ySORvpmoJHGOtSSnrWXd3XlpKzqyKpwC2PmHqPb61cY3IZZeQ9qK5b/hIYTKQWIGeuaK6vqs10MnUR3AIxSMcc0zeo6kZ9KCc1xWN7iqwPGc9qf6iolxUqnINNghpHApQMnOBkdKXHXk00njpRcQ1zULyYPNPc8cmoWIPJFWkSxd2BShxnk1CzEdR2rD1TXBYzKirvYjJycYFawpubsiJSS3OmQkk4qeMZIA59a57SL17/8Aeb9qZ5Uetb0bgDjp61lODi7MuLTRMyhTzSKKXOSCx5FOXkdKzLDHy0uB+VH55pUzzmi4BFhsFcEEAgjoalHA7GmBSGyM4PUf1qUenapbBDYWJLD0b9KnHamAYNSDkDmoZSBlDAg80hOPpSk0jEe1IY0sMdRzS+9NPPNL2pgB6U3t2oJpRTENIFNPGeac3+c1ExqkJikj/wCtUbuPbFKx5BzUEjY5zimkK4rvjgGq0kpHPanu+FOegrG1nUUs7feVJ5xgeta04OTsiJSsrli6vI4Vcy/IB1asJLuS5u2TAkgc8D2qtFqSasGt5EKFvQ56Ve0/S1gulmSVjhcba71CNJPm3Mebm2NGzsoomyi4PrWvEMVVhXA5z+FW4+OtcdSTluaxRYXjp+dPUnvUatxTlYj6Vzs2RKCfwoPPv+NNDce3c07tjNSMTpUbnipPamMAaaEVZDnP9ayNVt/Pt3jzw3FbEp4JqlcEZ7g1tTdnczkeftoNwLggjKdd1FdsygfePNFej9cmc7poulsgHgkHjP8An2qWJm+bfjrxgdB/U1WQ8e9Kkm714rzmjpLIbJwfyqVTj6VXjUbs96lzx9KTAlzmmk4GKaCSpIPNIx4pJAyNnB9+SKjJzn2FK/PJzmomP61okQNlGemM1g6roovXEisVcDvW83Kjtn0p2zkAY59a1hUdN3REoqW5R0axWzgEa5PqT3NbUQ4qGJQKsopABrKpNyd2XFWJO3vUkY4HrUYqVe/pWLNEPxTgBg8U3OKfUjEOAeMU5KY/3eaegxmk9gHjGf8APFSrgGowPzpRnpUFIc7Z5warzSBFLHOBUnb3qI7iWDbdvG31/GqSBjIHZ0BL7snIO3Bx2H/16sdfxqIcDAHApwPFNkocT82O49qQ4IPvkYpN3B+tN6E+1KwxW9eaiY5p56VC7YqkSxsjjFVpHHU4p0jdR261i6pqC2xUOrEt0xW0IOTsjOTNCR9w4NZWqWqXUTRPnB5yKfHcb1DAcdeae0nPI9q3inB3Rm3fcyNK0hLWQuTvfoO2BW9EoAFRoOfSrEQ9O1OpUc3dhGKWxPHwDxk4qdDUMY45qdevFc8jVAAMk5YGgGUHlo2HptK/rk04c0FckYNQWPiw4ZO/Qg9/8RU0aqiBVAVVGAAOAKjRVYEFQQDnB/z70qqyqRGc46Bjn9etQykSH2qKXkHb196dHKsm4AH5euaZI4VlU5yx2j8if6UloMqzuQOeTXK+ItWe1cRwnDYyTiuvkjDA561z+s6VBeSgsWDgda7MPKCl7+xjNO2hW8PX8l9Cxm6juOARRVywtEs4tkQoqqjTk3HYiKaWp//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_25_26014=[""].join("\n");
var outline_f25_25_26014=null;
var title_f25_25_26015="Treatment of osteoarthritis";
var content_f25_25_26015=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F75993&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F75993&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 505px\">",
"   <div class=\"ttl\">",
"    Therapeutic approach to osteoarthritis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 485px; height: 580px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Inflammatory arthritis is evidenced by history of swelling, night pain, morning stiffness greater than 30 minutes; active synovitis on physical examination; chondrocalcinosis on radiographs; rhomboid, positively-birefringent crystals from arthroscentesis; or visualization of crystalline material upon arthroscopy.",
"     <br>",
"      <span class=\"bullet\">",
"       &bull;",
"      </span>",
"      Including education regarding joint protection, dietary modification for weight loss (if appropriate), temperature modalities, hydrotherapy, rubifacients, physical/occupational therapy for supervised exercise program to preserve strength and range of motion and to provide orthoses as needed. Nonpharmacologic interventions should be continued together with pharmacologic therapies.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_25_26015=[""].join("\n");
var outline_f25_25_26015=null;
